

ELAN CORP PLC  
Form 20-F  
February 28, 2007

**Table of Contents**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION,  
Washington, D.C. 20549  
Form 20-F**

(Mark One)

- o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR(g) OF THE SECURITIES EXCHANGE ACT OF 1934**  
**OR**
- o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
**For the fiscal year ended: December 31, 2006**  
**OR**
- o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
**OR**
- o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
**For the transition period from            to**

**Commission file number: 001-13896**

**Elan Corporation, plc**

*(Exact name of Registrant as specified in its charter)*

**Ireland**

*(Jurisdiction of incorporation  
or organization)*

**Treasury Building, Lower Grand Canal Street,**

**Dublin 2, Ireland**

*(Address of principal executive offices)*

**Securities registered or to be registered pursuant to Section 12(b) of the Act:**

**Title of Each Class**

**Name of Exchange on Which Registered**

American Depositary Shares (ADSs), representing  
Ordinary Shares,  
Par value 0.05 each (Ordinary Shares)  
Ordinary Shares

New York Stock Exchange

New York Stock Exchange

**Securities registered or to be registered pursuant to Section 12(g) of the Act:**

**None**

*(Title of Class)*

**Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:**

**None**

*(Title of Class)*

Edgar Filing: ELAN CORP PLC - Form 20-F

Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report: 467,485,612 Ordinary Shares.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes  No

Note: Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer  Accelerated filer  Non-accelerated filer

Indicate by check mark which financial statement item the registrant has elected to follow: Item 17  Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes  No

---

## TABLE OF CONTENTS

	Page
<b><u>General</u></b>	3
<b><u>Forward-Looking Statements</u></b>	3
<b><u>Part I</u></b>	
<u>Item 1.</u>	4
<u>Item 2.</u>	4
<u>Item 3.</u>	4
<u>Item 4.</u>	13
<u>Item 4A.</u>	29
<u>Item 5.</u>	29
<u>Item 6.</u>	56
<u>Item 7.</u>	68
<u>Item 8.</u>	70
<u>Item 9.</u>	70
<u>Item 10.</u>	71
<u>Item 11.</u>	77
<u>Item 12.</u>	79
<b><u>Part II</u></b>	
<u>Item 13.</u>	79
<u>Item 14.</u>	79
<u>Item 15.</u>	80
<u>Item 16.</u>	82
<u>Item 16A.</u>	82
<u>Item 16B.</u>	82
<u>Item 16C.</u>	82
<u>Item 16D.</u>	84
<u>Item 16E.</u>	84
<b><u>Part III</u></b>	
<u>Item 17.</u>	84
<u>Item 18.</u>	84
<u>Item 19.</u>	148
<u>Signatures</u>	150
<u>Financial Statement Schedule</u>	151
<u>EXHIBIT 2.(B)(2)</u>	
<u>EXHIBIT 2.(B)(3)</u>	
<u>EXHIBIT 2.(B)(4)</u>	
<u>EXHIBIT 4.(C)(10)</u>	
<u>EXHIBIT 4.(C)(14)</u>	
<u>EXHIBIT 4.(C)(17)</u>	
<u>EXHIBIT 8.1</u>	
<u>EXHIBIT 12.1</u>	
<u>EXHIBIT 12.2</u>	
<u>EXHIBIT 13.1</u>	
<u>EXHIBIT 13.2</u>	

EXHIBIT 15.1

## Table of Contents

### **General**

As used herein, we, our, us, Elan and the Company refer to Elan Corporation, plc (public limited company) and consolidated subsidiaries, unless the context requires otherwise. All product names appearing in italics are trademarks of Elan. Non-italicized product names are trademarks of other companies.

Our Consolidated Financial Statements contained in this Form 20-F have been prepared on the basis of accounting principles generally accepted in the United States (US GAAP). In addition to the Consolidated Financial Statements contained in this Form 20-F, we also prepare separate Consolidated Financial Statements, included in our Annual Report, in accordance with International Financial Reporting Standards (IFRS), which differ in certain significant respects from US GAAP. The Annual Report under IFRS is a separate document from this Form 20-F.

Unless otherwise indicated, our Consolidated Financial Statements and other financial data contained in this Form 20-F are presented in United States (US) dollars (\$). We prepare our Consolidated Financial Statements on the basis of a calendar fiscal year beginning on January 1 and ending on December 31. References to a fiscal year in this Form 20-F shall be references to the fiscal year ending on December 31 of that year. In this Form 20-F, financial results and operating statistics are, unless otherwise indicated, stated on the basis of such fiscal years.

### **Forward-Looking Statements**

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements are made pursuant to the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, our results could be materially affected.

This Form 20-F contains forward-looking statements about our financial condition, results of operations and estimates, business prospects and products and potential products that involve substantial risks and uncertainties. These statements can be identified by the fact that they use words such as anticipate, estimate, project, intend, plan, believe and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or events. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: (1) the potential of *Tysabri*<sup>®</sup> (*natalizumab*), the incidence of serious adverse events associated with *Tysabri* (including cases of progressive multifocal leukoencephalopathy (PML)) and the potential for the successful development and commercialization of additional products; (2) the potential of *Prial*<sup>™</sup> (*ziconotide intrathecal infusion*) as an intrathecal treatment for severe pain; (3) our ability to maintain financial flexibility and sufficient cash, cash equivalents, and investments and other assets capable of being monetized to meet our liquidity requirements; (4) whether restrictive covenants in our debt obligations will adversely affect us; (5) competitive developments affecting our products, including the introduction of generic competition following the scheduled loss of patent protection or marketing exclusivity for our products (including, in particular, *Maxipime*<sup>™</sup> (*cefepime hydrochloride*), which loses its basic US patent protection in March 2007 and *Azactam*<sup>™</sup> (*aztreonam for injection, USP*), which lost its basic US patent protection in October 2005); (6) our ability to protect our patents and other intellectual property; (7) difficulties or delays in manufacturing (including, in particular, with respect to *Maxipime*); (8) trade buying patterns; (9) pricing pressures and uncertainties regarding healthcare reimbursement and reform; (10) the failure to comply with anti-kickback and false claims laws in the United States (including, in particular, with respect to past marketing practices with respect to our former *Zonegran*<sup>™</sup> product, which are being investigated by the US Department of Justice and the US Department of Health and Human Services. The resolution of the *Zonegran* matter could require us to pay substantial fines and to take other actions that could have a material adverse effect on us); (11) the success of our research and development (R&D) activities (including, in particular,

whether the Phase 2 clinical trials for AAB-001 and the Phase 1 clinical trials for ACC-001 are successful) and the speed with which regulatory authorizations and product launches may be achieved; (12) extensive government regulation; (13) risks from potential environmental liabilities; (14) failure to comply with our reporting and payment obligations under Medicaid or other government programs; (15) exposure to product liability risks; (16) an adverse effect that could result from the putative class action lawsuits initiated following the voluntary suspension of the commercialization and clinical dosing of *Tysabri* and the outcome of our other pending or future litigation; (17) the volatility of our stock price; and

**Table of Contents**

(18) some of our agreements that may discourage or prevent someone from acquiring us. We assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

**Part I****Item 1. Identity of Directors, Senior Management and Advisers.**

Not applicable.

**Item 2. Offer Statistics and Expected Timetable.**

Not applicable.

**Item 3. Key Information.****A. Selected Financial Data**

The selected financial data set forth below is derived from our Consolidated Financial Statements and should be read in conjunction with, and is qualified by reference to, Item 5. Operating and Financial Review and Prospects and our Consolidated Financial Statements and related notes thereto.

<b>Years Ended December 31,</b>	<b>2006</b>	<b>2005</b>	<b>2004</b>	<b>2003</b>	<b>2002</b>
	<b>(In millions, except per share data)</b>				
<b>Income Statement Data:</b>					
Total revenue	\$ 560.4	\$ 490.3	\$ 481.7	\$ 685.6	\$ 1,093.1
Operating loss	\$ (166.4) <sup>(1)</sup>	\$ (198.5) <sup>(2)</sup>	\$ (302.1) <sup>(3)</sup>	\$ (360.5) <sup>(4)</sup>	\$ (608.7) <sup>(5)</sup>
Net loss from continuing operations	\$ (267.3)	\$ (384.2)	\$ (413.7)	\$ (474.6)	\$ (2,169.6)
Net income/(loss) from discontinued operations		0.6	19.0	(31.5)	(188.6)
Net loss	\$ (267.3) <sup>(1)</sup>	\$ (383.6) <sup>(6)</sup>	\$ (394.7) <sup>(3)</sup>	\$ (506.1) <sup>(7)</sup>	\$ (2,358.2) <sup>(8)</sup>
Basic loss per Ordinary Share <sup>(9)</sup> from continuing operations	\$ (0.62)	\$ (0.93)	\$ (1.06)	\$ (1.33)	\$ (6.20)
from discontinued operations			0.05	(0.09)	(0.54)
Total basic loss per Ordinary Share	\$ (0.62)	\$ (0.93)	\$ (1.01)	\$ (1.42)	\$ (6.74)
Diluted loss per Ordinary Share <sup>(9)</sup> from continuing operations	\$ (0.62)	\$ (0.93)	\$ (1.06)	\$ (1.33)	\$ (6.20)
from discontinued operations			0.05	(0.09)	(0.54)
Total diluted loss per Ordinary Share	\$ (0.62)	\$ (0.93)	\$ (1.01)	\$ (1.42)	\$ (6.74)

<b>At December 31,</b>	<b>2006</b>	<b>2005</b>	<b>2004</b>	<b>2003</b>	<b>2002</b>
------------------------	-------------	-------------	-------------	-------------	-------------



**(In millions)**

## Balance Sheet Data:

Cash and cash equivalents	\$ 1,510.6	\$ 1,080.7	\$ 1,347.6	\$ 778.2	\$ 984.5
Restricted cash	\$ 23.2	\$ 24.9	\$ 192.7	\$ 33.1	\$ 29.4
Investment securities - current	\$ 11.2	\$ 10.0	\$ 65.5	\$ 349.4	\$ 450.6
Total assets	\$ 2,746.3	\$ 2,340.9	\$ 2,975.9	\$ 3,029.8	\$ 4,031.7
Debts	\$ 2,378.2	\$ 2,017.2	\$ 2,260.0	\$ 1,500.0	\$ 1,046.3
Total shareholders' equity	\$ 85.1	\$ 16.9	\$ 205.0	\$ 617.9	\$ 843.1
Weighted-average number of shares outstanding - Basic and diluted	433.3	413.5	390.1	356.0	349.7

**Table of Contents**

- (1) *After other net gains of \$20.3 million, primarily relating to an arbitration award of \$49.8 million, offset by acquired in-process research and development costs of \$22.0 million and severance, restructuring and other costs of \$7.5 million; and after a \$43.1 million net gain on sale of products and businesses.*
- (2) *After other net charges of \$4.4 million, primarily relating to net severance, restructuring and other costs of \$14.4 million, offset by a credit of \$10.0 million primarily associated with a litigation settlement; and after a \$103.4 million net gain on sale of businesses.*
- (3) *After other net charges of \$59.8 million, primarily relating to the settlement of the US Securities and Exchange Commission (SEC) investigation and the shareholder class action lawsuit of \$56.0 million; and after a \$44.2 million net gain on sale of businesses.*
- (4) *After other net charges of \$403.2 million, primarily relating to asset impairments of \$32.6 million, severance, restructuring and other costs of \$29.7 million, EPIL III/EPIL II waiver fee of \$16.8 million, and the purchase of royalty rights of \$297.6 million; and after a net gain of \$267.8 million on the sale of businesses and repurchase of debt.*
- (5) *After other net charges of \$500.7 million, primarily relating to asset impairments of \$266.1 million, severance, restructuring and other costs of \$77.8 million and the purchase of royalty rights of \$121.0 million, partially offset by a gain of \$37.7 million on the repurchase of debt.*
- (6) *After other net charges of \$4.4 million, primarily relating to net severance, restructuring and other costs of \$14.4 million, offset by a credit of \$10.0 million primarily associated with a litigation settlement; a \$103.4 million net gain on sale of businesses; and after a net charge of \$51.8 million on the retirement of debt.*
- (7) *After other net charges of \$403.2 million, primarily relating to asset impairments of \$32.6 million, severance, restructuring and other costs of \$29.7 million and the purchase of royalty rights of \$297.6 million, offset by a net gain of \$267.8 million on the sale of businesses and repurchase of debt; and after charges of \$136.5 million, primarily relating to investments and the guarantee issued to the noteholders of Elan Pharmaceutical Investments II, Ltd. (EPIL II).*
- (8) *After other net charges of \$500.7 million, primarily relating to asset impairments of \$266.1 million, severance, restructuring and other costs of \$77.8 million and the purchase of royalty rights of \$121.0 million, partially offset by a gain of \$37.7 million on the repurchase of debt; and after charges of \$1,443.0 million, primarily relating to investment impairments and the guarantee issued to the noteholders of EPIL II.*
- (9) *Earnings per share is based on the weighted-average number of outstanding Ordinary Shares and the effect of potential dilutive securities including options, warrants and convertible securities, unless anti-dilutive.*

**B. Capitalization and Indebtedness**

Not applicable.

**C. Reasons for the Offer and Use of Proceeds**

Not applicable.

**D. Risk Factors**

*You should carefully consider all of the information set forth in this Form 20-F, including the following risk factors, when investing in our securities. The risks described below are not the only ones that we face. Additional risks not currently known to us or that we presently deem immaterial may also impair our business operations. We could be materially adversely affected by any of these risks. This Form 20-F also contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those contemplated by such forward-looking statements.*

***Our future success depends upon the successful commercialization of Tysabri and the successful development and commercialization of additional products. If Tysabri is not commercially successful, either because of the incidence of serious adverse events associated with Tysabri (including cases of PML) or for other reasons, and if we do not successfully develop and commercialize additional products, we will be materially and adversely affected.***

While approximately half of our 2006 revenue was generated by our Elan Drug Technologies (EDT) business unit, we have only four marketed products and several potential products in the early stages of clinical development. Our future success depends upon the successful commercialization of *Tysabri* and the development and the successful commercialization of additional products.

Uncertainty created by the serious adverse events that have occurred or may occur, with respect to *Tysabri*, and the restrictive labeling and distribution system for *Tysabri* mandated by regulatory agencies, may significantly impair the commercial potential for *Tysabri*. If there are more serious adverse events in patients treated with *Tysabri* (including cases of PML), then we may be seriously and adversely affected.

**Table of Contents**

We commit substantial resources to our R&D activities, including collaborations with third parties such as Biogen Idec Inc. (Biogen Idec) with respect to *Tysabri*. We have committed significant resources to the development and the commercialization of *Tysabri* and to the other potential products in our development pipeline. These investments may not be successful.

In the pharmaceutical industry, the R&D process is lengthy, expensive and involves a high degree of risk and uncertainty. This process is conducted in various stages and, during each stage, there is a substantial risk that potential products in our R&D pipeline, including product candidates from our Alzheimer's disease research programs such as AAB-001, AZD-103/ELND-005 and ACC-001, will experience difficulties, delays or failures. A number of factors could affect our ability to successfully develop and commercialize products, including our ability to:

- Establish sufficient safety and efficacy of new drugs or biologics;
- Obtain and protect necessary intellectual property for new technologies, products and processes;
- Recruit patients in clinical trials;
- Complete clinical trials on a timely basis;
- Observe applicable regulatory requirements;
- Receive and maintain required regulatory approvals;
- Obtain competitive/favorable reimbursement coverage for developed products on a timely basis;
- Manufacture or have manufactured sufficient commercial quantities of products at reasonable costs;
- Effectively market developed products; and
- Compete successfully against alternative products or therapies.

Even if we obtain positive results from preclinical or clinical trials, we may not achieve the same success in future trials. Earlier stage trials are generally based on a limited number of patients and may, upon review, be revised or negated by authorities or by later stage clinical results. The results from preclinical testing and early clinical trials have often not been predictive of results obtained in later clinical trials. A number of new drugs and biologics have shown promising results in initial clinical trials, but subsequently failed to establish sufficient safety and effectiveness data to obtain necessary regulatory approvals. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. Clinical trials may not demonstrate statistically sufficient safety and effectiveness to obtain the requisite regulatory approvals for product candidates. In addition, as happened with *Tysabri*, unexpected serious adverse events can occur in patients taking a product after the product has been commercialized.

Our failure to successfully develop and commercialize *Tysabri* and other products would materially adversely affect us.

***We have substantial future cash needs and potential cash needs and we may not be successful in generating or otherwise obtaining the funds necessary to meet our other future and potential needs.***

At December 31, 2006, we had \$2,378.2 million of debt. At such date, we had cash and cash equivalents and restricted cash of \$1,533.8 million. Our substantial indebtedness could have important consequences to us. For example, it could:

Increase our vulnerability to general adverse economic and industry conditions;

Require us to dedicate a substantial portion of our cash flow from operations to payments on indebtedness, thereby reducing the availability of our cash flow to fund R&D, working capital, capital expenditures, acquisitions, investments and other general corporate purposes;

Limit our flexibility in planning for, or reacting to, changes in our businesses and the markets in which we operate;

**Table of Contents**

Place us at a competitive disadvantage compared to our competitors that have less debt; and

Limit our ability to borrow additional funds.

We estimate that we have sufficient cash, liquid resources and current assets and investments to meet our liquidity requirements for at least the next twelve months. Although we expect to continue to incur operating losses in 2007, in making our liquidity estimates, we have also assumed a certain level of operating performance. Our future operating performance will be affected by general economic, financial, competitive, legislative, regulatory and business conditions and other factors, many of which are beyond our control. If our future operating performance does not meet our expectations, including our failure to successfully commercialize *Tysabri* on a timely basis, then we could be required to obtain additional funds. If our estimates are incorrect or are not consistent with actual future developments and we are required to obtain additional funds, then we may not be able to obtain those funds on commercially reasonable terms, or at all, which would have a material adverse effect on our financial condition. In addition, if we are not able to generate sufficient liquidity from operations, we may be forced to curtail programs, sell assets or otherwise take steps to reduce expenses. Any of these steps may have a material adverse effect on our prospects.

***Restrictive covenants in our debt instruments restrict or prohibit our ability to engage in or enter into a variety of transactions, which could adversely affect us.***

The agreements governing our outstanding indebtedness contain various restrictive covenants that limit our financial and operating flexibility. The covenants do not require us to maintain or adhere to any specific financial ratio, but do restrict within limits our ability to, among other things:

Incur additional debt;

Create liens;

Enter into transactions with related parties;

Enter into some types of investment transactions;

Engage in some asset sales or sale and leaseback transactions;

Pay dividends or buy back our Ordinary Shares; and

Consolidate, merge with, or sell substantially all our assets to, another entity.

The breach of any of these covenants may result in a default under the applicable agreement, which could result in the indebtedness under the agreement becoming immediately due and payable. Any such acceleration would result in a default under our other indebtedness subject to cross-acceleration provisions. If this were to occur, we might not be able to pay our debts or obtain sufficient funds to refinance them on reasonable terms, or at all. In addition, complying with these covenants may make it more difficult for us to successfully execute our business strategies and compete against companies not subject to similar constraints.

***Our industry and the markets for our products are highly competitive.***

The pharmaceutical industry is highly competitive. Our principal pharmaceutical competitors consist of major international companies, many of which are larger and have greater financial resources, technical staff, manufacturing,

R&D and marketing capabilities than Elan. We also compete with smaller research companies and generic drug manufacturers.

A drug may be subject to competition from alternative therapies during the period of patent protection or regulatory exclusivity and, thereafter, it may be subject to further competition from generic products. The price of pharmaceutical products typically declines as competition increases.

Our product *Azactam* lost its basic US patent protection in October 2005. We expect that *Azactam* will be subject to generic competition in 2007 and that our sales of *Azactam* will be materially and adversely affected by such generic competition. However, to date, no generic *Azactam* product has been approved.

**Table of Contents**

In addition, the US basic patent covering our product *Maxipime* for injection expires in March 2007. Two formulation US patents covering *Maxipime* expire in February 2008. *Maxipime* may become subject to generic competition following the expiration of the basic patent or after expiration of the formulation patents and that would materially and adversely affect our sales of *Maxipime*.

Generic competitors may also challenge existing patent protection or regulatory exclusivity. Generic competitors do not have to bear the same level of R&D and other expenses associated with bringing a new branded product to market. As a result, they can charge much less for a competing version of our product. Managed care organizations typically favor generics over brand name drugs, and governments encourage, or under some circumstances mandate, the use of generic products, thereby reducing the sales of branded products that are no longer patent protected. Governmental and other pressures toward the dispensing of generic products may rapidly and significantly reduce, or slow the growth in, the sales and profitability of any of our products not protected by patents or regulatory exclusivity and may adversely affect our future results and financial condition. The launch of competitor products, including generic versions of our products, may materially adversely affect us.

Our competitive position depends, in part, upon our continuing ability to discover, acquire and develop innovative, cost-effective new products, as well as new indications and product improvements protected by patents and other intellectual property rights. We also compete on the basis of price and product differentiation and through our sales and marketing organization. If we fail to maintain our competitive position, then we may be materially adversely affected.

***If we are unable to secure or enforce patent rights, trade secrets or other intellectual property, then we could be materially adversely affected.***

Because of the significant time and expense involved in developing new products and obtaining regulatory approvals, it is very important to obtain patent and intellectual property protection for new technologies, products and processes. Our success depends in large part on our continued ability to obtain patents for our products and technologies, maintain patent protection for both acquired and developed products, preserve our trade secrets, obtain and preserve other intellectual property such as trademarks and copyrights, and operate without infringing the proprietary rights of third parties.

The degree of patent protection that will be afforded to technologies, products and processes, including ours, in the United States and in other markets is dependent upon the scope of protection decided upon by patent offices, courts and legislatures in these countries. There is no certainty that our existing patents or, if obtained, future patents, will provide us substantial protection or commercial benefit. In addition, there is no assurance that our patent applications or patent applications licensed from third parties will ultimately be granted or that those patents that have been issued or are issued in the future will prevail in any court challenge. Our competitors may also develop products, including generic products, similar to ours using methods and technologies that are beyond the scope of our patent protection, which could adversely affect the sales of our products.

Although we believe that we make reasonable efforts to protect our intellectual property rights and to ensure that our proprietary technology does not infringe the rights of other parties, we cannot ascertain the existence of all potentially conflicting claims. Therefore, there is a risk that third parties may make claims of infringement against our products or technologies. In addition, third parties may be able to obtain patents that prevent the sale of our products or require us to obtain a license and pay significant fees or royalties in order to continue selling our products.

There has been, and we expect there will continue to be, significant litigation in the industry regarding patents and other intellectual property rights. Litigation and other proceedings concerning patents and other intellectual property



rights may be protracted, expensive and distracting to our management. Our competitors may sue us as a means of delaying the introduction of our products. Any litigation, including any interference proceedings to determine priority of inventions, oppositions to patents or litigation against our licensors may be costly and time consuming and could adversely affect us. In addition, litigation may be necessary in some instances to determine the validity, scope or non-infringement of patent rights claimed by third parties to be pertinent to the manufacturing, use or sale of our products. The outcome of any such litigation could adversely affect the validity and scope of our patents or other intellectual property rights and hinder or delay the marketing and sale of our products.

**Table of Contents**

If we are unable to secure or enforce patent rights, trademarks, trade secrets or other intellectual property, then we could be materially adversely affected.

***If we experience significant delays in the manufacture of our products or in the supply of raw materials for our products, then sales of our products could be materially adversely affected.***

We do not manufacture *Tysabri*, *Prialt*, *Maxipime* or *Azactam*. Our dependence upon collaborators and third parties for the manufacture of our products may result in unforeseen delays or other problems beyond our control. For example, if our third-party manufacturers are not in compliance with current good manufacturing practices (cGMP) or other applicable regulatory requirements, then the supply of our products could be materially adversely affected. If we are unable to retain or obtain replacements for our third-party manufacturers or if we experience delays or difficulties with our third-party manufacturers in producing our products (as we did with *Maxipime* in 2006 and prior years), then sales of these products could be materially and adversely affected. In this event, we may be unable to enter into alternative manufacturing arrangements on commercially reasonable terms, if at all.

Our manufacturers require supplies of raw materials for the manufacture of our products. We do not have dual sourcing of our required raw materials. The inability to obtain sufficient quantities of required raw materials could materially adversely affect the supply of our products.

***Buying patterns of wholesalers and distributors may cause fluctuations in our periodic results.***

Our product revenue may vary periodically due, in part, to buying patterns of our wholesalers and distributors. In the event that wholesalers and distributors determine, for any reason, to limit purchases of our products, sales of those products would be adversely affected. For example, wholesalers and distributors may order products in larger than normal quantities prior to anticipated price increases for those products. This excess purchasing in any period could cause sales of those products to be lower than expected in subsequent periods.

***We are subject to pricing pressures and uncertainties regarding healthcare reimbursement and reform.***

In the United States, many pharmaceutical products and biologics are subject to increasing pricing pressures, including pressures arising from recent Medicare reform. Our ability to commercialize products successfully depends, in part, upon the extent to which health care providers are reimbursed by third-party payers, such as governmental agencies, including the Centers for Medicare and Medicaid Services, private health insurers and other organizations, such as health maintenance organizations (HMOs), for the cost of such products and related treatments. In addition, if health care providers do not view current or future Medicare reimbursements for our products favorably, then they may not prescribe our products. Third-party payers are increasingly challenging the pricing of pharmaceutical products by, among other things, limiting the pharmaceutical products that are on their formulary lists. As a result, competition among pharmaceutical companies to place their products on these formulary lists has reduced product prices. If reasonable reimbursement for our products is unavailable or if significant downward pricing pressures in the industry occur, then we could be materially adversely affected.

Recent reforms in Medicare added a prescription drug reimbursement benefit for all Medicare beneficiaries. Although we cannot predict the full effects on our business of this legislation, it is possible that the new benefit, which is being managed by private health insurers, pharmacy benefit managers, and other managed care organizations, will result in decreased reimbursement for prescription drugs, which may further exacerbate industry-wide pressure to reduce the prices charged for prescription drugs. This could harm our ability to generate revenues. In addition, Managed Care Organizations, HMOs, Preferred Provider Organizations, institutions and other government agencies continue to seek price discounts. In addition, certain states have proposed and certain other states have adopted various programs to

control prices for their seniors and low-income drug programs, including price or patient reimbursement constraints, restrictions on access to certain products, importation from other countries, such as Canada, and bulk purchasing of drugs.

We encounter similar regulatory and legislative issues in most other countries. In the European Union (EU) and some other international markets, the government provides health care at low direct cost to consumers and regulates pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored health care system. This price regulation may lead to inconsistent prices and some third-party trade in our products from

**Table of Contents**

markets with lower prices. Such trade exploiting price differences between countries could undermine our sales in markets with higher prices.

***The pharmaceutical industry is subject to anti-kickback and false claims laws in the United States.***

In addition to the US Food and Drug Administration (FDA) restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict some marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes and false claims statutes.

The federal health care program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or in return for purchasing, leasing, ordering, or arranging for the purchase, lease, or order of any health care item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one-hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting some common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability.

Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. Recently, several pharmaceutical and other health care companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Additionally, another pharmaceutical company settled charges under the federal False Claims Act relating to off-label promotion. The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer. Sanctions under these federal and state laws may include civil monetary penalties, exclusion of a manufacturer's products from reimbursement under government programs, criminal fines, and imprisonment.

Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition and results of operations.

In January 2006, Elan received a subpoena from the US Department of Justice and the Department of Health and Human Services, Office of Inspector General asking for documents and materials primarily related to our marketing practices for Zonegran. In April 2004, we completed the sale of our interests in Zonegran in North America and Europe to Eisai Co. Ltd. (Eisai). We are cooperating with the government in its investigation. The resolution of this Zonegran matter could require Elan to pay substantial fines and to take other actions that could have a material adverse effect on Elan. In April 2006, Eisai delivered to Elan a notice making a contractual claim for indemnification in connection with a similar subpoena received by Eisai.

***We are subject to extensive government regulation, which may adversely affect our ability to bring new products to market and may adversely affect our ability to manufacture and market our existing products.***

The pharmaceutical industry is subject to significant regulation by state, local, national and international governmental regulatory authorities. In the United States, the FDA regulates the design, development, pre-clinical and clinical testing, manufacturing, labeling, storing, distribution, import, export, record keeping, reporting, marketing and

promotion of our pharmaceutical products, which include drugs, biologics and medical devices. Failure to comply with regulatory requirements at any stage during the regulatory process could result in, among other things, delays in the approval of applications or supplements to approved applications, refusal of a regulatory authority to review pending market approval applications or supplements to approved applications, warning letters, fines, import or export restrictions, product recalls or seizures, injunctions, total or partial suspension of production, civil penalties, withdrawals of previously approved marketing applications or licenses, recommendations by the FDA or other regulatory authorities against governmental contracts, and criminal prosecutions.

**Table of Contents**

We must obtain and maintain approval for our products from regulatory authorities before such products may be sold in a particular jurisdiction. The submission of an application to a regulatory authority with respect to a product does not guarantee that approval to market the product will be granted. Each authority generally imposes its own requirements and may delay or refuse to grant approval, even though a product has been approved in another country. In our principal markets, including the United States, the approval process for a new product is complex, lengthy, expensive and subject to unanticipated delays. We cannot be sure when or whether approvals from regulatory authorities will be received or that the terms of any approval will not impose significant limitations that could negatively impact the potential profitability of the approved product. Even after a product is approved, it may be subject to regulatory action based on newly discovered facts about the safety and efficacy of the product, on any activities that regulatory authorities consider to be improper or as a result of changes in regulatory policy. Regulatory action may have a material adverse effect on the marketing of a product, require changes in the product's labeling or even lead to the withdrawal of the regulatory marketing approval of the product.

All facilities and manufacturing techniques used for the manufacture of products and devices for clinical use or for sale in the United States must be operated in conformity with cGMPs, the FDA's regulations governing the production of pharmaceutical products. There are comparable regulations in other countries. Any finding by the FDA or other regulatory authority that we are not in substantial compliance with cGMP regulations or that we or our employees have engaged in activities in violation of these regulations could interfere with the continued manufacture and distribution of the affected products, up to the entire output of such products, and, in some cases, might also require the recall of previously distributed products. Any such finding by the FDA or other regulatory agency could also affect our ability to obtain new approvals until such issues are resolved. The FDA and other regulatory authorities conduct scheduled periodic regulatory inspections of our facilities to ensure compliance with cGMP regulations. Any determination by the FDA or other regulatory authority that we, or one of our suppliers, are not in substantial compliance with these regulations or are otherwise engaged in improper or illegal activities could have a material adverse effect on us.

***Our business exposes us to risks of environmental liabilities.***

We use hazardous materials, chemicals and toxic compounds that could expose people or property to accidental contamination, events of non-compliance with environmental laws, regulatory enforcement and claims related to personal injury and property damage. If an accident occurred or if we were to discover contamination caused by prior operations, then we could be liable for cleanup, damages or fines, which could have an adverse effect on us.

The environmental laws of many jurisdictions impose actual and potential obligations on us to remediate contaminated sites. These obligations may relate to sites that we currently own or lease, sites that we formerly owned or operated, or sites where waste from our operations was disposed. These environmental remediation obligations could significantly impact our operating results. Stricter environmental, safety and health laws and enforcement policies could result in substantial costs and liabilities to us, and could subject our handling, manufacture, use, reuse or disposal of substances or pollutants to more rigorous scrutiny than is currently the case. Consequently, compliance with these laws could result in significant capital expenditures, as well as other costs and liabilities, which could materially adversely affect us.

***If we fail to comply with our reporting and payment obligations under the Medicaid rebate program or other governmental pricing programs, then we could be subject to additional reimbursements, penalties, sanctions and fines, which could have a material adverse effect on our business.***

As a condition of reimbursement under Medicaid, we participate in the US federal Medicaid rebate program, as well as several state rebate programs. Under the federal and state Medicaid rebate programs, we pay a rebate to each state

for our products that are reimbursed by those programs. The amount of the rebate for each unit of product is set by law based on reported pricing data. The rebate amount may also include a penalty if our prices increase faster than the rate of inflation.

As a manufacturer of single source, innovator and non-innovator multiple source products, rebate calculations vary among products and programs. The calculations are complex and, in some respects, subject to interpretation by

## **Table of Contents**

governmental or regulatory agencies, the courts and us. The Medicaid rebate amount is computed each quarter based on our pricing data submission to the Centers for Medicare and Medicaid Services at the US Department of Health and Human Services. The terms of our participation in the program impose an obligation to correct the prices reported in previous quarters, as may be necessary. Any such corrections could result in an overage or shortfall in our rebate liability for past quarters (up to 12 past quarters), depending on the direction of the correction. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid.

US Federal law requires that any company that participates in the federal Medicaid rebate program extend comparable discounts to qualified purchasers under the Public Health Services pharmaceutical pricing program. This pricing program extends discounts comparable to the Medicaid net price to a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as outpatient utilization at hospitals that serve a disproportionate share of poor patients.

Additionally, each calendar quarter, we calculate and report an Average Sales Price (ASP) for all products covered by Medicare Part B (primarily injectable or infused products). We submit ASP information for each such product within 30 days of the end of each calendar quarter. This information is then used to set reimbursement levels to reimburse Part B providers for the drugs and biologicals dispensed to Medicare Part B participants.

Furthermore, pursuant to the Veterans Health Care Act, a Non-Federal Average Manufacturer Price is calculated each quarter and a Federal Ceiling Price is calculated each year for every Covered Drug marketed by us. These prices are used to set pricing for purchases by the military arm of the government.

These price reporting obligations are complicated and often involve decisions regarding issues for which there is no clear-cut guidance from the government. Failure to submit correct pricing data can subject us to civil, administrative, and criminal penalties, and could have a material adverse effect on our business, financial condition and results of operations.

***We are subject to continuing potential product liability risks, which could harm our business.***

Risks relating to product liability claims are inherent in the development, manufacturing and marketing of our products. Any person who is injured while using one of our products or products which we are responsible for, may have a product liability claim against us. Since we distribute and sell our products to a wide number of end users, the risk of such claims could be material. Persons who participate in clinical trials involving our products may also bring product liability claims.

Excluding any self-insured arrangements we currently do not maintain product liability insurance for the first \$25.0 million of aggregate claims, but do maintain coverage for the next \$150.0 million with our insurers. Our insurance coverage may not be sufficient to cover fully all potential claims, nor can we guarantee the solvency of any of our insurers.

If our claims experience results in higher rates, or if product liability insurance otherwise becomes costlier because of general economic, market or industry conditions, then we may not be able to maintain product liability coverage on acceptable terms. If sales of our products increase materially, or if we add significant products to our portfolio, then we will require increased coverage and may not be able to secure such coverage at reasonable rates or terms.

***We and some of our officers and directors have been named as defendants in putative class actions; an adverse outcome in the class actions could have a material adverse effect on us.***



We and some of our officers and directors have been named as defendants in putative class actions filed in 2005. The class action complaints allege claims under the US federal securities laws and state laws. The complaints allege that we caused the release of materially false or misleading information regarding *Tysabri*. The complaints seek damages and other relief that the courts may deem just and proper. We believe that the claims in the lawsuits are without merit and intend to defend against them vigorously.

An adverse result in the lawsuits could have a material adverse effect on us.

**Table of Contents**

***Our stock price is volatile, which could result in substantial losses for investors purchasing shares.***

The market prices for our shares and for securities of other companies engaged primarily in biotechnology and pharmaceutical development, manufacture and distribution are highly volatile. The market price of our shares likely will continue to fluctuate due to a variety of factors, including:

Material public announcements by us;

Developments regarding *Tysabri*;

The timing of new product launches by others and us;

Events related to our marketed products and those of our competitors;

Regulatory issues affecting us;

Availability and level of third-party reimbursement;

Developments relating to patents and other intellectual property rights;

Results of clinical trials with respect to our products under development and those of our competitors;

Political developments and proposed legislation affecting the pharmaceutical industry;

Economic and other external factors;

Hedge or arbitrage activities by holders of our securities;

Period-to-period fluctuations in our financial results or results that do not meet or exceed market expectations; and

Market trends relating to or affecting stock prices across our industry, whether or not related to results or news regarding our competitors or us.

***Certain provisions of agreements to which we are a party may discourage or prevent a third party from acquiring us and could prevent shareholders from receiving a premium for their shares.***

We are a party to agreements that may discourage a takeover attempt that might be viewed as beneficial to shareholders who wish to receive a premium for their shares from a potential bidder. For example:

Our collaboration agreement with Biogen Idec provides Biogen Idec with an option to buy the rights to *Tysabri* in the event that we undergo a change of control, which may limit our attractiveness to potential acquirers;

Until June 20, 2010, Biogen Idec and its affiliates are, subject to limited exceptions, restricted from, among other things, seeking to acquire or acquiring control of us;

Under the terms of indentures governing much of our debt, any acquirer would be required to make an offer to repurchase the debt for cash in connection with some change of control events; and

Our collaboration agreement with Wyeth restricts Wyeth and its subsidiaries from seeking to acquire us in some circumstances.

**Item 4. *Information on the Company.***

**A. History and Development of Elan**

Elan, an Irish public limited company, is a neuroscience-based biotechnology company headquartered in Dublin, Ireland. We were incorporated as a private limited company in Ireland in December 1969 and became a public limited company in January 1984. Our principal executive offices are located at Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland and our telephone number is 353-1-709-4000. Our principal R&D, manufacturing and marketing facilities are located in Ireland and the United States.

**Table of Contents****B. Business Overview**

Our operations are organized into two business units: Biopharmaceuticals and EDT. Biopharmaceuticals engages in research, development and commercial activities and includes our activities in the areas of autoimmune diseases, neurodegenerative diseases, and our specialty business group. EDT focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

In the area of autoimmune diseases, we continue to research and develop novel therapies that may help patients who suffer from diseases where an immune reaction is mistakenly directed at cells, tissues and organs in different parts of the body. Currently there are few autoimmune diseases for which the disease can be reversed or cured; autoimmune diseases are, therefore, often chronic, requiring life-long care. The wide range of autoimmune diseases includes multiple sclerosis (MS), Crohn's disease (CD), ulcerative colitis and rheumatoid arthritis (RA).

In the area of neurodegenerative diseases, we continue to focus on Alzheimer's disease and Parkinson's disease. Our R&D efforts in Alzheimer's disease and Parkinson's disease span more than two decades. In the United States and throughout the world, Alzheimer's disease and related disorders represent a significant unmet medical need. While a number of approved treatment options exist for Alzheimer's disease and Parkinson's disease, available options do not address the underlying causes of the diseases nor their progression.

Our specialty business group encompasses our commercial activities related to meeting the needs of specialists treating severe bacterial infections in hospitals, and pain specialists addressing severe chronic pain. Our products are the antibacterial hospital products *Maxipime* and *Azactam*, and *Prialt*, a new class of treatment for severe chronic pain, which we launched in the United States in January 2005.

EDT focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry. For more than 37 years, Elan has been applying its skills and knowledge to enhance the performance of dozens of drugs that have been marketed worldwide.

*AUTOIMMUNE DISEASES*

In autoimmune diseases, the immune system mistakenly targets the cells, tissues and organs of a person's body, generally causing inflammation. Inflammation is a response of body tissues to trauma, infection, chemical or physical injury, allergic reaction, or other factors. It is usually characterized by a collection of cells and molecules at a target site. Different autoimmune diseases affect the body in different ways. For example, in MS, the autoimmune reaction is directed against the brain. In CD, it is directed against the gastrointestinal tract; and in RA, it is directed against the joints. Autoimmune diseases are often chronic, affecting millions of people and requiring life-long care. Most autoimmune diseases cannot currently be reversed or cured.

Elan's therapeutic strategy for treating autoimmune diseases is to identify mechanisms common to autoimmune diseases, and develop novel therapeutics that stop the underlying causes of disease. Alpha 4 integrin is a protein expressed by immune cells that allows those cells to leave the blood stream and invade target tissue. Blocking alpha 4 integrin stops immune cells from entering tissues.

*Tysabri*

*Tysabri* is an alpha 4 integrin antagonist. *Tysabri* is designed to inhibit immune cells from leaving the bloodstream and to prevent these immune cells from migrating into chronically inflamed tissue where they may cause or maintain inflammation. *Tysabri* was developed and is now being commercialized by us in collaboration with Biogen Idec.

***FDA Review of Tysabri for the Treatment of Multiple Sclerosis***

In June 2006, the FDA approved the re-introduction of *Tysabri* for the treatment of relapsing forms of MS. Approval for the marketing of *Tysabri* in the European Union was also received in June 2006. The distribution of *Tysabri* in both the United States and European Union commenced in July 2006.

The FDA granted approval for the reintroduction of *Tysabri* based on the review of *Tysabri* clinical trial data, revised labeling with enhanced safety warnings, and a risk management plan called the *Tysabri* Outreach: Unified

**Table of Contents**

Commitment to Health (TOUCH Prescribing Program), which is designed to inform physicians and patients of the benefits and risks of *Tysabri* treatment and minimize potential risk of PML. Under the TOUCH Prescribing Program, only prescribers, infusion centers and pharmacies associated with infusion centers registered in the TOUCH Prescribing Program are able to prescribe, infuse or distribute *Tysabri*. Elan has contracted with a single distributor and twelve specialty pharmacies to distribute product in accordance with the requirements of the TOUCH Prescribing Program.

The reintroduction of *Tysabri* was the culmination of a 17-month process and encompassed the following events:

On February 28, 2005, we and Biogen Idec announced the voluntary suspension of the commercialization and dosing in clinical trials of *Tysabri*, based on two reports of PML. PML is an opportunistic viral infection of the brain that usually leads to death or severe disability.

We and Biogen Idec subsequently initiated a comprehensive safety evaluation of *Tysabri* and any possible link to PML. The safety evaluation was comprised of a complete review of all clinical trial data. We and Biogen Idec worked with clinical trial investigators and PML and neurology experts to evaluate more than 3,000 patients in MS, CD and RA trials. The safety evaluation also included a review of any reports of potential PML in patients receiving *Tysabri* in the commercial setting.

In March 2005, we announced that the safety evaluation had led to a posthumous reassessment of PML in a patient in an open label CD clinical trial. The patient died in December 2003, and the case was originally reported by a clinical trial investigator as malignant astrocytoma.

In August 2005, we reported that findings from the safety evaluation of *Tysabri* in patients with MS resulted in no new confirmed cases of PML beyond the three previously reported. In October 2005, we reported the same results from our evaluation of patients with CD and RA.

In September 2005, we and Biogen Idec announced that we had submitted a supplemental Biologics License Application (sBLA) for *Tysabri* to the FDA for the treatment of MS and would submit a similar data package to the European Medicines Agency (EMA). In November 2005, the sBLA was accepted and designated for Priority Review by the FDA, and the European submission was accepted for review.

In February 2006, we and Biogen Idec were informed by the FDA that it had removed the hold on clinical trial dosing of *Tysabri* in MS in the United States.

On March 8, 2006, the Peripheral and Central Nervous System Drug (PCNS) Advisory Committee voted unanimously to recommend that *Tysabri* be reintroduced as a treatment for relapsing forms of MS.

On March 29, 2006, we and Biogen Idec announced the re-initiation of *Tysabri* clinical trial dosing in MS. Specifically, it was announced that the first patients were enrolled and dosed in the *Tysabri* monotherapy safety extension study program in MS.

On April 28, 2006, we and Biogen Idec announced that the Committee for Medicinal Products for Human Use, the scientific committee of the EMA, issued a positive opinion recommending marketing authorization for *Tysabri* as a treatment for relapsing-remitting MS to delay the progression of disability and reduce the frequency of relapses.

On June 29, 2006, the EMA approved *Tysabri* for the treatment of relapsing-remitting forms of MS.

In both the United States and Europe, special provisions are in place to ensure patients are informed of the risks of therapy and to enhance collection of post-marketing safety data and utilization of *Tysabri* in MS.

*Evaluating Tysabri in Crohn's Disease*

In collaboration with Biogen Idec, we are evaluating *Tysabri* as a treatment for CD. In September 2004, we submitted a Marketing Authorization Application to the EMEA for the approval of *Tysabri* for the treatment of CD. Following approval of *Tysabri* as a treatment for MS in 2006, we have re-initiated discussion with the EMEA and expect European regulatory action regarding *Tysabri* in CD in 2007. A sBLA for *Tysabri* as a treatment for CD in the

## **Table of Contents**

United States was filed with the FDA on December 15, 2006 and has been accepted for review. The filing was based on the results of three randomized, double-blind, placebo-controlled, multi-center trials of *Tysabri* assessing its safety and efficacy as both an induction and maintenance therapy.

### ***Autoimmune Diseases Research & Development***

Our ongoing research in autoimmune diseases is primarily based on cell trafficking and focuses on discovering disease-modifying approaches to treating a wide range of autoimmune diseases, including MS, CD and RA. *Tysabri* emerged from this research program. We remain focused on discovering disease-modifying approaches to treating a wide range of autoimmune diseases, including MS, CD and RA. In 2006, we expanded our research in autoimmune diseases to include novel anti-inflammatory approaches in addition to our core alpha 4 integrin programs.

Since first publishing the hypothesis concerning the therapeutic potential of blocking alpha 4 integrin in 1992, our scientists have been expanding and refining our understanding of how cells enter tissues. We now have a clear understanding of how cells enter the gut, brain, or joints, and cause the damage characteristic of MS, CD, and RA. Through the course of this work we have developed small molecules that can selectively block particular alpha 4 integrin interactions. The first drug candidate evolving from this effort is ELND-001, which is in Phase 1. Further work is ongoing for other molecules that target the alpha 4 integrin pathway.

In June 2006, we entered into a multi-product alliance with Archemix Corp. (Archemix) to discover, develop and commercialize aptamer therapeutics for autoimmune diseases. This program is in the discovery phase.

### ***NEURODEGENERATIVE DISEASES***

In addition to Alzheimer's disease and Parkinson's disease, neurodegenerative diseases encompass other disorders that are characterized by changes in normal neuronal function. In most cases of degenerative disease, the risk of these changes increases with age, and the disease progression itself is progressive. Currently, neurodegenerative diseases are generally considered incurable. Several drugs are approved to alleviate some symptoms of some neurodegenerative diseases.

Alzheimer's disease is a degenerative brain disorder that primarily affects older persons. Alzheimer's disease can begin with forgetfulness and progress into more advanced symptoms, including confusion, language disturbances, personality and behavior changes, impaired judgment and profound dementia. As the disease advances, most patients will eventually need complete skilled nursing care, and in the absence of other illnesses, the progressive loss of brain function itself will likely cause death.

Parkinson's disease is a progressive degenerative neurologic movement disorder that destroys nerve cells in the part of the brain responsible for muscle control and movement. This creates problems walking, maintaining balance and coordination in patients diagnosed with the disease.

### ***Our Scientific Approach to Alzheimer's Disease and Related Disorders***

Our scientific approach to treating Alzheimer's disease focuses on the beta amyloid hypothesis, as it is believed that blocking the generation of beta amyloid in the brain or enhancing the clearance of beta amyloid will result in the successful treatment of Alzheimer's disease patients. The beta amyloid hypothesis asserts that beta amyloid is involved in the formation of the plaque that causes the disruption of memory and cognition that is the hallmark of Alzheimer's disease. This hypothesis is also the leading approach to developing therapeutic treatments that may fundamentally alter the progression of the disease, and evidence suggests that clearance of beta amyloid may lead to improved function in Alzheimer's disease patients.



Beta amyloid, also known as Abeta, is actually a small part of a larger protein called the amyloid precursor protein (APP). Beta amyloid is formed when certain enzymes called secretases clip (or cleave) APP. It is becoming increasingly clear that once beta amyloid is released, it exists in multiple physical forms with distinct functional activities. It is believed that the toxic effects of these forms are likely responsible for the complex mental disruption characteristic of Alzheimer's disease.

**Table of Contents**

***Alzheimer's Research and Development***

Our scientists are investigating three key therapeutic approaches that target the elimination and prevention of production or aggregation of beta amyloid. In collaboration with Wyeth, we are developing beta amyloid immunotherapies. Separately, we have research programs focused on small molecule inhibitors of beta secretase and gamma secretase, enzymes whose actions result in the over-production of beta amyloid in the brains of patients with Alzheimer's disease. In addition, in September 2006 we entered into a collaboration agreement with Transition Therapeutics, Inc. (Transition) to develop AZD-103 (also referred to as AZD-103/ELND-005), a small molecule therapeutic that acts by breaking down and preventing the aggregation of beta amyloid fibrils.

***Research in Beta Amyloid Immunotherapy***

Beta amyloid immunotherapy pioneered by Elan involves the treatment of Alzheimer's disease by inducing or enhancing the body's own immune response in order to clear beta amyloid from the brain. Active immunization stimulates the body's own immune system to manufacture anti beta amyloid antibodies that may attach to amyloid and clear it from the brain. This, in turn, appears to reduce the build-up of beta amyloid in the brain tissue of patients.

Through a monoclonal antibody approach (passive immunization), synthetically engineered antibodies directed at beta amyloid are injected into the bloodstream and are thought to help reverse beta amyloid accumulation.

Our scientists have developed a series of monoclonal antibodies and active immunization approaches that may have the ability to selectively clear a variety of beta amyloid species. These new approaches have the potential to deliver immunotherapies with potent and broad therapeutic activity. Our AAB-001, AAB-002 and ACC-001 programs have emerged from this work.

***AAB-001***

We, in collaboration with Wyeth, are pursuing beta amyloid immunotherapy for mild to moderate Alzheimer's disease in Phase 2 studies of a humanized monoclonal antibody, AAB-001. This therapeutic antibody is thought to bind and clear beta amyloid peptide and is designed to provide antibodies to beta amyloid directly to the patient, rather than requiring patients to mount their own responses.

Animal studies have shown that this approach is as effective in clearing beta amyloid from the brain as active immunization methods. By providing such a passive immunization approach for treatment of Alzheimer's disease, the benefits demonstrated with an earlier active immunization study may be retained, while the safety concerns of the earlier approach may be greatly reduced or eliminated due to the absence of stimulation of the patient's immune response to beta amyloid.

During the first half of 2005, we initiated two Phase 2 clinical trials with AAB-001. Both trials are randomized, double-blind, placebo-controlled, multiple ascending dose studies with four dose cohorts. One trial includes approximately 240 patients and the other includes approximately 30 patients, all with mild to moderate Alzheimer's disease. The patients are being followed for 18 months. Data from this clinical trial will be used to design the next phase of clinical trials. It will also determine the time point at which this program can progress into the next phase of clinical trials.

***AAB-002***

We anticipate a potential filing of an IND in 2007 for AAB-002, a follow-on antibody program, which is also in collaboration with Wyeth. This antibody has demonstrated unique attributes in our experimental animal models when compared to AAB-001.

## **Table of Contents**

### ***ACC-001***

We, in collaboration with Wyeth, are also developing ACC-001, a novel beta amyloid-related active immunization approach. ACC-001 is in a Phase 1 clinical study designed to study safety and immunogenicity in patients with mild to moderate Alzheimer's disease. The ACC-001 approach is intended to induce a highly specific antibody response to beta amyloid. The goal is to clear beta amyloid while minimizing side effects such as inflammation of the central nervous system. Initiation of Phase 2 clinical trials has been targeted for 2007.

### ***Our Secretase Inhibitor Research***

Beta and gamma secretases are proteases (enzymes that break down other proteins) that appear to clip the APP, resulting in the formation of beta amyloid. This is significant because if the clipping of APP could be prevented, the pathology of Alzheimer's disease may be changed. We have been at the forefront of research in this area, publishing extensively since 1989, and have developed and are pursuing advanced discovery programs focused on molecule inhibitors of beta and gamma secretases.

### ***Beta Secretase***

Beta secretase is believed to initiate the first step in the formation of beta amyloid, the precursor to plaque development in the brain. We have been an industry leader in beta secretase research for more than 10 years. Our findings concerning the role beta secretase plays in beta amyloid production, published in Nature in 1999, are considered a landmark discovery. Today, we continue to be at the center of understanding the complexities of beta secretase and advancing agents that inhibit its role in Alzheimer's disease pathology. In 2005, we resolved our dispute with Pfizer Inc. (Pfizer), our former collaborator on the beta secretase program. The settlement allows for both companies to operate with freedom in the beta secretase space. We are continuing our pre-clinical drug discovery efforts, including expansion of our strategic industry-leading patent portfolio covering beta secretase small molecule inhibitors.

### ***Gamma Secretase***

Gamma secretase is an unusual multi-protein complex that is thought to play a significant role in the formation of beta amyloid. We have played a critical leadership role in the increased awareness of how gamma secretase may affect Alzheimer's disease pathology. Our finding, published in 2001, that functional gamma secretase inhibitors appear to reduce beta amyloid levels in the brain, was an important step in this area of Alzheimer's disease research. We continued to progress our gamma secretase discovery program in 2006.

### ***AZD-103/ELND-005***

In 2006, we entered into a collaboration with Transition to develop a small molecule approach to the treatment of mild to moderate Alzheimer's disease. The molecule is a beta-amyloid anti-aggregate. Based upon pre-clinical data, by blocking the aggregation of amyloid beta, clearance of amyloid occurs and plaque build up is prevented.

Daily oral treatment with this compound has been shown to prevent cognition decline in a transgenic mouse model of Alzheimer's disease, with reduced amyloid plaque load in the brain accompanied with an increased survival rate of these animals.

In 2006, three Phase 1 Single Ascending Dose studies were conducted by Transition showing that AZD-103/ELND-005 has a favorable pharmacokinetic profile and is safe and well tolerated. No significant

drug-related adverse events have been reported to date.

In 2007, we will conduct additional clinical and non-clinical studies to support the initiation of a Phase 2 trial, targeted for 2007. This Phase 2 study will be a randomized, double-blind, placebo-controlled, dose-ranging study in mild to moderate Alzheimer's disease patients.

## **Table of Contents**

### ***Parkinson's Research***

Parkinson's disease is believed to be a result of misfolded proteins in the brain. Parkinson's disease is characterized by the accumulation of aggregated alpha-synuclein, or Lewy bodies, in degenerating neurons in particular regions of the brain.

Our early discovery efforts in Parkinson's disease are guided by our expertise and leadership in Alzheimer's disease research. We made significant scientific progress in 2006, identifying unusual modified forms of alpha-synuclein in human Parkinson's disease brain tissue. These unique forms have led us to a series of therapeutic targets that will be a focus of our small and large molecule drug discovery efforts over the next few years.

Our scientists are also studying parkin, a protein found in the brain that has been genetically linked to Parkinson's disease. Parkin may be involved in the elimination of misfolded proteins within neurons. Some familial forms of Parkinson's disease have been linked to mutations in parkin, and we are actively studying the relationship between parkin activity and neurodegeneration. This research is in the drug discovery stage.

### ***SPECIALTY BUSINESS GROUP***

Our specialty business group encompasses our commercial activities related to meeting the needs of specialists treating severe bacterial infections in hospitals, and pain specialists addressing severe chronic pain. Our products are the antibacterial hospital products *Maxipime* and *Azactam*, and *Prialt*, a new class of therapy for patients suffering from severe chronic pain.

### ***Prialt***

On December 28, 2004, the FDA approved *Prialt* for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine. *Prialt* is approved for use only in the Medtronic SynchroMed® EL, SynchroMed® II Infusion System and CADD-Micro® ambulatory infusion pump.

*Prialt* is administered through appropriate programmable microinfusion pumps that can be implanted or external, and which release the drug into the fluid surrounding the spinal cord. *Prialt* is in a class of non-opioid analgesics known as N-type calcium channel blockers. It is a synthetic equivalent of a naturally occurring conopeptide found in a marine snail known as *Conus magus*. Research suggests that the novel mechanism of action of *Prialt* works by targeting and blocking N-type calcium channels on nerves that ordinarily transmit pain signals.

In January 2005, we launched *Prialt* in the United States. We believe *Prialt* represents an important therapeutic option addressing an unmet need, and that it has the potential for significant patient impact and market contribution in the area of severe chronic pain. Revenue from sales of *Prialt* totaled \$12.1 million for 2006 (2005: \$6.3 million). In March 2006, Elan completed the sale of the *Prialt* rights in Europe to Eisai, while retaining the product rights in the United States.

### **Hospital Business and Products**

Severe bacterial infections remain a major medical concern. We market two products that treat severe bacterial infections, each designed to address medical needs within the hospital market.

### ***Maxipime***

We licensed the US marketing rights to *Maxipime* from Bristol-Myers Squibb Company (Bristol-Myers) in January 1999. *Maxipime* is a fourth-generation injectable cephalosporin antibiotic used to treat patients with serious and/or life-threatening infections. Pulmonologists, infectious disease specialists, emergency medicine specialists, surgeons, internal medicine physicians, hematologists and oncologists prescribe *Maxipime* for patients with severe infections requiring hospitalization, such as pneumonia, urinary tract infection and febrile neutropenia. Attributes of *Maxipime* are its broad spectrum of activity, including activity against many pathogens resistant to other antibiotics, ease of use and favorable pharmaco-economic profile. Revenue from sales of *Maxipime* totaled

**Table of Contents**

\$159.9 million for 2006 (2005: \$140.3 million). The basic US patent on *Maxipime* expires in March 2007. Two other US patents covering *Maxipime* formulations expire in February 2008.

***Azactam***

We licensed the US marketing rights to this injectable antibiotic from Bristol-Myers in January 1999. *Azactam* is a monobactam and is principally used by surgeons, infectious disease specialists and internal medicine physicians to treat pneumonia, post-surgical infections and septicemia. *Azactam* is often used in these infections for patients who have a known or suspected penicillin allergy. Revenue from sales of *Azactam* totaled \$77.9 million for 2006 (2005: \$57.7 million). The basic US patent on *Azactam* expired in October 2005. No generic *Azactam* product has been approved to date, however we expect that generic competition to *Azactam* will emerge in 2007.

Please refer to Item 5A. Operating Results for additional information concerning our revenue by category for 2006, 2005 and 2004.



**Table of Contents**

## **Table of Contents**

### *ELAN DRUG TECHNOLOGIES*

For more than 37 years, we have been applying our skills and knowledge to enhance the performance of dozens of drugs that have been marketed in many countries worldwide. EDT focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry. EDT offers the industry a suite of proprietary technology-driven solutions. EDT recorded total revenue of \$284.6 million in 2006 (2005: \$261.2 million).

Our *NanoCrystal*<sup>™</sup> technology continues to be one of the key platforms that differentiates EDT. Sales by third parties of products incorporating *NanoCrystal* technology continued to grow in 2006. During 2006, we signed a number of development agreements with third parties, including a license agreement with Abbott Pharmaceutical PR Ltd. (Abbott) to develop a single fixed-dose combination of TriCor<sup>®</sup> and Crestor<sup>®</sup> for high cholesterol patients.

### *Elan's Patented and Commercialized NanoCrystal Technology*

Elan's *NanoCrystal* technology is a drug optimization technology applicable to poorly water-soluble compounds. It is covered by numerous US and international patents and patent applications and is part of a suite of technologies that EDT offers to third-party clients.

*NanoCrystal* technology involves reducing crystalline drug to particles under 400 nanometers. By reducing particle size, the exposed surface area of the drug is increased and is then stabilized to maintain particle size. The drug in nano-form can be incorporated into common dosage forms, including tablets, capsules, inhalation devices, and sterile forms for injection, with the potential for substantial improvements to clinical performance.

Products developed and now commercialized in the United States using Elan's *NanoCrystal* technology include:

Emend<sup>®</sup> oral tablet form of aprepitant, a poorly water-soluble compound;

Megace<sup>®</sup> ES concentrated oral suspension, with reduced dose and improved dissolution and bioavailability;

Rapamune<sup>®</sup> convenient oral tablet form eliminating reconstitution and refrigerated storage of original compound; and

TriCor new formulation of Abbott's fenofibrate, which can be taken without regard to food.

### *Manufacturing and Scale-up Activities*

The combination of development and manufacturing capabilities on the same sites in EDT allows for streamlined scale-up and transfer to commercial scale manufacturing activities. EDT's principal manufacturing and development facilities are located in Athlone, Ireland and in King of Prussia, Pennsylvania and Gainesville, Georgia, in the United States. Our range of services includes formulation development, analytical development, clinical trial manufacturing and scale-up, including sterile fill and finish as well as product registration support. The Athlone campus comprises more than 460,000 square feet under roof, of which 218,000 square feet is dedicated to manufacturing.

### *ENVIRONMENT*

Many factors and elements contribute to the environment in which we conduct our activities. Key factors and elements include the pharmaceutical market, government regulation, the product approval process, manufacturing, patents and intellectual property rights, competition, distribution, raw materials and product supply, employees and

principal properties.

***Pharmaceutical Market***

The US market is our most important market. Please refer to Note 31 to the Consolidated Financial Statements for an analysis of revenue by geographic region. For this reason, the factors discussed below, such as Government Regulation and Product Approval, place emphasis on requirements in the United States.

**Table of Contents**

***Government Regulation***

The pharmaceutical industry is subject to significant regulation by international, national, state and local governmental regulatory agencies. Pharmaceutical product registration is primarily concerned with the safety, efficacy and quality of new drugs and devices, and, in some countries, their pricing. A product must generally undergo extensive clinical trials before it can be approved for marketing. The process of developing a new pharmaceutical product, from idea to commercialization, can take in excess of 10 years. This period varies considerably from case to case and from country to country.

An application for registration includes specific details concerning not only the chemical composition, but also the manufacturing plant and procedures involved in the production of the product. The time from submission of an application to commercialization of the product is typically two years or longer. After a product has been approved by the regulatory authorities and has been launched, it is a condition of the product approval that all aspects relating to its safety, efficacy and quality remain under review.

Governmental authorities, including the FDA and comparable regulatory authorities in other countries, regulate the design, development, testing, manufacturing and marketing of pharmaceutical products. For example, the Federal Food, Drug and Cosmetics Act, the Public Health Service Act, the Controlled Substances Act and other federal statutes and regulations impose requirements on the clinical and non-clinical testing, safety, effectiveness, manufacturing, labeling, storage, recordkeeping, reporting, advertising, marketing, import, export, distribution and approval of our products in the United States. Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product seizures, import restrictions, injunctive actions and criminal prosecutions. In addition, administrative remedies can involve requests to recall violative products, the refusal of the government to enter into supply contracts or the refusal to approve pending product approval applications for drugs, biological products, or medical devices, until manufacturing or other alleged deficiencies are brought into compliance. The FDA also has the authority to cause the withdrawal of approval of a marketed product or to impose labeling restrictions.

In addition, the US Centers for Disease Control and Prevention regulate select biologics and toxins. This includes registration and inspection of facilities involved in the transfer or receipt of select agents. Select agents are subject to specific regulations for packaging, labeling and transport. Non-compliance with applicable requirements could result in criminal penalties and the disallowance of research and manufacturing of clinical products. Exemptions are provided for select agents used for a legitimate medical purpose or for biomedical research, such as toxins for medical use and vaccines.

The pricing of pharmaceutical products is regulated in many countries. The mechanism of price regulation varies. For example, certain countries regulate the price of individual products while in other countries prices are controlled by limiting overall company profitability. In the United States, while there are limited indirect federal government price controls over private sector purchases of drugs, there have been ongoing discussions on potential reforms of the healthcare system, including the pricing of pharmaceuticals, which could result, directly or indirectly, in the implementation of price controls on a larger number of pharmaceutical products. Certain states are attempting to impose requirements, processes, or systems that would result in indirect price controls. It is not possible to predict future regulatory action on the pricing of pharmaceutical products.

In June 2002, we entered into a settlement with the US Federal Trade Commission (FTC) resolving the FTC's investigation of a licensing arrangement between us and Biovail Corporation (Biovail) relating to nifedipine, a generic version of the hypertension drug Adalat<sup>™</sup> CC. The settlement is reflected in a consent order which, by its terms, does not constitute an admission by us that any law had been violated, and does not provide for monetary fines or penalties.

We continue to satisfy all of the terms of the consent order.

In June 2001, we received a letter from the FTC stating that the FTC was conducting a non-public investigation to determine whether Brightstone Pharma, Inc. (Brightstone), Elan Corporation, plc or others may have engaged in an effort to restrain trade by entering into an agreement which may restrict the ability of Brightstone or others to market a bioequivalent or generic version of Naprelan<sup>tm</sup>. In October 2001, our counsel met informally with the FTC staff to discuss the matter. No further communication from the FTC was received until December 2002, when we were served with a subpoena duces tecum from the FTC for the production of documents related to Naprelan. We

## **Table of Contents**

have voluntarily provided documents and witness testimony in response to the subpoena and continue to cooperate with the FTC relating to this investigation. We do not believe that it is feasible to predict or determine the outcome of the investigation and any possible effect on our business, or to reasonably estimate the amounts or potential range of loss, if any, with respect to the resolution of the investigation.

In January 2006, Elan received a subpoena from the US Department of Justice and the Department of Health and Human Services, Office of Inspector General asking for documents and materials primarily related to our marketing practices for Zonegran. In April 2004, we completed the sale of our interests in Zonegran in North America and Europe to Eisai. We are cooperating with the government in its investigation. The resolution of this Zonegran matter could require Elan to pay substantial fines and to take other actions that could have a material adverse effect on Elan. In April 2006, Eisai delivered to Elan a notice making a contractual claim for indemnification in connection with a similar subpoena received by Eisai.

### ***Product Approval***

Pre-clinical tests assess the potential safety and efficacy of a product candidate in animal models. The results of these studies must be submitted to the FDA as part of an IND before human testing may proceed.

Under US law, an IND must be submitted to the FDA and become effective before human clinical trials may commence. US law further requires that studies conducted to support approval for product marketing be adequate and well controlled. In general, this means that either a placebo or a product already approved for the treatment of the disease or condition under study must be used as a reference control. Studies must also be conducted in compliance with good clinical practice (GCP) requirements, and adverse event and other reporting requirements must be followed.

The clinical trial process can take three to 10 years or more to complete, and there can be no assurance that the data collected will be in compliance with GCP regulations, will demonstrate that the product is safe or effective, or, in the case of a biologic product, pure and potent, or will provide sufficient data to support FDA approval of the product. The FDA may place clinical trials on hold at any point in this process if, among other reasons, it concludes that clinical subjects are being exposed to an unacceptable health risk. Trials may also be terminated by institutional review boards, which must review and approve all research involving human subjects. Side effects or adverse events that are reported during clinical trials can delay, impede, or prevent marketing authorization.

The results of the preclinical and clinical testing, along with information regarding the manufacturing of the product and proposed product labeling, are evaluated and, if determined appropriate, submitted to the FDA through a license application such as a New Drug Application (NDA) or a BLA. In certain cases an Abbreviated New Drug Application (ANDA) can be filed in lieu of filing an NDA. An ANDA relies on bioequivalency tests that compare the applicant's drug with an already approved reference drug rather than on clinical safety and efficacy studies. An ANDA might be available to us for a new formulation of a drug for which bioequivalent forms have already been approved by the FDA. In responding to applications for approval, the FDA could grant marketing approval, approve the product for a narrower indication, impose labeling or distribution restrictions, request additional information, require post-approval studies or deny the application. Applications are often referred to an outside FDA advisory committee of independent experts prior to the FDA acting on the application. Similar systems are in place for the testing and approval of biologics and medical devices.

There can be no marketing in the United States of any drug, biologic or device for which a marketing application is required until the application is approved by the FDA. Until an application is actually approved, there can be no assurance that the information requested and submitted will be considered adequate by the FDA. Additionally, any significant change in the approved product or in how it is manufactured, including changes in formulation or the site of manufacture, generally require prior FDA approval. The packaging and labeling of all products developed by us are

also subject to FDA approval and ongoing regulation.

In the United States, under the Prescription Drug User Fee Act and the Medical Device User Fee and Modernization Act, the FDA receives fees for reviewing product applications and supplements thereto, as well as annual fees for commercial manufacturing establishments and for approved products. These fees can be significant. For example, the NDA or BLA review fee alone can exceed \$0.5 million, although certain deferrals, waivers and

## **Table of Contents**

reductions may be available. Even when user fees are significant, they do not generally constitute a major expense relative to the overall cost associated with product development and regulatory approval.

Whether or not FDA approval has been obtained, approval of a pharmaceutical product by comparable regulatory authorities in other countries outside the United States must be obtained prior to the marketing of the product in those countries. The approval procedure varies from country to country. It can involve additional testing and the time required can differ from that required for FDA approval. Although there are procedures for unified filings for EU countries, in general, most other countries have their own procedures and requirements.

Once a product has been approved, significant legal and regulatory requirements apply in order to market a product. In the United States these include, among other things, requirements related to adverse event and other reporting, product advertising and promotion, and ongoing adherence to cGMP requirements, as well as the need to submit appropriate new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Adverse events that are reported after marketing authorization can result in additional limitations being placed on a product's use and, potentially, withdrawal of the product from the market. Any adverse event, either before or after marketing authorization, can result in product liability claims against us.

The FDA also enforces the requirements of the Prescription Drug Marketing Act, which, among other things, imposes various requirements in connection with the distribution of product samples to physicians. Sales, marketing and scientific/educational grant programs must comply with the Medicare-Medicaid Anti-Fraud and Abuse Act, as amended, the False Claims Act, as amended, and similar state laws. Pricing and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990, as amended. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply.

### ***Manufacturing***

Each manufacturing establishment, including any contract manufacturers, used to manufacture a product must be listed in the product application for such product. In the United States, this means that each manufacturing establishment must be listed in the drug, biologic, or device application, and must be registered with the FDA. The application will not be approved until the FDA conducts a manufacturing inspection, approves the applicable manufacturing process for the product, and determines that the facility is in compliance with cGMP requirements. If the manufacturing facilities and processes fail to pass the FDA inspection, the FDA will not grant approval to market the product. All facilities are also subject to periodic regulatory inspections to ensure ongoing compliance with cGMP. At December 31, 2006, we had manufacturing facilities in Ireland and the United States.

At December 31, 2006, we employed 543 people in our manufacturing and supply activities, over half of these in Athlone, Ireland. This facility is the primary location for the manufacture of oral solid dosage products, including instant, controlled-release and oral micro particulate products. Additional dosage capabilities may be added as required to support future product introductions. Our facility in Gainesville, Georgia, United States, provides additional oral controlled-release dosage product manufacturing capability and is registered with the US Drug Enforcement Administration for the manufacture, packaging and distribution of Schedule II controlled drugs.

All facilities and manufacturing techniques used for the manufacture of products and devices for clinical use or for sale in the United States must be operated in conformity with cGMP regulations. There are FDA regulations governing the production of pharmaceutical products. Our facilities are also subject to periodic regulatory inspections to ensure ongoing compliance with cGMP regulations.



In May 2001, Elan Holdings, Inc. (Elan Holdings), a wholly owned subsidiary of Elan, the late Donal J. Geaney, then chairman and chief executive officer of Elan, William C. Clark, then president, operations, and two then employees of Elan Holdings, Hal Herring and Cheryl Schuster, entered into a consent decree of permanent injunction with the US Attorney for the Northern District of Georgia, on behalf of the FDA, relating to alleged violations of cGMP at our Gainesville facility. The facility manufactured, and continues to manufacture, verapamil hydrochloride controlled-release capsules used in the treatment of high blood pressure, Avinza<sup>tm</sup> once-daily, novel dual release morphine sulphate, RitalinLA<sup>®</sup> once-daily, pulsatile release of methylphenidate and Focalin XR<sup>®</sup>

## **Table of Contents**

once daily dexamethylphenidate for treatment of Attention-Deficit Hyperactivity Disorder. The consent decree did not represent an admission by Elan Holdings of any of the allegations set forth in the decree. Under the terms of the consent decree, Elan Holdings is permanently enjoined from violating cGMP regulations. The consent decree was removed in 2006.

### ***Patents and Intellectual Property Rights***

Our competitive position depends on our ability to obtain patents on our technologies and products, to defend our patents, to protect our trade secrets and to operate without infringing the valid patents or trade secrets of others. We own or license a number of patents in the United States and other countries.

These patents cover, for example:

Pharmaceutical active ingredients, products containing them and their uses;

Pharmaceutical formulations; and

Product manufacturing processes.

Patents for products extend for varying periods according to the date of patent filing or grant and the legal term of patents in various countries. The actual protection afforded by a patent, which can vary from country to country, depends upon the type of patent, the scope of its coverage and the availability of legal remedies in the country.

*Tysabri* is covered by a number of pending patent applications and issued patents in the United States and many other countries. Elan has a basic US patent for *Tysabri* covering the humanized antibody and its use to treat MS, which expires in 2014, subject to any available patent term extensions. Additional US patents and patent applications of Elan and/or its collaborator, Biogen Idec, which cover i) the use of *Tysabri* to treat irritable bowel disease and a variety of other indications and ii) methods of manufacturing *Tysabri* generally expire between 2012 and 2020. Outside the United States, patents and patent applications on i) the product and methods of manufacturing the product, and ii) methods of treatment would generally expire in the 2014 to 2016 and 2012 to 2020 timeframes, respectively. If *Tysabri* receives regulatory approval in those jurisdictions, those patents may be eligible for supplemental protection certificates.

In addition to our *Tysabri* collaboration with Biogen Idec, we have entered into licenses covering intellectual property related to *Tysabri*. We will pay royalties under these licenses based upon the level of *Tysabri* sales. We may be required to enter into additional licenses related to *Tysabri* intellectual property. If these licenses are not available, or are not available on reasonable terms, we may be materially and adversely affected.

The fundamental US patent covering the use of *Prialt* to produce analgesia expires in 2011. A further US patent covering the stabilized formulation of *Prialt* expires in 2015. One of our patents covering *Prialt* may qualify for a US patent term extension of up to five years.

The basic US patent for *Maxipime* expires in March 2007. However, two US patents covering *Maxipime* formulations may provide patent protection until February 2008. The basic US patent for *Azactam* expired in October 2005. *Maxipime* and *Azactam* are expected to face generic competition, which is expected to have a substantial adverse effect on our revenues from, and gross margin for, these products.

The primary patents covering Elan's *NanoCrystal* technology expire in the United States in 2011 and in countries outside the United States in 2012. We also have numerous US and international patents and patent applications that

relate to our *NanoCrystal* drug optimization technology applicable to poorly water-soluble compounds.

In addition, we have a large patent estate resulting from our Alzheimer's disease research.

Our products are sold around the world under brand name, logo and product design trademarks that we consider in the aggregate to be of material importance. Trademark protection continues in some countries for as long as the mark is used and, in other countries, for as long as it is registered. Registrations generally are for fixed, but renewable, terms.

## **Table of Contents**

### ***Competition***

The pharmaceutical industry is highly competitive. Our principal pharmaceutical competitors consist of major international companies, many of which are larger and have greater financial resources, technical staff, manufacturing, R&D and marketing capabilities than us. We also compete with smaller research companies and generic drug manufacturers.

*Tysabri*, a treatment for relapsing forms of MS, competes primarily with Avonex<sup>®</sup> marketed by our collaborator Biogen Idec; Betaseron<sup>®</sup> marketed by Berlex (an affiliate of Bayer Schering Pharma AG) in the United States and sold under the name Betaferon<sup>®</sup> by Bayer Schering Pharma in Europe; Rebif<sup>®</sup> marketed by Merck Serono and Pfizer in the United States and by Merck Serono in Europe; and Copaxone<sup>®</sup> marketed by Teva Neurosciences, Inc. (Teva) in the United States and co-promoted by Teva and Sanofi-Aventis in Europe. Many companies are working to develop new therapies or alternative formulations of products for MS, which if successfully developed would compete with *Tysabri*.

A drug may be subject to competition from alternative therapies during the period of patent protection or regulatory exclusivity and, thereafter, it may be subject to further competition from generic products. Our product *Azactam* lost its basic US patent protection in October 2005. We expect that generic competition to *Azactam* will emerge in 2007 and will have a material and adverse effect on our sales of *Azactam*. The basic US patent for *Maxipime* expires in March 2007. However, two US patents covering *Maxipime* formulations may provide patent protection until February 2008. When a generic competitor for *Maxipime* enters the market, it will have a material and adverse effect on our sales of *Maxipime*.

Generic competitors may also challenge existing patent protection or regulatory exclusivity. Governmental and other pressures toward the dispensing of generic products may rapidly and significantly reduce, slow, or reverse the growth in, sales and profitability of any of our products not protected by patents or regulatory exclusivity, and may adversely affect our future results and financial condition. The launch of competitor products, including generic versions of our products, may materially adversely affect our business, financial condition and results of operations.

Our competitive position depends, in part, upon our continuing ability to discover, acquire and develop innovative, cost-effective new products, as well as new indications and product improvements protected by patents and other intellectual property rights. We also compete on the basis of price and product differentiation and through our sales and marketing organization that provides information to medical professionals and launches new products. If we fail to maintain our competitive position, our business, financial condition and results of operations may be materially adversely affected.

### ***Distribution***

We sell our pharmaceutical products primarily to drug wholesalers. Our revenue reflects the demand from these wholesalers to meet the in-market consumption of our products and to reflect the level of inventory that wholesalers of our products carry. Changes in the level of inventory can directly impact our revenue and could result in our revenue not reflecting in-market consumption of our products.

We often manufacture our drug delivery products for licensees and distributors but do not usually engage in any direct sales of drug delivery products.

### ***Raw Materials and Product Supply***

Raw materials and supplies are generally available in quantities adequate to meet the needs of our business. We are dependent on third-party manufacturers for the pharmaceutical products that we market. An inability to obtain raw materials or product supply could have a material adverse impact on our business, financial condition and results of operations.

**Table of Contents*****Employees***

On December 31, 2006, we had 1,734 employees worldwide, of whom 494 were engaged in R&D activities, 543 were engaged in manufacturing and supply activities, 328 were engaged in sales and marketing activities and the remainder worked in general and administrative areas.

**C. Organizational Structure**

At December 31, 2006, we had the following principal subsidiary undertakings:

<b>Company</b>	<b>Nature of Business</b>	<b>Group Share %</b>	<b>Registered Office &amp; Country of Incorporation Operation</b>
Athena Neurosciences, Inc.	Holding company	100	800 Gateway Blvd South San Francisco, CA, United States
Elan Capital Corp., Ltd.	Financial services company	100	Clarendon House 2 Church St Hamilton, Bermuda
Elan Drug Delivery, Inc.	R&D	100	3000 Horizon Drive King of Prussia, PA, United States
Elan Finance plc	Financial services company	100	Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland
Elan Holdings, Inc.	Manufacture of pharmaceutical and medical device products	100	1300 Gould Drive Gainesville, GA, United States
Elan Holdings Ltd.	Holding company	100	Monksland, Athlone Co. Westmeath, Ireland
Elan International Services Ltd.	Financial services company	100	Clarendon House, 2 Church St Hamilton, Bermuda
Elan Management Ltd.	Provision of management services	100	Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland
Elan Pharma International Ltd.	R&D, manufacture, sale and distribution of pharmaceutical products and financial services	100	Monksland, Athlone Co. Westmeath, Ireland
Elan Pharmaceuticals, Inc.	R&D and sale of pharmaceutical products	100	800 Gateway Blvd South San Francisco, CA, United States
Monksland Holding BV	Financial services company	100	Amsteldijk 166 6th Floor

Neuralab Ltd.	Non-trading	100	1079 LH Amsterdam The Netherlands Clarendon House, 2 Church St Hamilton, Bermuda
---------------	-------------	-----	--

**D. Property, Plant and Equipment**

We consider that our properties are in good operating condition and that our machinery and equipment has been well maintained. Facilities for the manufacture of products are suitable for their intended purposes and have capacities adequate for current and projected needs.

For additional information, please refer to Note 14 to the Consolidated Financial Statements, which discloses amounts invested in land and buildings and plant and equipment, Note 22 to the Consolidated Financial Statements, which discloses future minimum rental commitments, Note 27 to the Consolidated Financial Statements, which

**Table of Contents**

discloses capital commitments for the purchase of property, plant and equipment and Item 5 B. Liquidity and Capital Resources, which discloses our capital expenditures.

The following table lists the location, ownership interest, use and approximate size of our principal properties:

<b>Location and Ownership Interest</b>	<b>Use</b>	<b>Size (Sq. Ft.)</b>
Owned: Athlone, Ireland	R&D, manufacturing and administration	463,000
Owned: Gainesville, Georgia United States	R&D, manufacturing and administration	84,000
Leased: South San Francisco, California, United States	R&D and administration	213,000
Leased: King of Prussia, Pennsylvania, United States	R&D, manufacturing, sales and administration	113,000
Leased: San Diego, California, United States	Sales, marketing and administration	68,000
Leased: Stevenage, United Kingdom	Product development and administration	8,000
Leased: Dublin, Ireland	Corporate administration	20,000
Leased: New York City, New York, United States	Corporate administration	14,000

**Item 4A. *Unresolved Staff Comments***

Not applicable.

**Item 5. *Operating and Financial Review and Prospects***

The following discussion and analysis should be read in conjunction with our Consolidated Financial Statements, the accompanying notes thereto and other financial information, appearing in Item 18. Consolidated Financial Statements.

Our Consolidated Financial Statements contained in this Form 20-F have been prepared on the basis of US GAAP. In addition to the Consolidated Financial Statements contained in this Form 20-F, we also prepare separate Consolidated Financial Statements, included in our Annual Report, in accordance with IFRS, which differ in certain significant respects from US GAAP. The Annual Report under IFRS is a separate document from this Form 20-F.

This financial review primarily discusses:

Current operations;

Critical accounting policies;

Recently issued accounting pronouncements;

Post balance sheet events;

Results of operations for the year ended December 31, 2006 compared to 2005;

Results of operations for the year ended December 31, 2005 compared to 2004;

Segment analysis; and



Our financial position, including capitalization and liquidity.

Our operating results may be affected by a number of factors, including those described under Item 3. D Risk Factors .

*CURRENT OPERATIONS*

Our business is organized into two business units: Biopharmaceuticals and EDT. Biopharmaceuticals engages in research, development and commercial activities and includes our activities in the areas of autoimmune diseases, neurodegenerative diseases and our specialty business group. EDT focuses on product development, scale-up and

## **Table of Contents**

manufacturing to address drug optimization challenges of the pharmaceutical industry. For additional information on our current operations, please refer to Item 4B on pages 14 to 28.

### *CRITICAL ACCOUNTING POLICIES*

The Consolidated Financial Statements include certain estimates based on management's best judgments. Estimates are used in determining items such as the carrying values of intangible assets and tangible fixed assets, revenue recognition, the accounting for contingencies, the fair value of share-based compensation and estimating sales rebates and discounts, among other items. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.

### *Goodwill, Other Intangible Assets, Tangible Fixed Assets and Impairment*

We account for goodwill and identifiable intangible assets in accordance with the Financial Accounting Standards Board's (FASB) Statement No. 142, *Goodwill and Other Intangible Assets*, (SFAS 142). Pursuant to SFAS 142, goodwill and identifiable intangible assets with indefinite useful lives are no longer amortized, but instead are tested for impairment at least annually. Intangible assets with estimable useful lives are amortized on a straight-line basis over their respective estimated useful lives to their estimated residual values and reviewed for impairment in accordance with SFAS No. 144, *Accounting for the Impairment or Disposal of Long-Lived Assets*.

We review our goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. At December 31, 2006, we had no other intangible assets with indefinite lives.

The goodwill impairment test is performed at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment as defined by SFAS No. 131, *Disclosures About Segments of an Enterprise and Related Information*. We have two reporting units: Biopharmaceuticals and EDT. We compare the fair value of each reporting unit with its carrying value, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered impaired. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test would be performed to measure the amount of impairment charge, if any. The second step compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill, and any excess of the carrying amount over the implied fair value is recognized as an impairment charge. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination is determined, by allocating the fair value of a reporting unit to individual assets and liabilities. The excess of the fair value of a reporting unit over the amounts assigned to its assets and liabilities is the implied fair value of goodwill. The results of our goodwill impairment tests did not indicate any impairment in 2006.

There were no material impairment charges relating to intangible assets in either 2006, 2005 or 2004. For additional information on goodwill and other intangible assets, please refer to Note 15 to the Consolidated Financial Statements.

Total goodwill and other intangible assets amounted to \$575.9 million at December 31, 2006 (2005: \$665.5 million). If we were to use different estimates, particularly with respect to the likelihood of R&D success, the likelihood and date of commencement of generic competition or the impact of any reorganization or change of business focus, then a material impairment charge could arise. We believe that we have used reasonable estimates in assessing the carrying values of our intangible assets.

In January 2005, we launched *Prialt* in the United States. Revenues from sales of *Prialt* totaled \$12.1 million and \$6.3 million in 2006 and 2005, respectively. These revenues were lower than our initial forecast. Our estimates of the

fair value of this product, based on future net cash flows, are well in excess of the asset's carrying value of \$64.5 million at December 31, 2006. We believe that we have used reasonable estimates in assessing the carrying value of this intangible. Nevertheless, should our future revenues from this product fail to meet our expectations, the carrying value of this asset may become impaired.

We have invested significant resources in our manufacturing facilities in Ireland to provide us with the capability to manufacture products from our product development pipeline. To the extent that we are not successful

**Table of Contents**

in developing these pipeline products or do not acquire products to be manufactured at our facilities, the carrying value of these facilities may become impaired. At December 31, 2006, our best estimates of the likely success of development and commercialization of our pipeline products support the carrying value of our manufacturing facilities.

***Revenue Recognition***

We recognize revenue from the sale of our products, royalties earned and contract arrangements in accordance with the SEC's Staff Accounting Bulletin No. 104, Revenue Recognition, (SAB 104), which requires the deferral and amortization of up-front fees when there is a significant continuing involvement (such as an ongoing product manufacturing contract) by the seller after an asset disposal. We defer and amortize up-front license fees to the income statement over the performance period. The performance period is the period over which we expect to provide services to the licensee as determined by the contract provisions. Generally, milestone payments are recognized when earned and non-refundable, and when we have no future legal obligation pursuant to the payment. However, the actual accounting for milestones depends on the facts and circumstances of each contract. We apply the substantive milestone method in accounting for milestone payments. This method requires that substantive effort must have been applied to achieve the milestone prior to revenue recognition. If substantive effort has been applied, the milestone is recognized as revenue, subject to it being earned, non-refundable and not subject to future legal obligation. This requires an examination of the facts and circumstances of each contract. Substantive effort may be demonstrated by various factors, including the risks associated with achieving the milestone, the period of time over which effort was expended to achieve the milestone, the economic basis for the milestone payment and licensing arrangement and the costs and staffing to achieve the milestone. It is expected that the substantive milestone method will be appropriate for most contracts. If we determine the substantive milestone method is not appropriate, we apply the proportional performance method to the relevant contract. This method recognizes as revenue the percentage of cumulative non-refundable cash payments earned under the contract, based on the percentage of costs incurred to date compared to the total costs expected under the contract.

***Share-based Compensation***

On January 1, 2006, we adopted SFAS No. 123 (revised 2004), Share-Based Payment, (SFAS 123R) which requires the measurement and recognition of compensation expense for all share-based awards made to employees and directors based on estimated fair values. These awards include employee stock options, Restricted Stock Units (RSUs) and stock purchases related to our employee equity purchase plans. SFAS 123R supersedes our previous accounting under Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, (APB 25) beginning January 1, 2006. In March 2005, the SEC issued SAB No. 107, Share-based Payment, (SAB 107) relating to SFAS 123R. We have applied the provisions of SAB 107 in our adoption of SFAS 123R.

We adopted SFAS 123R using the modified prospective transition method, which requires that share-based compensation expense be recorded for (a) any share-based awards granted through but not vested as of December 31, 2005, based on the grant date fair value estimated in accordance with the pro-forma provisions of SFAS No. 123, Accounting for Stock-Based Compensation, (SFAS 123), and (b) any share-based awards granted or modified subsequent to December 31, 2005, based on the grant date fair value estimated in accordance with the provisions of SFAS 123R. Our Consolidated Financial Statements as of and for the year ended December 31, 2006 reflect the impact of SFAS 123R. In accordance with the modified prospective transition method, our Consolidated Financial Statements for prior periods have not been restated to reflect, and do not include, the impact of SFAS 123R. The adoption of SFAS 123R has had a material effect on our reported financial results. Share-based compensation expense recognized under SFAS 123R for the year ended December 31, 2006 was \$47.1 million. See Note 26 to the Consolidated Financial Statements for additional information.

SFAS 123R requires companies to estimate the fair values of share-based awards on the date of grant using an option-pricing model. The value of awards expected to vest is recognized as an expense over the requisite service periods. Prior to the adoption of SFAS 123R, we accounted for share-based awards to employees and directors using the intrinsic value method in accordance with APB 25 as allowed under SFAS 123. Under the intrinsic value method, no share-based compensation expense had been recognized in our Consolidated Statement of Operations, other than as related to modifications and compensatory employee equity purchase plans, because the exercise price

**Table of Contents**

of the stock options granted to employees and directors equaled the fair market value of the underlying stock at the date of grant.

Estimating the fair value of share-based awards as of the date of grant using an option-pricing model, such as the binomial model, is affected by our stock price as well as assumptions regarding a number of complex variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, risk-free interest rates, and actual and projected employee exercise behaviors. If factors change and/or we employ different assumptions in the application of SFAS 123R in future periods, the compensation expense that we record under SFAS 123R for future grants may differ significantly from what we have recorded in the Consolidated Financial Statements. However, we believe we have used reasonable assumptions to estimate the fair value of our share-based awards.

***Contingencies Relating to Actual or Potential Administrative and Legal Proceedings***

We are currently involved in legal and administrative proceedings, relating to securities matters, patent matters, antitrust matters and other matters, as described in Note 28 to the Consolidated Financial Statements. In accordance with SFAS No. 5, Accounting for Contingencies, we assess the likelihood of any adverse outcomes to contingencies, including legal matters, as well as potential ranges of probable losses. We record accruals for such contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. If an unfavorable outcome is probable, but the amount of the loss cannot be reasonably estimated, we estimate the range of probable loss and accrue the most probable loss within the range. If no amount within the range is deemed more probable, we accrue the minimum amount within the range. If neither a range of loss nor a minimum amount of loss is estimable, then appropriate disclosure is provided, but no amounts are accrued. As of December 31, 2006, we had accrued \$5.0 million, representing our estimates of liability and costs for the resolution of these matters. We developed estimates in consultation with outside counsel handling our defense in these matters using the facts and circumstances known to us. The factors that we consider in developing our legal contingency accrual include the merits and jurisdiction of the litigation, the nature and number of other similar current and past litigation cases, the nature of the product and assessment of the science subject to the litigation, and the likelihood of settlement and state of settlement discussions, if any. We believe that the legal contingency accrual that we have established is appropriate based on current factors and circumstances. However, it is possible that other people applying reasonable judgment to the same facts and circumstances could develop a different liability amount. The nature of these matters is highly uncertain and subject to change. As a result, the amount of our liability for certain of these matters could exceed or be less than the amount of our estimates, depending on the outcome of these matters.

***Sales Discounts and Allowances***

We recognize revenue on a gross revenue basis and make various deductions to arrive at net revenue as reported in the Consolidated Statements of Operations. These adjustments are referred to as sales discounts and allowances and are described in detail below. Sales discounts and allowances include charge-backs, managed health care and Medicaid rebates, cash discounts, sales returns and other adjustments. Estimating these sales discounts and allowances is complex and involves significant estimates and judgments, and we use information from both internal and external sources to generate reasonable and reliable estimates. We believe that we have used reasonable judgments in assessing our estimates, and this is borne out by our historical experience. At December 31, 2006, we had total provisions of \$16.5 million for sales discounts and allowances, of which approximately 65.6% and 27.6% related to *Maxipime* and *Azactam*, respectively. We have over eight years of experience in relation to *Maxipime* and *Azactam*. The sales discounts and allowances related to *Tysabri* are estimated based on historical data of a similar product and our experience to date with this product. We do not expect *Tysabri* sales returns to be material given the manner in which this product is prescribed and used.

We do not conduct our sales using the consignment model. All of our product sales transactions are based on normal and customary terms whereby title to the product and substantially all of the risks and rewards transfer to the customer upon either shipment or delivery. Furthermore, we do not have an incentive program which would compensate a wholesaler for the costs of holding inventory above normal inventory levels thereby encouraging wholesalers to hold excess inventory.

**Table of Contents**

We account for sales discounts, allowances and returns in accordance with the FASB's Emerging Issues Task Force Issue No. 01-9, Accounting for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor's Products), and SFAS No. 48, Revenue Recognition When Right of Return Exists, (SFAS 48) as applicable.

The table below summarizes our sales discounts and allowances to adjust gross revenue to net revenue for each significant category. An analysis of the separate components of our revenue is set out in Item 5A. Operating Results, and in Note 3 to the Consolidated Financial Statements.

	<b>Years Ended December 31,</b>		
	<b>2006</b>	<b>2005</b>	<b>2004</b>
Gross revenue subject to discounts and allowances	\$ 311.3	\$ 273.2	\$ 291.7
Manufacturing revenue and royalties	234.8	207.1	130.9
Contract revenue	27.5	32.2	77.3
Amortized revenue Adalat/Avinza	30.7	34.0	34.0
Gross revenue	\$ 604.3	\$ 546.5	\$ 533.9
Sales discounts and allowances:			
Charge-backs	\$ (28.6)	\$ (22.8)	\$ (24.6)
Managed health care rebates and other contract discounts	(3.7)	(2.9)	(5.1)
Medicaid rebates	(1.2)	(1.6)	(8.2)
Cash discounts	(6.5)	(5.5)	(5.6)
Sales returns	(0.6)	(20.9)	(7.1)
Other adjustments	(3.3)	(2.5)	(1.6)
Total sales discounts and allowances	\$ (43.9)	\$ (56.2)	\$ (52.2)
Net revenue subject to discounts and allowances	267.4	217.0	239.5
Manufacturing revenue and royalties	234.8	207.1	130.9
Contract revenue	27.5	32.2	77.3
Amortized revenue Adalat/Avinza	30.7	34.0	34.0
Net revenue	\$ 560.4	\$ 490.3	\$ 481.7

Total sales discounts and allowances increased from 17.9% of gross revenue subject to discounts and allowances in 2004 to 20.6% in 2005, and decreased to 14.1% in 2006, as detailed in the rollforward below and as further explained in the following paragraphs.

Charge-backs decreased slightly as a percentage of gross revenue subject to discounts and allowances from 8.4% in 2004 to 8.3% in 2005, and increased to 9.2% in 2006. The managed health care and Medicaid rebates as a percentage of gross revenue subject to discounts and allowances have declined from 1.7% and 2.8%, respectively, in 2004, to 1.1% and 0.6% in 2005, and to 1.2% and 0.4% in 2006, respectively. These changes are due primarily to changes in the product mix.



Cash discounts as a percentage of gross revenue subject to discounts and allowances remained fairly consistent at 1.9% in 2004, compared to 2.0% in 2005 and to 2.1% in 2006. In the United States, we offer cash discounts, generally at 2% of the sales price, as an incentive for prompt payment by our customers.

Sales returns as a percentage of gross revenue subject to discounts and allowances increased from 2.4% in 2004 to 7.6% in 2005, and decreased to 0.2% in 2006. The increase in 2005, compared to 2004 and 2006, was principally due to the voluntary suspension of *Tysabri* in February 2005, which increased the provision for returns in 2005, and changes in the product mix.

**Table of Contents**

The following table sets forth the activities and ending balances of each significant category of adjustments for the sales discounts and allowances (in millions):

	<b>Charge-Backs</b>	<b>Managed Health Care Rebates and Other Contract Discounts</b>	<b>Medicaid Rebates</b>	<b>Cash Discounts</b>	<b>Sales Returns</b>	<b>Other Adjustments</b>	<b>Total</b>
Balance at December 31, 2004	\$ 8.9	\$ 2.1	\$ 1.7	\$ 0.4	\$ 8.6	\$ 0.4	\$ 22.1
Provision related to sales made in current period	22.8	2.9	1.6	5.5	22.4	2.5	57.7
Provision related to sales made in prior periods					(1.5)		(1.5)
Returns and payments	(24.9)	(3.3)	(1.9)	(5.0)	(22.8)	(2.4)	(60.3)
Divestments	(0.1)	(0.3)	(0.3)		(0.1)		(0.8)
Balance at December 31, 2005	6.7	1.4	1.1	0.9	6.6	0.5	17.2
Provision related to sales made in current period	28.6	3.7	1.2	6.5	2.3	3.3	45.6
Provision related to sales made in prior periods					(1.7)		(1.7)
Returns and payments	(28.6)	(3.5)	(1.4)	(6.3)	(2.0)	(2.8)	(44.6)
Balance at December 31, 2006	\$ 6.7	\$ 1.6	\$ 0.9	\$ 1.1	\$ 5.2	\$ 1.0	\$ 16.5

**(a) Charge-backs**

In the United States, we participate in charge-back programs with a number of entities, principally the US Department of Defense, the US Department of Veterans Affairs, Group Purchasing Organizations and other parties whereby pricing on products is extended below wholesalers' list prices to participating entities. These entities purchase products through wholesalers at the lower negotiated price, and the wholesalers charge the difference between these entities' acquisition cost and the lower negotiated price back to us. We account for charge-backs by reducing accounts receivable in an amount equal to our estimate of charge-back claims attributable to a sale. We determine our estimate of the charge-backs primarily based on historical experience on a product-by-product and program basis, and current contract prices under the charge-back programs. We consider vendor payments, estimated levels of inventory in the distribution channel, and our claim processing time lag and adjust accounts receivable and revenue periodically throughout each year to reflect actual and future estimated experience.

As described above, there are a number of factors involved in estimating the accrual for charge-backs, but the principal factor relates to our estimate of the levels of inventory in the distribution channel. At December 31, 2006, *Maxipime* and *Azactam* represented approximately 91.7% and 7.2%, respectively, of the total charge-backs accrual balance of \$6.7 million. If we were to increase/(decrease) our estimated level of inventory in the distribution channel by one month's worth of demand for *Maxipime* and *Azactam*, the accrual for charge-backs would increase/(decrease) by approximately \$2.7 million. We believe that our estimate of the levels of inventory for *Maxipime* and *Azactam* in the distribution channel is reasonable because it is based upon multiple sources of information, including data received from all of the major wholesalers with respect to their inventory levels and sell-through to customers, third-party market research data, and our internal information.

***(b) Managed health care rebates and other contract discounts***

We offer rebates and discounts to managed health care organizations in the United States. We account for managed health care rebates and other contract discounts by establishing an accrual equal to our estimate of the amount attributable to a sale. We determine our estimate of this accrual primarily based on historical experience on a product-by-product and program basis and current contract prices. We consider the sales performance of products subject to managed health care rebates and other contract discounts, processing claim lag time and estimated levels

**Table of Contents**

of inventory in the distribution channel, and adjust the accrual and revenue periodically throughout each year to reflect actual and future estimated experience.

As described above, there are a number of factors involved in estimating this accrual, but the principal factor relates to our estimate of the levels of inventory in the distribution channel. At December 31, 2006, *Maxipime* and *Azactam* represented approximately 67.7% and 29.2%, respectively, of the total managed health care rebates and other contract discounts accrual balance of \$1.6 million. If we were to increase/(decrease) our estimated level of inventory in the distribution channel by one month's worth of demand for *Maxipime* and *Azactam*, the accrual would increase/(decrease) by approximately \$0.3 million. We believe that our estimate of the levels of inventory for *Maxipime* and *Azactam* in the distribution channel is reasonable because it is based upon multiple sources of information, including data received from all of the major wholesalers with respect to their inventory levels and sell-through to customers, third-party market research data, and our internal information.

***(c) Medicaid rebates***

In the United States, we are required by law to participate in state government-managed Medicaid programs as well as certain other qualifying federal and state government programs whereby discounts and rebates are provided to participating state and local government entities. Discounts and rebates provided through these other qualifying federal and state government programs are included in our Medicaid rebate accrual and are considered Medicaid rebates for the purposes of this discussion. We account for Medicaid rebates by establishing an accrual in an amount equal to our estimate of Medicaid rebate claims attributable to a sale. We determine our estimate of the Medicaid rebates accrual primarily based on historical experience regarding Medicaid rebates, legal interpretations of the applicable laws related to the Medicaid and qualifying federal and state government programs, and any new information regarding changes in the Medicaid programs' regulations and guidelines that would impact the amount of the rebates on a product-by-product basis. We consider outstanding Medicaid claims, Medicaid payments, claims processing lag time and estimated levels of inventory in the distribution channel and adjust the accrual and revenue periodically throughout each year to reflect actual and future estimated experience.

***(d) Cash discounts***

In the United States, we offer cash discounts, generally at 2% of the sales price, as an incentive for prompt payment. We account for cash discounts by reducing accounts receivable by the full amount of the discounts. We consider payment performance of each customer and adjust the accrual and revenue periodically throughout each year to reflect actual experience and future estimates.

***(e) Sales returns***

We account for sales returns in accordance with SFAS 48 by establishing an accrual in an amount equal to our estimate of revenue recorded for which the related products are expected to be returned.

For returns of established products, our sales return accrual is estimated principally based on historical experience, the estimated shelf life of inventory in the distribution channel, price increases, and our return goods policy (goods may only be returned six months prior to expiration date and for up to twelve months after expiration date). We also take into account product recalls and introductions of generic products. All of these factors are used to adjust the accrual and revenue periodically throughout each year to reflect actual and future estimated experience.

In the event of a product recall, product discontinuance or introduction of a generic product, we consider a number of factors, including the estimated level of inventory in the distribution channel that could potentially be returned, historical experience, estimates of the severity of generic product impact, estimates of continuing demand and our

return goods policy. We consider the reasons for, and impact of, such actions and adjust the sales returns accrual and revenue as appropriate.

Returns from newly introduced products are significantly more difficult for us to assess. We determine our estimate of the sales return accrual primarily based on the historical sales returns experience of similar products, such as those within the same or similar therapeutic category. We also consider the shelf life of new products and

**Table of Contents**

determine whether we believe an adjustment to the sales return accrual is appropriate. The shelf life in connection with new products tends to be shorter than the shelf life for more established products because we may still be developing the optimal stability duration for the new product that would lengthen its shelf life, or an amount of launch quantities may have been manufactured in advance of the launch date to ensure sufficient supply exists to satisfy market demand. In those cases, we assess the reduced shelf life, together with estimated levels of inventory in the distribution channel and projected demand, and determine whether we believe an adjustment to the sales return accrual is appropriate. While it is inherently more difficult to assess returns from newly introduced products than from established products, nevertheless in all instances we believe we have been able to gather sufficient information in order to establish reasonable estimates.

As described above, there are a number of factors involved in estimating this accrual, but the principal factor relates to our estimate of the shelf life of inventory in the distribution channel. At December 31, 2006, *Maxipime* and *Azactam* represented approximately 32.5% and 63.3%, respectively, of the total sales returns accrual balance of \$5.2 million. At December 31, 2006, we have estimated the gross revenue value of *Maxipime* and *Azactam* inventory in the distribution channel to be approximately \$22.5 million (2005: \$32.1 million) and \$10.0 million (2005: \$5.5 million), respectively. Assuming inventory leaves the distribution channel on a first-in first-out basis, we have estimated that this distribution channel inventory has a shelf life running to various dates during 2008 (gross revenue value approximately \$1.5 million) and 2009 (gross revenue value approximately \$31.0 million). *Azactam* lost its patent exclusivity in October 2005; however, to date no generic *Azactam* product has been approved. We believe, based upon both the estimated shelf life and also our historical sales returns experience, that the vast majority of this inventory will be sold prior to its expiration date, and accordingly believe that our sales returns accrual is appropriate.

***(f) Other adjustments***

In addition to the significant sales discounts and allowances described above, we make other individually insignificant sales adjustments. We generally account for these other sales discounts and allowances by establishing an accrual in an amount equal to our estimate of the adjustments attributable to the sale. We generally determine our estimates of the accruals for these other adjustments primarily based on historical experience, performance on commitments to government entities and other relevant factors, including estimated levels of inventory in the distribution channel in some cases, and adjust the accruals and revenue periodically throughout each year to reflect actual experience.

***(g) Provisions related to sales made in prior periods***

During 2006, we recorded \$1.7 million of adjustments to reduce the discounts and allowances related to sales made in prior periods, primarily due to the availability of additional information relating to our actual returns experience for *Maxipime* and *Azactam*.

***(h) Divestments***

Since the beginning of 2003 we have divested a number of businesses, including principally our primary care franchise, Frova<sup>™</sup>, Zonegran and our European sales and marketing business. The divestment adjustments arise primarily as a result of the negotiated terms of these divestments. For example, we have entered into terms that would either extend or limit our liability for discounts and allowances related to the divested businesses. We have accordingly adjusted our discounts and allowances accruals to reflect the terms of the agreements. Divestment adjustments also include post-divestment revisions resulting from the availability of additional information. Divestment adjustments are recorded as part of the gain/(loss) on sale of businesses, and not as an increase or decrease from gross revenue.



**Table of Contents**

***(i) Use of information from external sources***

We use information from external sources to estimate our significant sales discounts and allowances. Our estimates of inventory at the wholesalers are based on:

The actual and projected prescription demand-based sales for our products and historical inventory experience;

Our analysis of third-party information, including written and oral information obtained from all of the major wholesalers with respect to their inventory levels and sell-through to customers, and third-party market research data; and

Our internal information.

The inventory information received from wholesalers is a product of their record-keeping process and excludes inventory held by intermediaries to whom they sell, such as retailers and hospitals. We receive information from IMS Health, a supplier of market research to the pharmaceutical industry, which we use to project the prescription demand-based sales for our pharmaceutical products. We also use information from external sources to identify prescription trends and patient demand. Up to 2004, we received inventory pipeline data from IMS Health. Since 2004, IMS Health no longer provides this service and we have been receiving such pipeline data directly from the three major wholesalers (McKesson Corp., Cardinal Health, Inc. and AmerisourceBergen Corp.). Our estimates are subject to inherent limitations of estimates that rely on third-party information, as certain third-party information is itself in the form of estimates, and reflect other limitations including lags between the date as of which third-party information is generated and the date on which we receive such information.

***RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS***

In February 2007, the FASB issued Statement No. 159, *The Fair Value Option for Financial Assets and Financial and Financial Liabilities*, (SFAS 159), which is effective as of the beginning of fiscal years beginning after November 15, 2007. SFAS 159 provides companies with the option to measure specified financial instruments and warranty and insurance contracts at fair value on a contract-by-contract basis, with changes in fair value recognized in earnings each reporting period. We are currently evaluating the provisions of SFAS 159, however we do not expect that its adoption will have a material impact on our financial position or results of operations.

In September 2006, the FASB issued Statement No. 157, *Fair Value Measurements*, (SFAS 157), which is effective for financial statements issued for fiscal years beginning after November 15, 2007. SFAS 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. We do not expect that the adoption of SFAS 157 will have a material impact on our financial position or results from operations.

In July 2006, the FASB issued Interpretation No. 48, *Accounting for Uncertainty in Income Taxes*, (FIN 48), which is effective for fiscal years beginning after December 15, 2006. FIN 48 applies to all tax positions related to income taxes subject to Statement No. 109, *Accounting for Income Taxes*. Under FIN 48, a company would recognize the benefit from a tax position only if it is more-likely-than-not that the position would be sustained upon audit based solely on the technical merits of the tax position. FIN 48 clarifies how a company would measure the income tax benefits from the tax positions that are recognized, provides guidance as to the timing of the derecognition of previously recognized tax benefits and describes the methods for classifying and disclosing the liabilities within the financial statements for any unrecognized tax benefits. FIN 48 also addresses when a company should record interest and penalties related to tax positions and how the interest and penalties may be classified within the income statement



and presented in the balance sheet. We do not expect that the adoption of FIN 48 will have a material impact on our financial position or results from operations.

In September 2006, the FASB issued Statement No. 158, *Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans - An Amendment of FASB No. 87, 88, 106 and 132R*, (SFAS 158). SFAS 158 requires that the funded status of defined benefit postretirement plans be recognized on the company's balance sheet, and changes in the funded status be reflected in comprehensive income, effective fiscal years ending after December 15, 2006. The standard also requires companies to measure the funded status of the plan as of the date of

**Table of Contents**

its fiscal year-end, effective for fiscal years ending after December 15, 2008. We adopted SFAS 158 as of December 31, 2006. See Note 26 to the Consolidated Financial Statements for additional details.

In September 2006, the SEC issued SAB No. 108, *Considering the Effects of Prior Year Misstatements When Quantifying Misstatements in Current Year Financial Statements*, (SAB 108) which provides interpretive guidance on how registrants should quantify financial statement misstatements. Under SAB 108 registrants are required to consider both a rollover method which focuses primarily on the income statement impact of misstatements and the iron curtain method which focuses primarily on the balance sheet impact of misstatements. The transition provisions of SAB 108 permit a registrant to adjust retained earnings for the cumulative effect of immaterial errors relating to prior years. We were required to adopt SAB 108 in our current fiscal year. There were no historical uncorrected differences that required correction upon adoption of SAB 108 and consequently there were no changes made to the opening retained earnings balance.

In May 2005, the FASB issued Statement No. 154, *Accounting Changes and Error Corrections*, (SFAS 154), which changes the requirements for the accounting for and reporting of a change in accounting principle. Previously, most voluntary changes in accounting principles required recognition via a cumulative effect adjustment within net income of the period of the change. SFAS 154 requires retrospective application to prior periods financial statements, unless it is impracticable to determine either the period-specific effects or the cumulative effect of the change. However, SFAS 154 does not change the transition provisions of any existing accounting pronouncements. The provisions were effective for Elan beginning in the first quarter of fiscal year 2006.

*POST BALANCE SHEET EVENTS*

In December 2006, Elan issued an early redemption notice for the 7.25% senior notes (Athena Notes), which were due in February 2008. In January 2007, the remaining aggregate principal amount of \$613.2 million of the Athena Notes was redeemed and the related \$300.0 million of interest rate swaps were cancelled. As a result, Elan will record a net charge on debt retirement of approximately \$20 million in 2007. As of December 31, 2006, the \$613.2 million of aggregate principal amount for the Athena Notes were classified as current liabilities.

**Table of Contents****A. OPERATING RESULTS***2006 Compared to 2005 (in millions, except share and per share amounts)*

	<b>2006</b>	<b>2005</b>	<b>% Increase/ (Decrease)</b>
Product revenue	\$ 532.9	\$ 458.1	16%
Contract revenue	27.5	32.2	(15)%
Total revenue	560.4	490.3	14%
Operating expenses:			
Cost of sales	211.2	196.1	8%
Selling, general and administrative expenses	363.1	358.4	1%
Research and development expenses	215.9	233.3	(7)%
Net gain on divestment of products and businesses	(43.1)	(103.4)	(58)%
Other net (gains)/charges	(20.3)	4.4	(561)%
Total operating expenses	726.8	688.8	6%
Operating loss	(166.4)	(198.5)	(16)%
Net interest and investment (gains) and losses:			
Net interest expense	111.5	125.7	(11)%
Net investment (gains)/losses	(1.6)	7.2	(122)%
Net charge on debt retirements		51.8	(100)%
Net interest and investment losses	109.9	184.7	(41)%
Loss from continuing operations before provision for/(benefit from) income taxes	(276.3)	(383.2)	(28)%
Provision for/(benefit from) income taxes	(9.0)	1.0	(1,000)%
Net loss from continuing operations	(267.3)	(384.2)	(30)%
Net income from discontinued operations (net of tax)		0.6	(100)%
Net loss	\$ (267.3)	\$ (383.6)	(30)%
Basic and diluted net loss per ordinary share:			
Net loss from continuing operations	\$ (0.62)	\$ (0.93)	(33)%
Net income from discontinued operations (net of tax)			
Net loss	\$ (0.62)	\$ (0.93)	(33)%



**Table of Contents****Product Revenue**

Total product revenue increased 16% to \$532.9 million in 2006 from \$458.1 million in 2005. The increase was primarily due to the growth of revenue from marketed products and manufacturing revenue and royalties, partially offset by a decrease in amortized revenue. The components of product revenue are set out below (in millions):

	2006	2005	% Increase/ (Decrease)
(A) Marketed products			
Tysabri- US	\$ 28.2	\$ 11.0	156%
Tysabri- EU	(10.7)		
Maxipime	159.9	140.3	14%
Azactam	77.9	57.7	35%
Prialt	12.1	6.3	92%
Total revenue from marketed products	267.4	215.3	24%
(B) Manufacturing revenue and royalties	234.8	207.1	13%
(C) Amortized revenue Adalat/Avinza	30.7	34.0	(10)%
Revenue from divested products <sup>(1)</sup>		1.7	(100)%
Total product revenue	\$ 532.9	\$ 458.1	16%

(1) Products described as *Divested Products* include products or businesses divested since the beginning of 2004.

**(A) Revenue from marketed products**

Total revenue from marketed products increased 24% to \$267.4 million in 2006 from \$215.3 million in 2005. The increase reflects higher sales of *Tysabri*, *Maxipime*, *Azactam* and *Prialt*.

In June 2006, the FDA approved the re-introduction of *Tysabri* for the treatment of relapsing forms of MS. Approval for the marketing of *Tysabri* in the European Union was also received in June 2006 and, in October 2006, approval was received for the marketing of *Tysabri* in Canada. The distribution of *Tysabri* in both the United States and European Union commenced in July 2006. Global in-market net sales of *Tysabri* in 2006 were \$38.1 million, consisting of \$28.2 million in the United States and \$9.9 million in the European Union, compared to \$11.0 million in 2005.

*Tysabri* was developed and is now being marketed in collaboration with Biogen Idec. In general, subject to certain limitations imposed by the parties, we share with Biogen Idec most development and commercialization costs. Biogen Idec is responsible for manufacturing the product. In the United States, we purchase *Tysabri* from Biogen Idec and are responsible for distribution. Consequently, we record as revenue the net sales of *Tysabri* in the US market. We purchase product from Biogen Idec as required at a price which includes the cost of manufacturing, plus Biogen Idec's gross profit on *Tysabri* and this cost, together with royalties payable to other third parties, is included in cost of sales. During 2006, Elan recorded net sales of \$28.2 million (2005: \$11.0 million) in the US market.



**Table of Contents**

In the EU market, Biogen Idec is responsible for distribution and we record as revenue our share of the profit or loss on EU sales of *Tysabri*, plus our directly-incurred expenses on these sales. In 2006, Elan recorded negative revenue of \$10.7 million (2005: \$Nil), which was calculated as follows:

	<b>2006</b>
EU in-market sales by Biogen Idec	\$ 9.9
EU operating expenses incurred by Elan and Biogen Idec	(34.3)
EU operating loss incurred by Elan and Biogen Idec	(24.4)
Elan's 50% share of Tysabri EU collaboration operating loss	(12.2)
Elan's directly-incurred costs	1.5
Net Tysabri EU negative revenue	\$ (10.7)

*Maxipime* revenue increased 14% to \$159.9 million in 2006 from \$140.3 million in 2005. The increase primarily reflects growth in the demand for the product. The basic patent on *Maxipime* will expire in March 2007. Two other US patents covering *Maxipime* formulations expire in February 2008. We expect generic competition for the product, which is expected to adversely impact future revenues.

*Azactam* revenue increased 35% to \$77.9 million in 2006 from \$57.7 million in 2005 primarily due to increased demand. *Azactam* lost its patent exclusivity in October 2005 and its sales are expected to be adversely impacted by generic competition. However, to date, no generic *Azactam* product has been approved.

*Prialt* revenue increased to \$12.1 million in 2006 from \$6.3 million in 2005, which was primarily due to increased demand. *Prialt* was launched in the US market in the first quarter of 2005. In March 2006, we completed the sale of the European rights to *Prialt* to Eisai, while retaining the product rights in the United States. We had not made any commercial sales of *Prialt* in Europe prior to this divestment.

**(B) Manufacturing revenue and royalties**

Manufacturing revenue and royalties are as follows (in millions):

	<b>2006</b>	<b>2005</b>	<b>% Increase/ (Decrease)</b>
Tricor	\$ 52.1	\$ 45.4	15%
Skelaxin™	36.5	17.9	104%
Verelan™	36.3	34.7	5%
Focalin/Ritalin	22.5	17.8	26%
Diltiazem	19.5	18.6	5%
Other	67.9	72.7	(7)%

Total	\$ 234.8	\$ 207.1	13%
-------	----------	----------	-----

Manufacturing revenue and royalties from our EDT business comprises revenue earned from products we manufacture for third parties and royalties we earn principally on sales by third parties of products that incorporate our technologies.

Manufacturing revenue and royalties increased 13% to \$234.8 million in 2006 from \$207.1 million in 2005. The increase was primarily due to increased royalties on sales by third parties, primarily Tricor and Skelaxin, and increased manufacturing activity. In January 2006, our royalty on Skelaxin changed from 5% on all net sales of the product by King Pharmaceuticals, Inc. (King) in 2005, to 10% on net sales in excess of \$50.0 million in each calendar year going forward. Except as noted above, no other single product accounted for more than 10% of our manufacturing revenue and royalties in either 2006 or 2005. In 2006, 40% of these revenues consisted of royalties received on products that we do not manufacture, compared to 34% in 2005.



**Table of Contents*****(C) Amortized revenue Adalat/Avinza***

Amortized revenue of \$30.7 million in 2006 (2005: \$34.0 million) related to the licensing to Watson Pharmaceuticals, Inc. (Watson) of rights to our generic form of Adalat CC (\$9.0 million) and the restructuring of our Avinza license agreement with Ligand Pharmaceuticals, Inc (Ligand) (\$21.7 million). Both of these transactions occurred in 2002. The remaining \$4.5 million of unamortized deferred revenue relating to Adalat CC will be recognized as revenue during 2007. The deferred revenue relating to Avinza was fully amortized by December 31, 2006.

***Contract Revenue***

	<b>2006</b>	<b>2005</b>	<b>% Increase/ (Decrease)</b>
	<b>(In millions)</b>		
Amortized fees	\$ 12.7	\$ 16.4	(23)%
Research revenues/milestones	14.8	15.8	(6)%
Total contract revenue	\$ 27.5	\$ 32.2	(15)%

Contract revenue consists of research revenue and milestones arising from R&D activities we perform on behalf of third parties. The decrease in contract revenue was primarily due to the timing of milestone receipts and a reduction in R&D activities for third parties.

***Cost of Sales***

Cost of sales was \$211.2 million in 2006 (including share-based compensation of \$4.2 million), compared to \$196.1 million in 2005 (including share-based compensation of \$Nil). The cost of sales as a percentage of product revenue was 40% for 2006 and 43% for 2005, resulting in a gross profit margin of 60% in 2006 and 57% in 2005. The improvement in gross profit margin was primarily due to the change in the mix of product sales and the inclusion in 2005 of costs related to the voluntary suspension of *Tysabri* in the United States.

***Selling, General and Administrative Expenses (SG&A)***

SG&A expenses were \$363.1 million in 2006, compared to \$358.4 million in 2005, and included \$75.0 million (2005: \$84.7 million) in relation to *Tysabri*. The increase in total SG&A expenses reflects the expensing of share-based compensation of \$28.8 million in 2006 (2005: \$Nil), offset by decreased expenses in relation to *Tysabri* and also due to ongoing financial discipline. The decrease in SG&A expenses related to *Tysabri* reflects the impact of the temporary suspension of *Tysabri* in 2005, the re-launch of *Tysabri* in the United States in 2006, and the launch of *Tysabri* in the European Union in 2006, partially offset by the expensing of shared-based compensation of \$2.5 million (2005: \$Nil).

***Research and Development Expenses***

R&D expenses were \$215.9 million in 2006, compared to \$233.3 million in 2005, and included \$31.6 million (2005: \$66.9 million) in relation to *Tysabri*. This reduction of 7% reflects the completion of the safety evaluation related to

*Tysabri* in 2005, offset by increased spending relating to the progression of key Alzheimer's programs, particularly AAB-001, the initiation of new collaborations in the areas of autoimmune diseases and neurodegeneration with Archemix and Transition, and by the cost of expensing share-based compensation of \$14.1 million in 2006 (2005: \$Nil).

**Table of Contents*****Net Gain on Divestment of Products and Businesses***

	<b>2006</b>	<b>2005</b>
	<b>(In millions)</b>	
Prialt European rights	\$ (43.3)	\$
Zonegran		(85.6)
European business	0.2	(17.1)
Other		(0.7)
<b>Total</b>	<b>\$ (43.1)</b>	<b>\$ (103.4)</b>

In March 2006, we sold the *Prialt* European rights to Eisai. We received \$50.0 million at closing and are entitled to receive an additional \$10.0 million on the earlier of two years from closing or launches of *Prialt* in key European markets. We recorded a gain of \$43.3 million on this sale. We may also receive an additional \$40.0 million contingent on *Prialt* achieving revenue related milestones in Europe. As of December 31, 2006, we have received \$4.0 million of the \$10.0 million related to the launches of *Prialt* in key European markets.

In April 2004, we sold our interests in Zonegran in North America and Europe to Eisai for initial net consideration of \$113.5 million at closing. We were also entitled to receive additional consideration of up to \$110.0 million from Eisai if no generic Zonegran was approved by certain dates up through January 1, 2006. We received \$85.0 million of this contingent consideration prior to the approval of generic Zonegran in December 2005. Consequently, the total net proceeds received from the sale of Zonegran amounted to \$198.5 million and resulted in a cumulative net gain of \$128.5 million, of which \$85.6 million was recognized in 2005 and \$42.9 million in 2004.

In February 2004, we sold our European sales and marketing business to Zeneus Pharma Ltd. (Zeneus) for initial net cash proceeds of \$93.2 million, resulting in a loss of \$2.9 million in 2004. We received an additional \$6.0 million in February 2005, which was accrued at December 31, 2004, and \$15.0 million of contingent consideration in December 2005, which resulted in a net gain of \$17.1 million in 2005 after the release of contingent liabilities of \$2.1 million, which were not ultimately required. We will not receive any further consideration in respect of this disposal.

***Other Net (Gains)/Charges***

The principal items classified as other charges/(gains) include acquired in-process research and development, severance, restructuring and other costs, legal settlements and awards, and losses incurred from certain litigation or regulatory actions. These items have been treated consistently from period to period. We believe that disclosure of significant other charges/(gains) is meaningful because it provides additional information in relation to these material items.

	<b>2006</b>	<b>2005</b>
	<b>(In millions)</b>	
(A) Acquired in-process research and development costs	\$ 22.0	\$
(B) Legal settlements and awards	(49.8)	(7.4)
(C) Severance, restructuring and other costs, net	7.5	11.8

Total other net (gains)/charges	\$ (20.3)	\$ 4.4
---------------------------------	-----------	--------

***(A) Acquired in-process research and development costs***

In July 2006, Elan and Archemix entered into a multi-year, multi-product alliance focused on the discovery, development and commercialization of aptamer therapeutics to treat autoimmune diseases. As a result of the alliance, Elan paid Archemix an upfront payment of \$7.0 million. In addition, in September 2006, Elan and Transition announced an exclusive, worldwide collaboration agreement for the joint development and commercialization of AZD-103, for the treatment of Alzheimer's disease. Elan incurred a charge related to the license fee of \$15.0 million, of which \$7.5 million was paid to Transition in the fourth quarter of 2006 and the

**Table of Contents**

remaining balance is due to be paid in 2007. For additional information, please refer to Item 4B. Business Overview, which describes our R&D programs in detail.

***(B) Legal settlements and awards***

In December 2006, we were awarded \$49.8 million following the conclusion of binding arbitration proceedings which were initiated against King with respect to an agreement to reformulate Sonata<sup>®</sup>. This award was recognized as a gain in 2006 and was received in January 2007.

During 2005, we recorded a net gain of \$7.4 million related primarily to the Pfizer litigation settlement in which we received a payment of \$7.0 million. The settlement arose from a claim concerning intellectual property rights and the development of target compounds arising from a collaboration with Pfizer.

***(C) Severance, restructuring and other costs***

During 2006, we incurred net severance, restructuring and other costs of \$7.5 million (2005: \$11.8 million) arising from the realignment of our resources to meet our current business structure. The restructuring and severance charges in 2006 were primarily related to the consolidation of our Biopharmaceuticals R&D activities into our South San Francisco facility. These charges arose from termination of certain operating leases, reduction and relocation of employees, and they include the reversal of a \$9.4 million charge for future lease payments on an unutilized facility in South San Francisco. As a part of the restructuring of our Biopharmaceutical R&D activities, this facility has now been brought back into use.

***Net Interest Expense***

Net interest expense was \$111.5 million in 2006, compared to \$125.7 million in 2005. The decrease of 11% primarily reflects the decrease in interest expense associated with the early retirement of \$36.8 million of the Athena Notes due in 2008 and the early conversion of \$206.0 million in aggregate principal amount of 6.5% Convertible Notes in the second quarter of 2005 and increased income associated with higher cash balances and interest rates, partially offset by interest expense related to the 8.875% senior notes due in 2013 (8.875% Notes) and senior floating rate notes due in 2013 (Floating Rate Notes due 2013), both of which were issued in November 2006.

***Net Investment (Gains)/Losses***

Net investment gains were \$1.6 million in 2006, compared to a loss of \$7.2 million in 2005. The net investment gains were primarily comprised of gains on the sale and maturity of investment securities of \$8.3 million (2005: \$17.5 million) and impairment of investments of \$7.3 million (2005: \$24.0 million). In 2006, we raised \$14.1 million (2005: \$62.7 million) in net cash proceeds from the disposal of investment securities. The \$8.3 million in gains on the sale and maturity of investment securities in 2006 includes gains on sale of securities of Salu, Inc. of \$3.0 million, Nobex Corporation of \$2.5 million and Women First Healthcare, Inc. of \$1.0 million. The \$17.5 million of gains on the sale and maturity of investment securities in 2005 included a gain on the sale of securities of Allergy Therapeutics plc of \$10.0 million, Iomai Corporation of \$3.2 million and Emisphere Technologies, Inc. of \$1.8 million.

During 2006, investment impairment charges of \$7.3 million (2005: \$24.0 million) reflect other-than-temporary impairments to the value of a number of investments, primarily in emerging pharmaceutical and biotechnology companies.

***Net Charge on Debt Retirements***

In June 2005, we incurred a net charge of \$51.8 million associated with the early retirement of \$36.8 million of the Athena Notes due in 2008 and the early conversion of \$206.0 million in aggregate principal amount of the 6.5% Convertible Notes due in 2008. For additional information, please refer to Note 18 to the Consolidated Financial Statements.

**Table of Contents*****Provision for/(Benefit from) Income Taxes***

We had a net tax benefit of \$9.0 million for 2006, compared to a net tax provision of \$1.0 million for 2005. The overall tax benefit for 2006 was \$11.0 million. Of this amount, \$2.0 million has been credited to shareholders' equity to reflect utilization of stock option deductions. The remaining \$9.0 million benefit is allocated to ordinary activities. The tax benefit reflected the availability of tax losses, tax at standard rates in the jurisdictions in which we operate, income derived from Irish patents and foreign withholding tax. Our Irish patent derived income was exempt from tax pursuant to Irish legislation, which exempts from Irish tax income derived from qualifying patents. Currently, there is no termination date in effect for such exemption. For additional information regarding tax, please refer to Note 21 to the Consolidated Financial Statements.

***2005 Compared to 2004 (in millions, except share and per share amounts)***

	<b>2005</b>	<b>2004</b>	<b>% Increase/ (Decrease)</b>
Product revenue	\$ 458.1	\$ 404.4	13%
Contract revenue	32.2	77.3	(58)%
Total revenue	490.3	481.7	2%
Operating expenses:			
Cost of sales	196.1	173.6	13%
Selling, general and administrative expenses	358.4	337.3	6%
Research and development expenses	233.3	257.3	(9)%
Net gain on sale of products and businesses	(103.4)	(44.2)	134%
Other net (gains)/charges	4.4	59.8	(93)%
Total operating expenses	688.8	783.8	(12)%
Operating loss	(198.5)	(302.1)	(34)%
Net interest and investment (gains) and losses:			
Net interest expense	125.7	109.0	15%
Net investment (gains)/losses	7.2	(42.8)	117%
Net charge on debt retirements	51.8		
Charge arising from guarantee to EPIL II noteholders		47.1	(100)%
Net interest and investment losses	184.7	113.3	63%
Loss from continuing operations before provision for/(benefit from) income taxes	(383.2)	(415.4)	(8)%
Provision for/(benefit from) income taxes	1.0	(1.7)	159%
Net loss from continuing operations	(384.2)	(413.7)	(7)%
Net income from discontinued operations (net of tax)	0.6	19.0	(97)%

Net loss	\$ (383.6)	\$ (394.7)	(3)%
Basic and diluted net loss per ordinary share:			
Net loss from continuing operations	\$ (0.93)	\$ (1.06)	(12)%
Net income from discontinued operations (net of tax)		0.05	(100)%
Net loss	\$ (0.93)	\$ (1.01)	(8)%

***Product Revenue***

The increase of 13% in total product revenue in 2005 was primarily due to the growth of product revenue from our core business. Product revenue from our core business increased 34% from 2004 and more than compensated



**Table of Contents**

for the loss of revenue from products divested during 2004. The components of product revenue are set out below (in millions):

	2005	2004	% Increase/ (Decrease)
(A) Marketed products			
Maxipime	\$ 140.3	\$ 117.5	19%
Azactam	57.7	50.6	14%
Tysabri	11.0	6.4	72%
Prialt	6.3		
Total revenue from marketed products	215.3	174.5	23%
(B) Manufacturing revenue and royalties	207.1	130.9	58%
(C) Amortized revenue Adalat/Avinza	34.0	34.0	0%
Total product revenue from core business	456.4	339.4	34%
(D) Divested products <sup>(1)</sup>			
European business <sup>(2)</sup>		10.5	(100)%
Zonegran <sup>(3)</sup>		41.2	(100)%
Other	1.7	13.3	(87)%
Total revenue from divested products	1.7	65.0	(97)%
Total product revenue	\$ 458.1	\$ 404.4	13%

(1) Products described as *Divested Products* include products or businesses divested since the beginning of 2004.

(2) Sold to Zeneus in February 2004.

(3) Sold to Eisai in April 2004.

**(A) Revenue from marketed products**

Total revenue from marketed products increased to \$215.3 million in 2005 from \$174.5 million in 2004. The increase of 23% primarily reflects higher sales of *Maxipime* and *Azactam*, and initial sales of *Tysabri* and *Prialt*. *Azactam* lost its patent exclusivity in October 2005, and the basic patent on *Maxipime* expires in March 2007. Two US patents covering *Maxipime* formulations may provide patent protection until February 2008. The expiration of these patents is expected to result in generic competition for these products, which is expected to adversely impact future revenues. However, to date, no generic *Azactam* product has been approved.

*Maxipime* revenue increased from \$117.5 million in 2004 to \$140.3 million in 2005. The 19% increase reflects growth in demand, a price increase of 8% taken at the end of 2004, and improved supply conditions. We experienced third

party supply shortages and disruptions with *Maxipime* during 2005. This led to a significant decline in inventories held by our wholesale customers and hospitals and, consequently, affected our ability to meet demand. The supply situation improved beginning in the third quarter of 2005.

As reported by IMS Health Inc., *Azactam* prescription demand for 2005 increased by 6% over 2004, while the corresponding revenues increased from \$50.6 million in 2004 to \$57.7 million in 2005, or 14%. The difference between prescription and revenue growth rates is due to changing wholesaler inventory levels and price increases taken during the period.

The FDA granted accelerated approval of *Tysabri* in late November 2004 for the treatment of patients in the United States with all forms of relapsing remitting MS. Revenue from *Tysabri* amounted to \$11.0 million in 2005 and \$6.4 million in 2004. The commercialization and clinical dosing of *Tysabri* was voluntarily suspended in February 2005. On March 7-8, 2006, the PCNS Advisory Committee reviewed and voted unanimously to recommend that *Tysabri* be reintroduced as a treatment for relapsing forms of MS. In June 2006, the FDA approved the re-introduction of *Tysabri* for the treatment of relapsing forms of MS. Approval for the marketing of *Tysabri* in the European Union was also received in June 2006, and in October 2006, approval was received for the

**Table of Contents**

marketing of *Tysabri* in Canada. The distribution of *Tysabri* in both the United States and European Union commenced in July 2006.

*Prialt*, a new treatment for severe chronic pain, was approved by the FDA in the United States in December 2004 and approved in Europe in February 2005. We began selling *Prialt* in the US market in early 2005 and revenue from sales of *Prialt* was \$6.3 million in 2005 (2004: \$Nil). On March 20, 2006, we completed the sale of the European rights to *Prialt* to Eisai, while retaining the product rights in the United States.

**(B) Manufacturing revenue and royalties**

Manufacturing revenue and royalties are as follows (in millions):

	2005	2004	% Increase/ (Decrease)
Tricor	\$ 45.4	\$ 4.5	909%
Verelan	34.7	27.8	25%
Diltiazem	18.6	19.3	(4)%
Skelaxin	17.9	12.2	47%
Ritalin	13.8	11.8	17%
Avinza	13.4	15.8	(15)%
Zanaflex <sup>tm</sup>	11.1		
Other	52.2	39.5	32%
Total	\$ 207.1	\$ 130.9	58%

Manufacturing revenue and royalties from our EDT business comprises revenue earned from products we manufacture for third parties and royalties we earn principally on sales by third parties of products that incorporate our technologies. The increase of 58% was primarily due to increased sales by third parties of products that incorporate Elan's technologies, predominantly Tricor, and increased manufacturing activity for third parties. Except as noted above, no other single product accounted for more than 10% of our manufacturing revenue and royalties in either 2005 or 2004. In 2005, 34% of these revenues consisted of royalties received on products that we do not manufacture, compared to 19% in 2004.

**(C) Amortized revenue - Adalat/Avinza**

Amortized revenue of \$34.0 million in both 2005 and 2004 related to the licensing to Watson Pharmaceuticals, Inc. (Watson) of rights to our generic form of Adalat CC (\$9.0 million) and the restructuring of our Avinza license agreement with Ligand Pharmaceuticals, Inc (Ligand) (\$25.0 million). Both of these transactions occurred in 2002. The remaining unamortized revenue on these products of \$35.2 million is included in deferred revenue, due to our ongoing involvement in the manufacturing of these products. Of the remaining \$35.2 million, \$13.5 million of the deferred revenue relates to generic Adalat CC and will be recognized as revenue through June 2007. The remaining deferred revenue of \$21.7 million relates to Avinza and will be recognized as revenue through November 2006.

**(D) Divested products**

During 2004, we sold a number of products and businesses as part of the recovery plan, which commenced in July 2002 and was completed in early 2004, and our subsequent strategic repositioning as a biotechnology company focused on a number of key therapeutic markets. The decrease in revenue from divested products in 2005 was primarily due to the divestment of a number of products and businesses during 2004, principally the European business and Zonegran, which are described below. No divestments occurred in 2005.

In February 2004, we completed the sale of our European sales and marketing business to Zeneus. Revenue for the divested European business was \$Nil for 2005 (2004: \$10.5 million).

In April 2004, we sold our interests in Zonegran for North America and Europe to Eisai. Zonegran generated revenue of \$Nil for 2005 (2004: \$41.2 million).

**Table of Contents*****Contract Revenue***

	<b>2005</b>	<b>2004</b>	<b>% Increase/ (Decrease)</b>
	<b>(In millions)</b>		
Amortized fees	\$ 16.4	\$ 17.6	(7)%
Research revenues/milestones	15.8	59.7	(74)%
Total contract revenue	\$ 32.2	\$ 77.3	(58)%

The decrease in contract revenue of 58% in 2005 is principally due to a reduction in research revenue and milestones arising from R&D activities we perform on behalf of third parties. The reduction resulted from, among other things, the timing of milestone receipts, the completion of transitional R&D activities related to certain divested products, and the suspension of activity related to Sonata.

***Cost of Sales***

Cost of sales was \$196.1 million in 2005, compared to \$173.6 million in 2004. The cost of sales as percentage of product revenue was 43% for both 2005 and 2004. The gross margin remained consistent with 2004 because of compensating changes in the mix of product revenues, the impact of the *Tysabri* voluntary suspension and the divestment of products in 2004.

***Selling, General and Administrative Expenses***

SG&A expenses were \$358.4 million in 2005, compared to \$337.3 million in 2004, and included \$84.7 million (2004: \$52.3 million) in relation to *Tysabri*. The increase of 6% reflects the costs of maintaining the *Tysabri* commercial infrastructure in place for the full year 2005 in anticipation of its potential return to market and the marketing cost of launching *Prialt* during 2005, offset by reduced costs in the rest of the business.

***Research and Development Expenses***

R&D expenses were \$233.3 million in 2005, compared to \$257.3 million in 2004, and included \$66.9 million (2004: \$84.2 million) in relation to *Tysabri*. The decrease of 9% reflects cost containment initiatives, the refocusing of R&D efforts on key Alzheimer's disease programs, and reduced spending on *Tysabri* as a result of the completion of clinical trials, offset by the cost of the extensive *Tysabri* safety evaluation.

***Net Gain on Sale of Businesses***

	<b>2005</b>	<b>2004</b>
	<b>(In millions)</b>	
Zonegran	\$ (85.6)	\$ (42.9)
European business	(17.1)	2.9

Other	(0.7)	(4.2)
Total	\$ (103.4)	\$ (44.2)

In April 2004, we sold our interests in Zonegran in North America and Europe to Eisai for initial net consideration of \$113.5 million at closing. We were also entitled to receive additional consideration of up to \$110.0 million from Eisai if no generic Zonegran was approved by certain dates up through January 1, 2006. We received \$85.0 million of this contingent consideration prior to the approval of generic Zonegran in December 2005. Consequently, the total net proceeds received from the sale of Zonegran amounted to \$198.5 million and resulted in a cumulative net gain of \$128.5 million, of which \$85.6 million was recognized in 2005 and \$42.9 million in 2004.

In February 2004, we sold our European sales and marketing business to Zeneus for initial net cash proceeds of \$93.2 million, resulting in a loss of \$2.9 million in 2004. We received an additional \$6.0 million in February 2005, which was accrued at December 31, 2004, and \$15.0 million of contingent consideration in December 2005, which resulted in a net gain of \$17.1 million in 2005 after the release of contingent liabilities of \$2.1 million, which were not required ultimately. We will not receive any further consideration in respect of this disposal.

**Table of Contents*****Other Net (Gains)/Charges***

The principal items classified as other charges/(gains) include severance, relocation and exit costs, litigation settlement receipts, and losses incurred from certain litigation or regulatory actions, including shareholder class action litigation and the SEC investigation. These items have been treated consistently from period to period. Our management believes that disclosure of other charges/(gains) is meaningful because it provides additional information in relation to these material items.

	<b>2005</b>	<b>2004</b>
	<b>(In millions)</b>	
(A) Pfizer litigation settlement, shareholder litigation, and SEC investigation	\$ (7.4)	\$ 56.0
(B) Severance, restructuring and other costs	11.8	3.8
Total other net charges	\$ 4.4	\$ 59.8

***(A) Pfizer litigation settlement, shareholder litigation, and SEC investigation***

During 2005, we recorded a net gain of \$7.4 million related primarily to the Pfizer litigation settlement in which we received a payment of \$7.0 million. The settlement arose from a claim concerning intellectual property rights and the development of target compounds arising from a collaboration with Pfizer.

The \$56.0 million charge recorded in 2004 arose primarily as a result of a \$55.0 million provision made in relation to settlements of the SEC investigation and the related shareholder class action lawsuit. We and certain of our former and current officers and directors were named as defendants in a class action filed in early 2002 alleging that our financial statements were not prepared in accordance with GAAP, and that the defendants disseminated materially false and misleading information concerning our business and financial results. We agreed to settle the action in October 2004 and the settlement was formally approved by the US District Court for the Southern District of New York in February 2005. The terms of the class action settlement received final court approval in April 2005. Under the class action settlement, all claims against us and the other named defendants were dismissed with no admission or finding of wrongdoing on the part of any defendant. The principal terms of the settlement provide for an aggregate cash payment to class members of \$75.0 million, out of which the court awarded attorneys' fees to plaintiffs' counsel, and \$35.0 million was paid by our insurance carrier.

We were also the subject of an investigation by the SEC's Division of Enforcement regarding matters similar to those alleged in the class action. We provisionally settled the investigation in October 2004 and the SEC formally approved the settlement in February 2005. Under the settlement agreement reached with the SEC, we neither admitted nor denied the allegations contained in the SEC's civil complaint, which included allegations of violations of certain provisions of the federal securities laws. The settlement contains a final judgment restraining and enjoining us from future violations of these provisions. In addition, under the final judgment, we paid a civil penalty of \$15.0 million. In connection with the settlement, we were not required to restate or adjust any of our historical financial results or information.

For additional information on litigation which we are involved in, please refer to Note 28 to the Consolidated Financial Statements.

***(B) Severance, restructuring and other costs***

During 2005, we incurred severance, restructuring and other costs of \$11.8 million arising from the realignment of our resources to meet our current business structure. These expenses arose from termination of certain operating leases and a reduction in employee headcount.

During 2004, we incurred severance, restructuring and other costs arising from the implementation of our recovery plan of \$3.8 million. The recovery plan, which commenced in July 2002 and was completed in February 2004, involved the restructuring of our businesses, assets and balance sheet. These expenses arose from a reduction in the scope of our activities and a reduction in employee headcount.



**Table of Contents*****Net Interest Expense***

Net interest expense was \$125.7 million in 2005, compared to \$109.0 million in 2004. The increase of 15% primarily reflects the interest costs associated with the issuance of \$850.0 million of 7.75% senior fixed rate notes (7.75% Notes) and \$300.0 million of senior floating rate notes due in 2011 (Floating Rate Notes due 2011) in November 2004, partially offset by the impact of the repayment of the Elan Pharmaceutical Investments III Ltd. (EPIL III) Series B and C guaranteed notes (collectively, EPIL III Notes) in November 2004, the early retirement of \$36.8 million of the Athena Notes due in 2008 and the early conversion of \$206.0 million in aggregate principal amount of 6.5% Convertible Notes due in 2008 in the second quarter of 2005, and increased interest income associated with higher cash balances and interest rates.

***Net Investment (Gains)/Losses***

Net investment losses were \$7.2 million in 2005, compared to net investment gains of \$42.8 in 2004. The net investment losses in 2005 comprised primarily of gains on sale and maturity of investment securities of \$17.5 million (2004: \$106.2) and impairment of investments of \$24.0 million (2004: \$72.4 million). In 2005, we raised \$62.7 million (2004: \$255.5 million) in net cash proceeds from the disposal of investment securities. The \$17.5 million in gains on the sale and maturity of investment securities in 2005 includes gains on the sale of securities of Allergy Therapeutics plc of \$10.0 million, Iomai Corporation of \$3.2 million and Emisphere Technologies, Inc. of \$1.8 million. The \$106.2 million in gains on the sale and maturity of investment securities in 2004 included a gain on the sale of securities of Warner Chilcott plc of \$43.6 million, DOV Pharmaceutical, Inc. of \$22.6 million, Curis, Inc. of \$15.3 million and Atrix Laboratories of \$13.1 million.

During 2005, investment impairment charges of \$24.0 million (2004: \$72.4 million) reflect other-than-temporary impairments to the value of a number of investments, primarily in privately-held biotech companies.

***Net Charge on Debt Retirements***

In June 2005, we incurred a net charge of \$51.8 million (2004: \$Nil) associated with the early retirement of \$36.8 million of the Athena Notes due in 2008 and the early conversion of \$206.0 million in aggregate principal amount of the 6.5% Convertible Notes due in 2008.

***Charge Arising from Guarantee to EPIL II Noteholders***

We had guaranteed EPIL II loan notes (EPIL II Notes) to the extent that the investments held by EPIL II were insufficient to repay the EPIL II Notes and accrued interest. EPIL II was a qualifying special purpose entity and was not consolidated under US GAAP. On June 28, 2004, the EPIL II Notes of \$450.0 million, together with accrued interest for the period from December 31, 2003 to June 28, 2004 of \$21.5 million, were repaid. Of the aggregate payment of \$471.5 million, \$79.7 million was funded from the cash resources in EPIL II and through the sale of EPIL II's entire investment portfolio. We funded the balance of \$391.8 million under our guarantee. This resulted in a charge of \$47.1 million in 2004, arising from interest of \$21.5 million and investment losses of \$25.6 million incurred by EPIL II during the first half of 2004.

***Provision for/(Benefit from) Income Taxes***

We had a net tax provision of \$1.0 million for 2005, compared to a net tax benefit of \$1.7 million for 2004. The overall tax provision for 2005 was \$0.4 million. Of this amount, \$0.6 million has been credited to shareholders' equity to reflect utilization of stock option deductions. The remaining \$1.0 million provision is allocated to ordinary

activities. The tax provision reflected tax at standard rates in the jurisdictions in which we operate, income derived from Irish patents, foreign withholding tax and the availability of tax losses. Our Irish patent derived income was exempt from tax pursuant to Irish legislation, which exempts from Irish tax income derived from qualifying patents. Currently, there is no termination date in effect for such exemption. For additional information regarding income taxes, please refer to Note 21 to the Consolidated Financial Statements.

**Table of Contents****Net Income/(Loss) from Discontinued Operations**

Net income from discontinued operations was \$0.6 million in 2005, compared to a net income from discontinued operations of \$19.0 million in 2004. The net income from discontinued operations includes a net gain on sale of businesses of \$0.5 million (2004: \$11.5 million). During the course of the completed recovery plan, we sold a number of products and businesses, including Athena Diagnostics, Elan Diagnostics, a portfolio of pain products (the Pain Portfolio), Actiq<sup>tm</sup>, the dermatology portfolio of products, Abelcet<sup>tm</sup> US/Canada, Myobloc<sup>tm</sup>, Myambutol<sup>tm</sup> and Frova, which are included in discontinued operations. We have recorded the results and gains or losses on the divestment of these operations within discontinued operations in the Consolidated Statement of Operations.

**SEGMENT ANALYSIS**

Our business is organized into two segments: Biopharmaceuticals and EDT. Biopharmaceuticals engages in research, development and commercial activities and includes our activities in the areas of autoimmune diseases, neurodegenerative diseases, and our specialty business group. EDT focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

**Analysis by Segment**

	Biopharmaceuticals			2006	EDT		2006	Total	
	2006	2005	2004		2005	2004		2005	2004
	(In millions)			(In millions)		(In millions)			
Revenue	\$ 275.8	\$ 229.1	\$ 259.8	\$ 284.6	\$ 261.2	\$ 221.9	\$ 560.4	\$ 490.3	\$ 481.7
Segmental operating income/(loss)	\$ (235.6)	\$ (245.4)	\$ (282.6)	\$ 69.1	\$ 47.6	\$ 43.6	\$ (166.5)	\$ (197.8)	\$ (239.0)
Corporate expense/(credit)							(0.1)	0.7	63.1
Operating loss							\$ (166.4)	\$ (198.5)	\$ (302.1)

Biopharmaceuticals revenue increased 20% to \$275.8 million in 2006 from \$229.1 million in 2005 and 6% from \$259.8 million in 2004. The increase is primarily due to the increase in revenue from increased sales of *Maxipime*, *Azactam* and *Tysabri*, offset by decreases in revenue from divested products. Biopharmaceuticals operating loss decreased 4% to \$235.6 million in 2006 from \$245.4 million in 2005 and 17% from \$282.6 million in 2004. The decrease in the operating loss was principally due to the increase in revenues, offset by a decrease in the gain on sale of products and businesses. Biopharmaceuticals net gain on sale of products and businesses decreased to \$43.1 million in 2006 (primarily related to the gain on sale of European rights to *Prialt*) from \$103.1 million in 2005 (primarily related to the gains on the sale of *Zonegran* and our European business). Biopharmaceuticals other net charges increased to \$26.3 million in 2006 from \$5.6 million in 2005, primarily due to acquired in-process research and development costs incurred in 2006.

EDT revenue increased 9% to \$284.6 million in 2006 from \$261.2 million in 2005 and increased 28% from \$221.9 million in 2004. The increase was due to increased manufacturing revenue and royalties, offset by decreased contract revenue. EDT operating income increased to \$69.1 million in 2006 from \$47.6 million in 2005 and from \$43.6 million in 2004. The increase was primarily due to the increase in revenues and also due to a net other gain of

\$47.2 million in 2006, which was primarily related to an arbitration award in our favor and against King in 2006.

**Table of Contents****B. Liquidity and Capital Resources*****Cash and Cash Equivalents, Liquid and Capital Resources***

Our liquid and capital resources at December 31 were as follows (in millions):

	<b>2006</b>	<b>2005</b>	<b>Increase/ (Decrease)</b>
Cash and cash equivalents	\$ 1,510.6	\$ 1,080.7	40%
Restricted cash	23.2	24.9	(7)%
Investment securities (current)	11.2	10.0	12%
Shareholders' equity	85.1	16.9	404%

We have historically financed our operating and capital resource requirements through cash flows from operations, sales of equity securities and borrowings. We consider all highly liquid deposits with an original maturity of three months or less to be cash equivalents. Our primary source of funds as of December 31, 2006 consisted of cash and cash equivalents of \$1,510.6 million, which excludes restricted cash of \$23.2 million, and current investment securities of \$11.2 million.

At December 31, 2006, our shareholders' equity was \$85.1 million, compared to \$16.9 million at December 31, 2005. The increase is due primarily to the conversion of convertible debt and proceeds from employee stock issuances, offset by the net loss incurred during the year.

***Cash Flows Summary***

	<b>2006</b>	<b>2005</b>	<b>2004</b>
		<b>(In millions)</b>	
Net cash used in operating activities	\$ (238.7)	\$ (283.5)	\$ (347.9)
Net cash provided by investing activities	34.7	120.9	474.2
Net cash provided by/(used in) financing activities	629.3	(99.7)	441.5
Effect of exchange rate changes on cash	4.6	(4.6)	1.6
Net increase/(decrease) in cash and cash equivalents	429.9	(266.9)	569.4
Cash and cash equivalents at beginning of year	1,080.7	1,347.6	778.2
Cash and cash equivalents at end of year	\$ 1,510.6	\$ 1,080.7	\$ 1,347.6

The results of our cash flow activities for 2006 and 2005 are described below.

2006

Net cash used in operating activities was \$238.7 million in 2006. The primary components of cash used in operating activities were the net loss (adjusted to exclude non-cash charges and benefits) and changes in working capital accounts. The changes in working capital accounts include the net increase in trade receivables and prepaid and other assets of \$79.2 million (principally \$49.8 million arbitration award entered in our favor and against King in December 2006, which was paid by King in January 2007), the increase in inventory of \$7.1 million, and the net increase of \$15.2 million in accounts payable and accrued and other liabilities.

Net cash provided by investing activities was \$34.7 million in 2006. The major component of cash generated from investing activities includes net proceeds of \$14.1 million from the sale and maturity of investment securities and \$54.2 million from the sale of the European rights to *Prialt* (net of transaction costs), partially offset by \$31.5 million for capital expenditures. As of December 31, 2006, we did not have any significant commitments to purchase property, plant and equipment, except for committed additional capital expenditures of \$5.6 million.

Net cash provided by financing activities totalled \$629.3 million in 2006, primarily reflecting the net proceeds of \$602.8 million from the issuances of \$465.0 million of the 8.875% Notes and \$150.0 million of the Floating Rate Notes due 2013, and \$29.8 million of net proceeds from employee stock issuances, offset by \$5.7 million related to the repayment of loans and capital lease obligations.

**Table of Contents**

We believe that our current liquid asset position will be sufficient to meet our needs for at least the next twelve months.

2005

Net cash used in operating activities was \$283.5 million in 2005. The primary components of cash used in operating activities were the net loss (adjusted to exclude non-cash charges and benefits) and changes in working capital accounts. The changes in working capital accounts include the net decrease in trade receivables and prepaid and other assets of \$159.4 million (principally related to the release of restricted cash of \$168.9 million), the decrease in inventory of \$3.5 million, and the net decrease of \$111.8 million in accounts payable and accrued and other liabilities.

Net cash provided by investing activities was \$120.9 million in 2005. The major component of cash generated from investing activities includes net proceeds of \$62.7 million sale and maturity of investment securities and \$108.8 million from business disposals (primarily Zonegran and the European business), partially offset by \$50.1 million for capital expenditures.

Net cash used in financing activities totalled \$99.7 million in 2005, primarily reflecting \$39.0 million for the repayment of EPIL III Notes and \$87.8 million for the early retirement of \$36.8 million of the Athena Notes and early conversion of \$206.0 million in aggregate principle amount of 6.5% Convertible Notes, offset by \$23.8 million of net proceeds from employee stock issuances and \$4.0 million of proceeds from government grants.

***Debt Facilities***

At December 31, 2006, we had outstanding debt of \$2,378.2 million which consisted of the following:

	<b>(In millions)</b>
Athena Notes (redeemed in full in January 2007)	\$ 613.2
7.75% Notes due 2011	850.0
Floating Rate Notes due 2011	300.0
8.875% Notes due 2013	465.0
Floating Rate Notes due 2013	150.0
	\$ 2,378.2

During 2006, as of December 31, 2006, and, as of the date of filing of this Form 20-F, we were not in violation of any of our debt covenants. For additional information regarding our outstanding debt, please refer to Note 18 to the Consolidated Financial Statements.

***Commitments and Contingencies***

For information regarding commitments and contingencies, please refer to Notes 27 and 28 to the Consolidated Financial Statements.

***Capital Expenditures***

We believe that our current and planned manufacturing, research, product development and corporate facilities will adequately meet our current and projected needs. We are reviewing the availability of additional space for our South San Francisco facility. We will use our resources to make capital expenditures as necessary from time to time and also to make investments in the purchase or licensing of products and technologies and in marketing and other alliances with third parties to support our long-term strategic objectives.

**C. Research and Development, Patents and Licenses, etc.**

See Item 4. B Business Overview for information on our R&D, patents and licenses, etc.



**Table of Contents****D. Trend Information**

Please see Item 4. B Business Overview and Item 5. A Operating Results for trend information.

**E. Off-Balance Sheet Arrangements**

As of December 31, 2006, we have no unconsolidated special purpose financing or partnership entities or other off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, that are material to investors.

**F. Tabular Disclosure of Contractual Obligations**

The following table sets out, at December 31, 2006, our main contractual obligations due by period for debt principal and interest repayments and capital and operating leases. These represent the major contractual, future payments that may be made by us. The table does not include items such as expected capital expenditures on plant and equipment, future investments in financial assets or future milestones we may elect to pay Biogen Idec. As of December 31, 2006, the directors had authorized capital commitments for the purchase of property, plant and equipment of \$5.6 million (2005: \$7.1 million).

	<b>Total</b>	<b>Less Than 1 Year</b>	<b>1-3 Years</b>	<b>3-5 Years</b>	<b>More Than 5 Years</b>
Athena Notes (redeemed in full in January 2007)	\$ 613.2	\$ 613.2	\$	\$	\$
7.75% Notes due 2011	850.0			850.0	
Floating Rate Notes due 2011	300.0			300.0	
8.875% Notes due 2013	465.0				465.0
Floating Rate Notes due 2013	150.0				150.0
Total debt principal obligations	2,378.2	613.2		1,150.0	615.0
Debt interest payments <sup>(1)</sup>	844.4	151.1	298.9	287.4	107.0
Capital lease obligations <sup>(2)</sup>	2.9	2.9			
Operating lease obligations <sup>(3)</sup>	127.5	18.8	37.3	41.1	30.3
Total contractual obligations	\$ 3,353.0	\$ 786.0	\$ 336.2	\$ 1,478.5	\$ 752.3

<sup>(1)</sup> The Floating Rate Notes due 2011 and Floating Rate Notes due 2013 bear interest at a rate, adjusted quarterly, equal to three-month London Interbank Offer Rate (LIBOR) plus 4.0%. and 4.125%, respectively. To calculate our interest payment obligation, we used the LIBOR at December 31, 2006.

<sup>(2)</sup> In prior years, we disposed of plant and equipment and subsequently leased them back and also entered into an arrangement with a third party bank, the substance of which allows us to require a net settlement of our obligations under the leases. The related assets and liabilities of these previous sale and leaseback transactions

*have been offset in the Consolidated Financial Statements in the amount of \$36.2 million at December 31, 2006 (2005: \$51.8 million).*

*(3) We are reviewing the availability of additional space for our South San Francisco facility.*

At December 31, 2006, we had commitments to invest \$2.4 million (2005: \$2.4 million) in healthcare managed funds.

Under our collaboration agreement with Biogen Idec, if global in-market net sales of *Tysabri* are, on average, for four calendar quarters, in excess of \$125 million per calendar quarter, then we may elect to make a milestone payment to Biogen Idec of \$75 million in order to maintain our percentage share of *Tysabri* at approximately 50% for annual global in-market net sales of *Tysabri* that are in excess of \$700 million. Additionally, if we have made this first milestone payment, then we may elect to pay a further \$50 million milestone to Biogen Idec if global in-market net sales of *Tysabri* are, on average, for four calendar quarters, in excess of \$200 million per calendar quarter, in order to maintain our percentage share of *Tysabri* at approximately 50% for annual global in-market net sales of *Tysabri* that are in excess of \$1.1 billion. Should we elect not to make the first milestone payment of \$75 million, then our percentage share of *Tysabri* will be reduced to approximately 35% for annual global in-market net sales of *Tysabri* exceeding \$700 million. If we elect to make the first milestone payment, but not the second milestone

**Table of Contents**

payment, then our percentage share of *Tysabri* will be reduced to approximately 35% for annual global net sales of *Tysabri* exceeding \$1.1 billion.

In disposing of assets or businesses, we often provide customary representations, warranties and indemnities (if any) to cover various risks. We do not have the ability to estimate the potential liability from such indemnities because they relate to unknown conditions. However, we have no reason to believe that these uncertainties would have a material adverse effect on our financial condition or results of operations.

The two major rating agencies covering our debt rate it as sub-investment grade debt. None of our debt has a rating trigger that would accelerate the repayment date upon a change in rating.

Our debt ratings as of December 31, 2006 were as follows:

	<b>Standard &amp; Poor's Rating Services</b>	<b>Moody's Investors Service</b>
Athena Notes (redeemed in full in January 2007)	B	B3
7.75% Notes	B	B3
Floating Rate Notes due 2011	B	B3
8.875% Notes	B	B3
Floating Rate Notes due 2013	B	B3

We believe that we have sufficient current cash, liquid resources, realizable assets and investments to meet our liquidity requirements for at least the next twelve months. Longer-term liquidity requirements and debt repayments will need to be met out of available cash resources, future operating cash flows, financial and other asset realizations and future financing. However, events, including a material deterioration in our operating performance as a result of our inability to sell significant amounts of *Tysabri*, material adverse legal judgments, fines, penalties or settlements arising from litigation or governmental investigations, failure to successfully develop and receive marketing approval for products under development or the occurrence of other circumstances or events described under Risk Factors, could materially adversely affect our ability to meet our longer-term liquidity requirements.

We commit substantial resources to our R&D activities, including collaborations with third parties such as Biogen Idec for the development of *Tysabri* and Wyeth for Alzheimer's disease. We expect to commit significant cash resources to the development and commercialization of products in our development pipeline.

We continually evaluate our liquidity requirements, capital needs and availability of resources in view of, among other things, alternative uses of capital, debt service requirements, the cost of debt and equity capital and estimated future operating cash flow. We may raise additional capital, restructure or refinance outstanding debt, repurchase material amounts of outstanding debt (including the 7.75% Notes and the Floating Rate Notes due 2011 and the 8.875% Notes and the Floating Rate Notes due 2013), consider the sale of interests in subsidiaries, investment securities or other assets or the rationalization of products, or take a combination of such steps or other steps to increase or manage our liquidity and capital resources. Any such actions or steps, including any repurchase of outstanding debt, could be material. In the normal course of business, we may investigate, evaluate, discuss and engage in future company or product acquisitions, capital expenditures, investments and other business opportunities. In the event of any future acquisitions, capital expenditures, investments or other business opportunities, we may consider using available cash or raising additional capital, including the issuance of additional debt.



**Table of Contents**

**Item 6. Directors, Senior Management and Employees**

**A. Directors and Senior Management**

***Directors***

*Kyran McLaughlin (62)*

*Non-Executive Chairman, Member of the Nominating Committee*

Mr. McLaughlin was appointed a director of Elan in January 1998 and was appointed chairman of Elan in January 2005. He is deputy chairman at Davy Stockbrokers, Ireland's largest stockbroker firm. He is also a director of Ryanair Holdings, plc and is a director of a number of private companies.

*Shane Cooke (44)*

*Executive Director and Chief Financial Officer*

Mr. Cooke was appointed a director of Elan in May 2005. He joined the company as executive vice president and chief financial officer in July 2001. Prior to joining Elan, Mr. Cooke was chief executive of Pembroke Capital Limited, an aviation leasing company, and prior to that held a number of senior positions in finance in the banking and aviation industries. Mr. Cooke is a chartered accountant and a graduate of University College Dublin.

*Laurence G. Crowley (69)*

*Non-Executive Director, Member of the Leadership, Development and Compensation Committee*

Mr. Crowley was appointed a director of Elan in March 1996. He was governor of the Bank of Ireland until his retirement in July 2005. He is presently chairman of PJ Carroll & Co. and is a director of a number of private companies.

*William F. Daniel (54)*

*Executive Director and Company Secretary*

Mr. Daniel was appointed a director of Elan in February 2003. He has served as the company secretary since December 2001, having joined Elan in March 1994 as group financial controller. In July 1996, he was appointed group vice president, finance, group controller and principal accounting officer. From 1990 to 1992, Mr. Daniel was financial director of Xtravision, plc. Mr. Daniel is a chartered accountant and a graduate of University College Dublin.

*Lars Ekman, MD, PhD (57)*

*Executive Director and President, Global Research and Development and Head of Neurodegeneration Franchise*

Dr. Ekman was appointed a director of Elan in May 2005 and joined Elan as executive vice president and president, global R&D in 2001. Prior to joining Elan, he was EVP, R&D, at Schwarz Pharma AG since 1997. From 1984 to 1997, Dr. Ekman was employed in a variety of senior scientific and clinical functions at Pharmacia (now Pfizer). Dr. Ekman is a board certified surgeon with a PhD in experimental biology and has held several clinical and academic positions in both the United States and Europe. He obtained his PhD and MD from the University of Gothenburg, Sweden.

*Alan R. Gillespie, CBE, PhD (56)*

*Non-Executive Director, Chairman of the Audit Committee*

Dr. Gillespie was appointed a director of Elan in March 1996. He is chairman of Ulster Bank Limited and chairman of the International Finance Facility. From November 1999 until November 2002, he was chief executive officer of CDC Group, plc and was previously a managing director of Goldman Sachs International.

*Ann Maynard Gray (61)*

*Non-Executive Director, Member of the Nominating Committee*

Ms. Maynard Gray was appointed a director of Elan in February 2001. She was formerly president of Diversified Publishing Group of Capital Cities/ABC, Inc. Ms. Gray is also a director of Duke Energy Corporation and The Phoenix Companies, Inc.

*Gary Kennedy (49)*

*Non-Executive Director, Member of the Audit Committee*

Mr. Kennedy was appointed a director of Elan in May 2005. From May 1997 to December 2005, he was Group Director, Finance & Enterprise Technology, at Allied Irish Banks, plc (AIB) and a member of the main Board of

**Table of Contents**

AIB and was also on the Board of M&T, AIB's associate in the United States. Prior to that, Mr. Kennedy was group vice president at Nortel Networks Europe after starting his management career at Deloitte & Touche. He served on the Board of the Industrial Development Authority of Ireland for 10 years until he retired in December 2005. He is a director of Calyx Group plc, the NUI Galway Development Board, and a number of private companies. Mr. Kennedy is a chartered accountant.

*G. Kelly Martin (47)*

*Executive Director, President and CEO*

Mr. Martin was appointed a director of Elan in February 2003 following his appointment as president and chief executive officer. He was formerly president of the International Private Client Group and a member of the executive management and operating committee of Merrill Lynch & Co., Inc. He spent over 20 years at Merrill Lynch & Co., Inc. in a broad array of operating and executive responsibilities on a global basis.

*Kieran McGowan (63)*

*Non-Executive Director, Lead Independent Director, Chairman of the Nominating Committee, Member of the Audit Committee*

Mr. McGowan was appointed a director of Elan in December 1998. From 1990 until his retirement in December 1998, he was chief executive of the Industrial Development Authority of Ireland. He is chairman of the governing authority of University College Dublin and is a director and chairman designate of CRH, plc, and a director of Irish Life and Permanent, plc, United Drug, plc, Enterprise Ireland, and a number of private companies.

*William Rohn (63)*

*Non-Executive Director, Member of the Leadership, Development and Compensation Committee*

Mr. Rohn was appointed a director of Elan in May 2006. He is currently vice chairman of Raven Biotechnologies, Inc., and a director of Metabasis Therapeutics, Inc., Cerus Corp and Pharmacyclics, Inc. Previously, he was chief operating officer of Biogen Idec until January 2005 and prior thereto president and chief operating officer of Idec Pharmaceutical Corporation from 1993.

*Dennis J. Selkoe, MD (63)*

*Non-Executive Director, Chairman of the Leadership, Development and Compensation Committee*

Dr. Selkoe was appointed a director of Elan in July 1996, following our acquisition of Athena Neurosciences, where he served as a director since July 1995. Dr. Selkoe was a founder of Athena Neurosciences. Dr. Selkoe, a neurologist, is a professor of neurology and neuroscience at Harvard Medical School. He also serves as co-director of the Center for Neurologic Diseases at The Brigham and Women's Hospital.

***Senior Management***

*Paul Breen (50)*

*Executive Vice President, Elan Drug Technologies*

Mr. Breen joined Elan in July 2001. Prior to joining Elan, he was vice president and joint managing director of Pfizer Pharmaceuticals Ireland. Prior thereto, he was vice president and managing director of Warner-Lambert Company's Irish operations. He is Chairman of the governing body of the Athlone Institute of Technology. Mr. Breen holds a degree in science and is a graduate of University College Dublin.

*Nigel Clerkin (33)*

*Senior Vice President, Finance and Group Controller*

Mr. Clerkin was appointed senior vice president, finance and group controller in January 2004, having previously held a number of financial and strategic planning positions since joining Elan in January 1998. He is also our principal accounting officer. Mr. Clerkin is a chartered accountant and a graduate of Queen's University Belfast.

*Richard Collier (53)*

*Executive Vice President and General Counsel*

Mr. Collier joined Elan as executive vice president and general counsel in November 2004. Prior to joining Elan, Mr. Collier was senior counsel at Morgan, Lewis & Bockius LLP. Prior to joining Morgan Lewis, he was senior vice president and general counsel at Pharmacia (now Pfizer), after serving in that same position at Pharmacia & Upjohn. Prior to his experience at Pharmacia, Mr. Collier spent 11 years at Rhone-Poulenc Rorer, Inc. Previously, he was in



**Table of Contents**

private practice after having served with the US Federal Trade Commission and US Department of Justice. Mr. Collier is a graduate of Temple University and also earned his Juris Doctor at Temple University.

*David W. Feigal, Jr, MD (57)*

*Senior Vice President, Head of Global Regulatory and Global Safety Surveillance*

Dr. Feigal joined us as senior vice president, head of global regulatory and global safety surveillance in November 2006. Prior to joining Elan, he served most recently as a principal with NDA Partners, and prior thereto spent twelve years with the FDA. Before joining the FDA, Dr. Feigal worked for ten years within the academic and hospital settings of the University of California in San Diego, San Francisco and Davis. Dr. Feigal holds a BA from University of Minnesota, an MD from Stanford University and a Master of Public Health from the University of California, Berkeley.

*Allison Hulme, PhD (43)*

*Executive Vice President, Autoimmune, Tysabri, Global Development*

Dr. Hulme was appointed executive vice president, autoimmune, *Tysabri*, global development, in January 2005. Previously, Dr. Hulme held the positions of executive vice president, *Tysabri* business enterprise, and senior vice president, head of global development. Prior to joining Elan in October 1995, Dr. Hulme held several positions in Clinical Research at Glaxo Wellcome Pharmaceuticals (United Kingdom) and served as a lecturer at Luton University. She holds a degree in science from Luton University and earned her PhD from Cranfield Institute of Technology.

*Karen S. Kim (44)*

*Executive Vice President, Corporate Strategy & Alliances, Communications, Branding and Specialty Business Group*

Ms. Kim was appointed executive vice president, corporate strategy & alliances, communications, branding and specialty group, in January 2005. She joined Elan in September 2003 as senior vice president, head of global corporate strategy and strategic alliances. Prior to joining Elan, Ms. Kim held senior management positions at Merrill Lynch & Co., which she joined in 1998, and where she was most recently head of Client Development in the International Private Client Group. Previously she held senior management positions at the Cambridge Group and The MAC Group/Gemini Consulting. She is a graduate of Wellesley College and earned her MBA from the Harvard Graduate School of Business Administration.

*Ivan Lieberburg, MD, PhD (57)*

*Executive Vice President and Chief Medical Officer*

Dr. Lieberburg is executive vice president and chief medical officer of Elan, where he has held a number of senior positions, most recently senior vice president of research. Prior to joining Athena Neurosciences in 1987, Dr. Lieberburg held faculty positions at the Albert Einstein College of Medicine and Mt. Sinai School of Medicine in New York. He received an AB from Cornell University and earned his PhD in Neurobiology from The Rockefeller University. Dr. Lieberburg was a Postdoctoral Fellow in Neurobiology at Rockefeller University. He earned his MD from the University of Miami. Dr. Lieberburg was a Research Endocrine Fellow at the University of California, San Francisco.

*Kathleen Martorano (45)*

*Executive Vice President, Strategic Human Resources*

Ms. Martorano was appointed executive vice president, strategic human resources, and a member of the office of the chief executive officer, in January 2005. She joined Elan in May 2003 as senior vice president, corporate marketing & communications. Prior to joining Elan, Ms. Martorano held senior management positions at Merrill Lynch & Co., which she joined in 1996, and where she was most recently first vice president of Marketing and Communications for the International Private Client Group. Previously, she held senior management positions with Salomon Brothers. Ms. Martorano holds a Bachelor of Science degree from Villanova University.

*Dale Schenk, PhD (49)*

*Senior Vice President and Chief Scientific Officer*

Dr. Schenk was appointed Elan's senior vice president and Elan's chief scientific officer in June 2003. From 1999 to 2003, Dr. Schenk was senior vice president of discovery research at Elan, and from 1998 to 1999, he was the company's vice president of neurobiology. Previously, Dr. Schenk was director of neurobiology for Athena Neurosciences from 1994 to 1998. Earlier at Athena, from 1987 to 1994, Dr. Schenk served as the leader of several research programs. Dr. Schenk earned his Bachelor's degree in Biology and a PhD in Physiology and Pharmacology from the University of California, San Diego.

**Table of Contents***Ted Yednock, PhD (49)**Senior Vice President, Head of Global Research*

Dr. Yednock was appointed senior vice president, head of global research, in September 2005. Dr. Yednock joined Athena Neurosciences in 1990 to initiate work on MS. He has contributed to a number of research efforts since that time in the areas of both autoimmune and neurodegeneration, and has held a number of scientific and management positions within the organization. Most recently, Dr. Yednock served as vice president, biology. He earned his Bachelor's degree in Biology and Chemistry from the University of Illinois and his PhD in Immunology from the University of California, San Francisco.

**B. Compensation*****Executive Officers and Directors Remuneration***

For the year ended December 31, 2006, all executive officers and outside directors as a group (19 persons) received total compensation of \$8.0 million.

We reimburse officers and outside directors for their actual business-related expenses. For the year ended December 31, 2006, an aggregate of \$0.2 million was accrued to provide pension, retirement and other similar benefits for directors and officers. We also maintain certain health and medical benefit plans for our employees in which our officers participate.

Officers serve at the discretion of the board of directors. No director or officer has a family relationship with any other director or officer.

***Directors Remuneration***

	Year Ended December 31					
	2006 Salary/Fees	2006 Annual Bonus	2006 Pension	2006 Benefit in Kind	2006 Total	2005 Total
Executive Directors:						
G. Kelly Martin	\$ 804,139	\$ 880,000 <sup>(1)</sup>	\$ 6,600	\$ 105,794	\$ 1,796,533	\$ 1,793,315
Shane Cooke	616,147	618,000			1,234,147	748,505 <sup>(2)</sup>
William F. Daniel	398,091	160,000	46,875	21,520	626,486	668,265
Lars Ekman, MD, PhD	455,192	400,000	10,065	119,543	984,800	775,881 <sup>(2)(3)</sup>
Total	2,273,569	2,058,000	63,540	246,857	4,641,966	3,985,966
Non-Executive Directors:						
Kyran McLaughlin	300,000				300,000	300,000
Göran Ando, MD <sup>(4)</sup>	115,500				115,500	36,661
Garro H. Armen, PhD <sup>(5)</sup>	22,038				22,038	55,000
Laurence G. Crowley	67,500				67,500	68,802
Alan R. Gillespie, CBE, PhD	75,000				75,000	67,500
Ann Maynard Gray	67,500				67,500	77,464

Edgar Filing: ELAN CORP PLC - Form 20-F

Gary Kennedy	67,500			67,500		36,661
Nancy Lurker <sup>(6)</sup>	28,156			28,156		36,661
Kieran McGowan	87,500			87,500		82,333
Kevin M. McIntyre, MD <sup>(5)</sup>	27,046			27,046		68,281
William Rohn <sup>(7)</sup>	38,101			38,101		
Dennis J. Selkoe, MD	128,878 <sup>(8)</sup>			128,878		97,916 <sup>(8)</sup>
Total	\$ 3,298,288	\$ 2,058,000	\$ 63,540	\$ 246,857	\$ 5,666,685	\$ 4,913,245

*(1) On February 21, 2007, Mr. Martin waived his 2006 performance cash bonus, which would have been paid in 2007, in exchange for the grant of a stock option exercisable for 101,746 ordinary shares with an exercise price of \$13.95 per share. The stock option was granted with a fair value of \$880,000. Mr. Martin also received an annual stock option grant exercisable for 393,109 ordinary shares on the same date.*

*(2) Appointed as director on May 26, 2005; and the remuneration was pro-rated for the period from May 26, 2005 to December 31, 2005.*

*(3) Includes \$240,000 for loan fully forgiven in December 2005.*

**Table of Contents**

(4) Resigned as director on December 31, 2006.

(5) Retired as director on May 25, 2006.

(6) Resigned as director on May 31, 2006.

(7) Appointed as director on May 25, 2006.

(8) Includes fees of \$50,000 in 2006 and \$25,000 in 2005 under a consultancy agreement. For additional information, please refer to page 69.

<b>Payments to Former Directors:</b>	<b>2006</b>	<b>2005</b>
<i>Pensions:</i>		
John Groom <sup>(1)</sup>	\$ 200,000	\$ 116,667
Donald Panoz		26,667
Nancy Panoz		4,166
	200,000	147,500
<i>Legal settlement:</i>		
Donal Geaney <sup>(2)</sup>		4,375,000
Total	\$ 200,000	\$ 4,522,500

(1) Effective July 1, 2003 we entered into a pension agreement of \$200,000 per annum payable to Mr. Groom until May 16, 2008. For additional information, refer to Note 29 to the Consolidated Financial Statements.

(2) On June 13, 2005, we agreed to settle an action taken by the late Mr. Geaney for a sum of 3.5 million (\$4.4 million), plus an agreed sum of legal fees. For additional information, refer to Note 29 to the Consolidated Financial Statements.

**C. Board Practices*****The Board***

The roles of the chairman and chief executive officer (CEO) are separated. The chairman of the board is responsible for the leadership and management of the Board. Our CEO is responsible for the operation of the business of the Company. Other significant commitments of the Chairman are set out on page 56. These commitments did not change during 2006.

The board regularly reviews its responsibilities and those of its committees and management. The board meets regularly throughout the year, and all of the directors have full and timely access to the information necessary to enable them to discharge their duties. All directors also have access to the advice and services of the Company Secretary.

The board has reserved certain matters to its exclusive jurisdiction, thereby maintaining control of the Company and its future direction. All directors are appointed by the board, as nominated by its nominating committee, and subsequently elected by the shareholders. Procedures are in place where directors and committees, in furtherance of their duties, may take independent professional advice, if necessary, at our expense. The board held six meetings during 2006.

Our guidelines require that the board will conduct a self-evaluation at least annually to determine whether it and its committees are functioning effectively. An evaluation of the performance of the board, the board committees, and individual directors was conducted during the year by the Lead Independent Director through meetings with each member of the board. The results were presented to the nominating committee and to the board. The board concluded that it and its committees had operated satisfactorily during the past year.

The board has delegated authority over certain areas of our activities to three standing committees, as more fully described below.

### ***Independence of Directors***

Under our guidelines, two-thirds of the board are required to be independent. The board currently includes eight independent, non-executive directors who constitute two-thirds of the board. We adopted a definition of independence based on the rules of the New York Stock Exchange (NYSE), the exchange on which the majority of

**Table of Contents**

our shares are traded. During 2006 the board considered the independence of each non-executive director and considers that all non-executive directors are independent in character and judgment and there are no relationships or circumstances that are likely to affect their independent judgment.

In reaching this conclusion the board gave due consideration to participation by board members in our equity compensation plans. In particular the board considered the position of Mr. McLaughlin, Chairman, Mr. Crowley, Dr. Gillespie and Dr. Selkoe. Mr. McLaughlin has served as a non-executive director for nine years. Dr. Gillespie, Mr. Crowley and Dr. Selkoe have served as non-executive directors for in excess of nine years. Additionally, Dr. Selkoe has an ongoing consultancy agreement with the company, which is set out in detail on page 69. It is the board's view that each of these non-executive directors discharges his duties in a thoroughly independent manner and constructively and appropriately challenge the executive directors and the board. For this reason the board considers that they are independent.

***Audit Committee***

The audit committee, composed entirely of independent non-executive directors, helps the board in its general oversight of the Company's accounting and financial reporting practices, internal controls and audit functions, and is directly responsible for the appointment, compensation and oversight of the work of our independent auditors. The members of the committee are Dr. Gillespie, Chairman, Mr. Kennedy, and Mr. McGowan. Mr. Kennedy qualifies as an audit committee financial expert. The audit committee held eight meetings during 2006. For additional information on the audit committee, please refer to Item 16A. Audit Committee Financial Expert and Item 16C. Report of the Audit Committee.

***Leadership Development and Compensation Committee***

The Leadership Development and Compensation Committee (LDCC), composed entirely of independent non-executive directors, reviews our compensation philosophy and policies with respect to executive compensation, fringe benefits and other compensation matters. The committee determines the compensation of the chief executive officer and other executive directors and reviews the compensation of the other members of the executive management. The members of the committee are Dr. Selkoe, Chairman, Mr. Crowley and Mr. Rohn (appointed July 31, 2006). The committee held six meetings during 2006. Further information about the work of the LDCC is set out in the Report of the Leadership Development and Compensation Committee on page 63.

***Nominating Committee***

The nominating committee, composed entirely of independent non-executive directors, reviews on an ongoing basis the membership of the board of directors and of the board committees and the performance of the directors. It recommends new appointments to fill any vacancy that is anticipated or arises on the board of directors. The committee reviews and recommends changes in the functions of the various committees of the board. The Guidelines and the charter of the committee set out the manner in which the performance evaluation of the board, its committees and the directors is to be performed and by whom. The members of the committee are Mr. Kieran McGowan, Chairman, Ms. Ann Maynard Gray and Mr. Kyran McLaughlin. The committee held five meetings during 2006.

**Table of Contents****Board and Board Committee Meetings**

The number of scheduled board and board committee meetings held and attended by each director during the year was as follows:

	<b>Board</b>	<b>Audit Committee</b>	<b>LDCC</b>	<b>Nominating Committee</b>
Kyran McLaughlin	6/6			5/5
Göran Ando, MD <sup>(1)</sup>	5/6		3/4	
Garó H. Armen, PhD <sup>(2)</sup>	1/2			
Shane Cooke	6/6			
Laurence G. Crowley	6/6		6/6	
William F. Daniel	6/6	8/8 <sup>(5)</sup>	6/6 <sup>(5)</sup>	5/5 <sup>(5)</sup>
Lars Ekman, MD, PhD	6/6			
Alan R. Gillespie, CBE, PhD	6/6	8/8		
Ann Maynard Gray	5/6			5/5
Gary Kennedy	6/6	8/8		
Nancy Lurker <sup>(3)</sup>	2/3		3/4	
G. Kelly Martin	6/6			
Kieran McGowan	6/6	8/8		5/5
Kevin M. McIntyre, MD <sup>(2)</sup>	2/2		4/4	
William R. Rohn <sup>(4)</sup>	1/2		1/2	
Dennis J. Selkoe, MD	6/6		6/6	

<sup>(1)</sup> Resigned as a director on December 31, 2006.

<sup>(2)</sup> Retired as director on May 25, 2006.

<sup>(3)</sup> Resigned as director on May 31, 2006.

<sup>(4)</sup> Appointed as director on May 25, 2006.

<sup>(5)</sup> William F. Daniel was secretary on these committees.

**Relations with Shareholders**

We communicate regularly with our shareholders throughout the year, specifically following the release of quarterly and annual results, and after major developments. Our annual general meetings, quarterly conference calls and presentations at healthcare investor conferences are webcast and are available on our website ([www.elan.com](http://www.elan.com)). All shareholders are given adequate notice of the annual general meeting. The board periodically receives presentations on investor perceptions. All directors normally attend the annual general meeting and shareholders are invited to ask questions during the meeting and to meet with directors after the formal proceedings have ended.

**Going Concern**



The directors, having made inquiries, believe that we have adequate resources to continue in operational existence for at least the next twelve months and that it is appropriate to continue to adopt the going concern basis in preparing our Consolidated Financial Statements.

***Internal Control***

The board of directors has overall responsibility for our system of internal control and for monitoring its effectiveness. The system of internal control is designed to provide reasonable, but not absolute, assurance against material misstatement or loss. The key procedures that have been established to provide effective internal control include:

A clear focus on business objectives is set by the board having considered the risk profile of Elan;

**Table of Contents**

A formalized risk reporting system. Significant business risks are addressed at each board meeting;

A clearly defined organizational structure under the day-to-day direction of our chief executive officer. Defined lines of responsibility and delegation of authority have been established within which our activities can be planned, executed, controlled and monitored to achieve the strategic objectives which the board has adopted for us;

A comprehensive system for reporting financial results to the board. This includes a budgeting system with an annual budget approved by the board;

A system of management and financial reporting, treasury management and project appraisal the system of reporting covers trading activities, operational issues, financial performance, working capital, cash flow and asset management; and

To support our system of internal control, we have separate Corporate Compliance, Internal Audit and Internal Control Departments. Each of these departments report periodically to the Audit Committee. The Internal Control function is primarily responsible for the Company's compliance with Section 404 of the Sarbanes-Oxley Act 2002.

The directors reviewed our system of internal control and also examined the full range of risks affecting us and the appropriateness of the internal control structures to manage and monitor these risks. This process involved a confirmation that appropriate systems of internal control were in place throughout the financial year and up to the date of signing of these financial statements. It also involved an assessment of the ongoing process for the identification, management and control of the individual risks and of the role of the various risk management functions and the extent to which areas of significant challenges facing us are understood and are being addressed. No material unaddressed issues emerged from this assessment.

Please refer to Item 15. Controls and Procedures, for management's annual report on internal control over financial reporting.

***Report of the Leadership Development and Compensation Committee***

The terms of reference for the committee are to determine the compensation, terms and conditions of employment of the chief executive officer and other executive directors and to review the recommendations of the chief executive officer with respect to the remuneration and terms and conditions of employment of our senior management. The committee also exercises all the powers of the board of directors to issue Ordinary Shares on the exercise of share options and vesting of RSUs and to generally administer our equity award plans.

Each member of the committee is nominated to serve for a three-year term subject to a maximum of two terms of continuous service.

***Remuneration Policy***

Our policy on executive directors' remuneration is to set remuneration levels that are appropriate for our senior executives having regard to their substantial responsibilities, their individual performance and our performance as a whole. The committee sets remuneration levels after reviewing remuneration packages of executives in the pharmaceutical and biotech industries. The committee takes external advice from independent benefit consultants and

considers Section B of the Code of Best Practice of The Combined Code as issued by the London and Irish Stock Exchanges.

The typical elements of the remuneration package for executive directors include basic salary and benefits, annual cash incentive bonus, pensions and participation in equity award plans. Non-executive directors are compensated with fee payments and stock options (with additional payments where directors are members of board committees) and are reimbursed for travel expenses to and from board meetings.

The committee grants equity awards to encourage identification with shareholders' interests.

**Table of Contents**

*Executive Directors Basic Salary*

The basic salaries of executive directors are reviewed annually having regard to personal performance, company performance and market practice.

*Annual Cash Incentive Bonus*

An annual cash incentive bonus, which is not pensionable, is paid to executive directors based on the recommendation of the committee. Bonus determination is not based on specific financial or operational targets, but on individual and company performance.

*Long Term Incentive Plan*

On May 25, 2006, our shareholders approved The Elan Corporation, plc 2006 Long Term Incentive Plan (LTIP). This had the effect of closing down and replacing all existing option and restricted stock unit (RSU) plans. It is the committee's policy, in common with other companies operating in the pharmaceutical and biotech industries, to award share options and RSUs to management and employees, taking into account the best interests of the Company. The equity awards generally vest between one and four years and do not contain any performance conditions.

*Employee Equity Purchase Plans*

In June 2004, our shareholders approved a qualified Employee Equity Purchase Plan (US Purchase Plan), under Sections 421 and 423 of the Internal Revenue Code (IRC), which became effective on January 1, 2005 for eligible employees based in the United States. The plan allows eligible employees to purchase common stock at 85% of the lower of the fair market value at the start of the offering period or the fair market value on the last trading day of the offering period. Purchases are limited to \$25,000 per calendar year, 1,000 shares per offering period, and subject to certain IRC restrictions.

The board of directors approved the Irish Sharesave Option Scheme 2004 and UK Sharesave Option Plan 2004, effective January 1, 2005, for employees based in Ireland and the United Kingdom, respectively (the Irish/UK Sharesave Plans). The Irish/UK Sharesave Plans allow eligible employees to purchase shares at no lower than 85% of the fair market value at the start of the thirty-six month saving period. The plan allows eligible employees to save up to 320 per month under the Irish Scheme or 250 pounds Sterling under the UK Plan and they may purchase shares anytime within six months after the end of the saving period.

In May 2006 our shareholders approved an increase of 1,500,000 shares in the number of shares available to employees to purchase in accordance with the terms of the US Purchase Plan. In total, 3,000,000 shares have been reserved for issuance under the Irish/UK Sharesave Plans and US Purchase Plan combined. In 2006, 394,533 shares (2005: 542,429 shares) were issued under the US Purchase Plan and as of December 31, 2006, 2,006,966 shares (2005: 957,571 shares) were reserved for future issuance under the US Purchase Plan and Irish/UK Sharesave Plans.

*Approved Profit Sharing Scheme*

Elan also operates an Irish Revenue Commissioners approved profit sharing scheme which permits employees and executive directors who meet the criteria laid down in the scheme to allocate a portion of their annual bonus to purchase shares. Participants may elect to take their bonus in cash subject to normal income tax deductions or may elect to have the bonus amount (subject to certain limits) paid to the independent trustees of the scheme who use the funds to acquire shares. In addition participants may voluntarily apply a certain percentage (subject to certain limits)

of their gross basic salary towards the purchase of shares in a similar manner. The shares must be held by the trustees for a minimum of two years after which participants may dispose of the shares but will be subject to normal income taxes until the shares have been held for a minimum of three years.

**Table of Contents****D. Employees**

See Item 4.B Business Overview Employees for information on our employees.

**E. Share Ownership*****Directors Ordinary Shares***

The beneficial interests of those persons who were directors and the secretary of Elan Corporation, plc at December 31, 2006, including their spouses and children under eighteen years of age, were as follows:

	Ordinary Shares; Par Value 5 Euro Cents Each	
	2006	2005
Kyran McLaughlin	190,000	150,000
Shane Cooke	250,000	250,000
Laurence G. Crowley	12,000	12,000
William F. Daniel	50,000	50,000
Lars Ekman, MD, PhD	30,100	30,100
Alan R. Gillespie, CBE, PhD	332,000	132,000
Ann Maynard Gray	3,500	3,500
Gary Kennedy	2,800	2,800
G. Kelly Martin	246,500	257,500
Kieran McGowan	1,200	1,200
William Rohn <sup>(1)</sup>	3,000	
Dennis J. Selkoe, MD	163,175	163,175

<sup>(1)</sup> Appointed as director on May 25, 2006.

***Directors Options and Restricted Stock Units***

Date of Grant	At		Granted 2006	Exercised 2006	Market	At December 31, 2006	Earliest Exercisable Date
	December 31, 2005	Exercise Price			Price At Exercise Date		
February 30, 1999	10,000	\$ 25.81			\$	10,000	April 30, 2002
March 2, 2001	5,000	54.85				5,000	March 2, 2002
March 10, 2004	40,000	16.27				40,000	March 10, 2005

Edgar Filing: ELAN CORP PLC - Form 20-F

March 10, 2005	7,500	7.47			7,500	January 1, 2006	
February 1, 2006		15.90	10,000		10,000	February 1, 2008	Ja
	62,500		10,000		72,500		
March 10, 2005	60,000	\$ 7.47		\$	60,000	January 1, 2006	
May 25, 2005	150,000	7.21			150,000	January 1, 2006	
February 1, 2006		15.90	63,899		63,899	January 1, 2007	Ja
February 1, 2006		RSU	12,579		12,579	February 1, 2007	Fe
	210,000		76,478		286,478		
April 30, 1999	10,000	\$ 25.81		\$	10,000	April 30, 2002	
March 2, 2001	5,000	54.85			5,000	March 2, 2002	
March 10, 2004	40,000	16.27			40,000	March 10, 2005	
March 10, 2005	7,500	7.47			7,500	January 1, 2006	
February 1, 2006		15.90	10,000	\$	10,000	February 1, 2008	Ja
	62,500		10,000		72,500		
December 4, 1998	40,000	\$ 32.69		\$	40,000	December 4, 2001	Dec
November 8, 1999	40,000	24.00			40,000	November 8, 2001	Nov
February 24, 2000	35,000	37.19			35,000	January 1, 2002	Feb
March 2, 2001	25,000	54.85			25,000	January 1, 2002	
March 1, 2002	30,000	14.07			30,000	January 1, 2003	Feb
August 20, 2002	150,000	2.11	50,000	15.00	100,000	February 20, 2003	A

**Table of Contents**

<b>Date of Grant</b>	<b>At December 31, 2005</b>	<b>Exercise Price</b>	<b>Granted 2006</b>	<b>Exercised 2006</b>	<b>Market Price At Exercise Date</b>	<b>At December 31, 2006</b>	<b>Earliest Exercisable Date</b>
May 1, 2003	6,000	3.84				6,000	January 1, 2004
December 23, 2004	705	22.29				705	February 1, 2008
March 10, 2004	30,000	16.27				30,000	January 1, 2005
March 10, 2005	50,000	7.47				50,000	January 1, 2006
February 1, 2006		15.90	47,925			47,925	January 1, 2007
February 1, 2006		RSU	9,434			9,434	February 1, 2007
	406,705		57,359	50,000		414,064	
December 7, 2000	125,000	\$ 53.25			\$	125,000	December 7, 2002
March 1, 2002	40,000	14.07				40,000	January 1, 2003
August 20, 2002	415,000	2.11		30,000	15.00	355,000	February 20, 2003
				30,000	15.00		
April 2, 2003	15,000	2.79				15,000	January 1, 2004
March 10, 2004	40,000	16.27				40,000	January 1, 2005
March 10, 2005	60,000	7.47				60,000	January 1, 2006
February 1, 2006		15.90	127,799			127,799	January 1, 2007
February 1, 2006		RSU	25,157			25,157	February 1, 2007
	695,000		152,956	60,000		787,956	
April 30, 1999	10,000	\$ 25.81			\$	10,000	April 30, 2002



Edgar Filing: ELAN CORP PLC - Form 20-F

March 2, 2001	5,000	54.85		5,000	March 2, 2005
March 10, 2004	40,000	16.27		40,000	March 10, 2005
March 10, 2005	7,500	7.47		7,500	January 1, 2006
February 1, 2006		15.90	10,000	10,000	February 1, 2008
	62,500		10,000	72,500	
March 2, 2001	5,000	\$ 54.85		\$ 5,000	February 1, 2003
March 10, 2004	40,000	16.27		40,000	March 10, 2005
March 10, 2005	7,500	7.47		7,500	January 1, 2006
February 1, 2006		15.90	10,000	10,000	February 1, 2008
	52,500		10,000	62,500	
May 26, 2005	15,000	\$ 8.05		\$ 15,000	May 26, 2007
February 1, 2006		15.90	10,000	10,000	February 1, 2008
	15,000		10,000	25,000	
February 6, 2003	1,000,000	\$ 3.85		\$ 1,000,000	December 31, 2003
November 13, 2003	1,000,000	5.28		1,000,000	December 31, 2003
March 10, 2004	60,000	16.27		60,000	January 1, 2005
March 10, 2005	280,000	7.47		280,000	January 1, 2006
December 7, 2005	750,000	12.03		750,000	December 31, 2006
	3,090,000			3,090,000	
April 30, 1999	10,000	\$ 25.81		\$ 10,000	April 30, 2002
March 2, 2001	5,000	54.85		5,000	March 2, 2002

Edgar Filing: ELAN CORP PLC - Form 20-F

March 10, 2004	40,000	16.27		40,000	March 10, 2005
March 10, 2005	7,500	7.47		7,500	January 1, 2006
February 1, 2006		15.90	10,000	10,000	February 1, 2008
	62,500		10,000	72,500	
May 25, 2006		\$ 18.13	20,000	\$ 20,000	May 25, 2007
			20,000	20,000	
April 30, 1999	10,000	\$ 25.81		\$ 10,000	April 30, 2002
March 2, 2001	5,000	54.85		\$ 5,000	March 2, 2002
March 10, 2004	40,000	16.27		40,000	March 10, 2005
March 10, 2005	7,500	7.47		7,500	January 1, 2006
February 1, 2006		15.90	10,000	10,000	February 1, 2008
	62,500		10,000	72,500	

<sup>(1)</sup> Appointed as director on May 25, 2006.

**Table of Contents**

Options outstanding at December 31, 2006 are exercisable at various dates between January 2007 and January 2016. During the year ended December 31, 2006, the closing market price ranged from \$12.50 to \$19.21 per ADS. The closing market price at February 22, 2007, on the NYSE, of our ADSs was \$13.94.

The following changes in directors' interests occurred between December 31, 2006 and February 22, 2007:

	<b>Grant Date</b>	<b>Exercise Price</b>	<b>No. of Options</b>	<b>No. of RSUs</b>
Kyran McLaughlin	February 21, 2007	\$ 13.95	10,000	
Shane Cooke	February 21, 2007	\$ 13.95	115,620	17,921
Laurence G. Crowley	February 21, 2007	\$ 13.95	10,000	
William F. Daniel	February 21, 2007	\$ 13.95	69,372	10,753
Lars Ekman, MD, PhD	February 21, 2007	\$ 13.95	106,371	16,487
Alan R. Gillespie, CBE, PhD	February 21, 2007	\$ 13.95	10,000	
Ann Maynard Gray	February 21, 2007	\$ 13.95	10,000	
Gary Kennedy	February 21, 2007	\$ 13.95	10,000	
G. Kelly Martin	February 21, 2007	\$ 13.95	494,855	
Kieran McGowan	February 21, 2007	\$ 13.95	10,000	
William R. Rohn	February 21, 2007	\$ 13.95	10,000	
Dennis J. Selkoe, MD	February 21, 2007	\$ 13.95	10,000	

	<b>Date</b>	<b>RSUs Vested</b>	<b>Options Exercised</b>	<b>ADRs Sold</b>
Shane Cooke	February 21, 2007	3,144		
William F. Daniel	February 21, 2007	2,358		
Lars Ekman, MD, PhD	February 21, 2007	6,289	40,000	42,893
Alan R. Gillespie, CBE, PhD	February 22, 2007			300,000

**Executive Directors Pension Arrangements**

Pensions for executive directors are calculated on basic salary only (no incentive or benefit elements are included).

Mr. Daniel participates in a defined benefit plan designed to provide two-thirds of basic salary at retirement at age 60 for full service. Mr. Cooke was a member of this plan from July 2001 until December 2004. The following table relating to the directors' participation in the defined benefit plan is denominated in Euro:

<b>Increase in Accrued Annual Benefit</b>		<b>Transfer Value Equivalent of Increase in Accrued Annual Benefit</b>		<b>Total Accumulated Accrued Annual Benefit</b>	
<b>2006</b>	<b>2005</b>	<b>2006</b>	<b>2005</b>	<b>2006</b>	<b>2005</b>

Shane Cooke					12,878	12,383
William F. Daniel	2,189	2,355	51,549	49,385	36,243	33,223

Mr. Martin and Dr. Ekman participate in a defined contribution plan (401(k) plan) for US based employees. Non-executive directors do not receive pensions.

For additional information on pension benefits for our employees, please refer to Note 26 to the Consolidated Financial Statements.

**Table of Contents****Item 7. Major Shareholders and Related Party Transactions.****A. Major Shareholders**

The following table sets forth certain information regarding the beneficial ownership of Ordinary Shares or American Depository Shares at February 22, 2007 by major shareholders and all of our directors and officers as a group (either directly or by virtue of ownership of our ADSs):

<b>Name of Owner or Identity of Group</b>	<b>No. of Shares</b>	<b>Date of Disclosure<sup>(1)</sup></b>	<b>Percent of Class<sup>(2)</sup></b>
Fidelity Management and Research Company	69,849,200	February 14, 2007	14.8%
Wellington Management	32,921,862	February 6, 2007	7.0%
Westfield Capital Management Co. LLC	19,827,758	February 7, 2007	4.2%
All directors and officers as a group (15 persons)	5,511,625 <sup>(3)</sup>		1.2%

*(1) Since the date of disclosure to us, the interest of any person listed above in our Ordinary Shares may have increased or decreased. No requirement to notify us of any change would have arisen unless the holding moved up or down through a whole number percentage level.*

*(2) Based on 467.5 million Ordinary Shares outstanding on February 22, 2007 and 4.5 million Ordinary Shares issuable upon the exercise of currently exercisable options held by directors and officers as a group as of February 22, 2007.*

*(3) Includes 4.5 million Ordinary Shares issuable upon exercise of currently exercisable options held by directors and officers as a group as of February 22, 2007.*

Except for these interests, we have not been notified at February 22, 2007 of any interest of 3% or more of our issued share capital. Neither Fidelity Management and Research Company, Wellington Management nor Westfield Capital Management Co. LLC has voting rights different from other shareholders.

We, to our knowledge, are not directly or indirectly owned or controlled by another entity or by any government. We do not know of any arrangements, the operation of which might result in a change of control of us.

A total of 467,485,612 Ordinary Shares of Elan were issued and outstanding at February 22, 2007, of which 5,013 Ordinary Shares were held by holders of record in the United States, excluding shares held in the form of American Depository Receipts (ADRs). 407,739,695 Ordinary Shares were represented by our ADSs, evidenced by ADRs, issued by The Bank of New York, as depository, pursuant to a deposit agreement. At February 22, 2007, the number of holders of record of Ordinary Shares was 12,086, which includes 15 holders of record in the United States, and the number of registered holders of ADRs was 3,293. Because certain of these Ordinary Shares and ADRs were held by brokers or other nominees, the number of holders of record or registered holders in the United States is not representative of the number of beneficial holders or of the residence of beneficial holders.

**B. Related Party Transactions**

There were no significant transactions with related parties during the year ended December 31, 2006 other than as outlined in Note 29 to the Consolidated Financial Statements.

*Transactions with Directors and Executive Officers*

Except as set out below, there are no service contracts in existence between any of the directors and Elan:

On January 7, 2003, we and EPI entered into an agreement with Mr. G. Kelly Martin such that Mr. Martin was appointed president and chief executive officer effective February 3, 2003.

Effective December 7, 2005, we and EPI entered into a new employment agreement with Mr. Martin, under which Mr. Martin continues to serve as our president and chief executive officer with an initial base annual salary of \$798,000. Mr. Martin is eligible to participate in our annual bonus plan, performance based stock awards and merit award plans. Under the new agreement, Mr. Martin was granted an option to purchase 750,000 Ordinary Shares with an exercise price per share of \$12.03, vesting in three equal annual installments (the 2005 Options).

**Table of Contents**

The agreement continues until Mr. Martin resigns, is involuntarily terminated, is terminated for cause or dies, or is disabled. In general, if Mr. Martin's employment is involuntarily terminated (other than for cause, death or disability) or Mr. Martin leaves for good reason, we will pay Mr. Martin a lump sum equal to two (three, in the event of a change in control) times his salary and target bonus and his 2005 options will vest and be exercisable for the following two years (three, in the event of a change in control).

In the event of such an involuntary termination (other than as the result of a change in control), Mr. Martin will, for a period of two years (three years in the event of a change in control), or until Mr. Martin obtains other employment, continue to participate in our health and medical plans or we shall pay him a lump sum equal to the present value of the cost of such coverage and we shall pay Mr. Martin a lump sum of \$50,000 to cover other costs and expenses. Mr. Martin will also be entitled to career transition assistance and the use of an office and the services of a full time secretary for a reasonable period of time not to exceed two years (three years in the event of a change in control).

In addition, if it is determined that any payment or distribution to Mr. Martin would be subject to excise tax under Section 4999 of the US Internal Revenue Code, or any interest or penalties are incurred by Mr. Martin with respect to such excise tax, then Mr. Martin shall be entitled to an additional payment in an amount such that after payment by Mr. Martin of all taxes on such additional payment, Mr. Martin retains an amount of such additional payment equal to such excise tax amount.

The agreement also obligates us to indemnify Mr. Martin if he is sued or threatened with suit as the result of serving as our officer or director. We will be obligated to pay Mr. Martin's attorney's fees if he has to bring an action to enforce any of his rights under the employment agreement.

Mr. Martin is eligible to participate in the pension, medical, disability and life insurance plans applicable to senior executives in accordance with the terms of those plans. He may also receive financial planning and tax support and advice from the provider of his choice at a reasonable and customary annual cost.

No other executive director has an employment contract extending beyond twelve months.

On July 1, 2006, EPI entered into a consultancy agreement with Dr. Selkoe whereby Dr. Selkoe agreed to provide consultant services with respect to the treatment and/or prevention of neurodegenerative and autoimmune diseases. We will pay Dr. Selkoe a fee of \$12,500 per quarter. The agreement is effective for three years unless terminated by either party upon thirty days written notice and supersedes all prior consulting agreements between Dr. Selkoe, and Elan. Prior thereto, Dr. Selkoe was party to various consultancy agreements with EPI and Athena Neurosciences, Inc. Under the consultancy agreements, Dr. Selkoe received \$50,000 in 2006 and \$25,000 in 2005.

***Arrangements with Former Directors***

On July 1, 2003, we entered into a pension agreement with Mr. John Groom, a former director of Elan Corporation, plc, whereby we shall pay him a pension of \$200,000 per annum, monthly in arrears, until May 16, 2008 in respect of his former senior executive roles.

On Dr. Garo Armen's retirement from the board in May 2006, we agreed to vest on his retirement 25,000 options that would otherwise have expired unvested on his retirement date, and have extended the exercise term of 50,000 options from ninety days to one year post-retirement.

***External Appointments and Retention of Fees***

Executive directors may accept external appointments as non-executive directors of other companies and retain any related fees paid to them. Dr. Ekman was appointed as a non-executive director of InterMune, Inc. on September 18, 2006. In respect of such position he retained the fees paid to him for such services. In 2006 this amounted to \$12,500.

**C. Interest of Experts and Counsel**

Not applicable.



**Table of Contents**

**Item 8. *Financial Information.***

**A. Consolidated Statements and Other Financial Information**

See item 18.

**B. Significant Changes**

None.

**Item 9. *The Offer and Listing.***

**A. Offer and Listing Details**

See item 9C.

**B. Plan of Distribution**

Not applicable.

**C. Markets**

The principal trading markets for our Ordinary Shares are the Irish Stock Exchange and the London Stock Exchange. Our ADSs, each representing one Ordinary Share and evidenced by one ADR, are traded on the NYSE under the symbol `ELN`. The ADR depository is The Bank of New York.

Our corporate governance practices do not differ in any significant way from those required of domestic companies under NYSE listing standards. A comparison of NYSE and Elan corporate governance standards is available on our website at [www.elan.com](http://www.elan.com).

In accordance with Section 303A.12(a) of the NYSE Listed Company Manual, the Chief Executive Officer of the Company submits annual certifications to the NYSE stating that he is not aware of any violations by the Company of the NYSE corporate governance listing standards, qualifying the certification to the extent necessary. The last such annual certification was submitted on April 18, 2006.

**Table of Contents**

The following table sets forth the high and low sales prices of the Ordinary Shares during the periods indicated, based upon mid-market prices at close of business on the Irish Stock Exchange and the high and low sales prices of the ADSs, as reported in published financial sources:

	<b>0.05 Ordinary Shares</b>		<b>American Depository Shares<sup>(1)</sup></b>	
	<b>High</b>	<b>Low</b>	<b>High</b>	<b>Low</b>
	<b>( )</b>		<b>( \$ )</b>	
Year ended December 31				
2002	50.27	1.23	45.18	1.03
2003	7.25	2.33	9.02	2.25
2004	23.80	5.40	30.09	7.06
2005	22.25	2.42	29.00	3.24
2006	14.90	10.27	19.21	12.50
<b>Calendar Year</b>				
2005				
Quarter 1	22.25	2.42	29.00	3.24
Quarter 2	6.42	2.64	8.05	3.38
Quarter 3	7.40	5.46	9.25	6.77
Quarter 4	11.54	6.47	14.23	7.70
2006				
Quarter 1	13.49	10.27	16.78	12.50
Quarter 2	14.90	11.27	19.21	14.13
Quarter 3	13.24	10.60	16.74	13.31
Quarter 4	12.50	10.48	15.88	13.95
<b>Month Ended</b>				
August 2006	12.80	11.35	16.74	14.56
September 2006	12.75	12.01	16.51	15.33
October 2006	12.50	11.29	15.88	14.48
November 2006	11.70	10.75	15.16	14.12
December 2006	10.96	10.48	14.80	13.95
January 2007	10.85	9.07	14.27	11.98

<sup>(1)</sup> An ADSs represents one Ordinary Share, par value 5 Euro cents.

**D. Selling Shareholders**

Not applicable.

**E. Dilution**

Not applicable.

**F. Expenses of the Issue**

Not applicable.

**Item 10. *Additional Information.***

**A. Share Capital**

Not applicable.